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Introduction, aim and 






Endometrial cancer (EC) is the sixth most commonly occurring cancer in women 
worldwide, with over 380,000 new cases and nearly 90,000 deaths in 20181. In the 
Western world, it is the most common gynaecological cancer, affecting more than 
one in 20 female cancers in Europe1,2. Majority of ECs occur in postmenopausal 
women, with median age at diagnosis of 61 years, while up to 14% occur in women 
of reproductive age3–8. The primary symptoms of EC are postmenopausal bleeding 
(PMB) and abnormal premenopausal bleeding. As a patient’s age increases after 
menopause, the probability that uterine bleeding is caused by EC progressively 
rises (Figure 1)3,9,10. 
Figure 1. Incidence of PMB per 1000 women (dotted line) and presence of EC in % (continuous 
line) in relationship to age
As most patients present with PMB, they are diagnosed at early stage disease11,12. 
This results in an overall good prognosis with 5-years survival over 90%, when 
diagnosed with FIGO stage 1 EC11,12. However, survival rates vary for the different 
subtypes EC. 
Tumour types
Generally, EC can be subdivided into two histological subtypes with differences in 
clinical outcomes13–15. Type I tumours that comprise the large majority of EC consist 
of endometrioid adenocarcinomas (EEC), are often preceded by endometrial 
hyperplasia and associated with unopposed oestrogen stimulation16. Type II 
tumours on the other hand consist of non-endometrioid tumours (NEEC) including 
serous carcinomas, clear cell carcinoma and carcinosarcoma. NEEC are commonly 
considered oestrogen independent, arising in atrophic endometrium deriving 
from intraepithelial carcinoma, as precursor lesions16. Type II tumours are poorly 
differentiated and have worse outcome than type I tumours17. The main risk factor 
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for the development of type I tumours is unopposed and prolonged oestrogen 
stimulation of the endometrium due to: obesity, metabolic syndrome, hormone 
therapy, nulliparity, early menarche and late menopause18–21. Although these risk 
factors have been mainly attributed to type I tumours, recent data illustrate that 
these are also related to type II tumours16.  In addition, type II tumours are also 
associated with hyperinsulinemia and diabetes mellitus (DM) independently of 
Body Mass Index (BMI), further supporting the resemblances in pathophysiology 
and aetiology of EEC and NEEC16. 
Recent genomic characterisation of EC through The Cancer Genome Atlas (TCGA) 
Project classified EC into four integrated clusters: POLE ultramutated (POLE), 
microsatellite instability hypermutated (MSI), copy-number low (CNL) and copy-
number high (CNH)22. The POLE, MSI and CNL clusters were composed mostly 
of endometrioid histology and most serous tumours were found in the CNH 
cluster22. POLE mutated tumours showed the best progression-free survival (PFS), 
while women with CNH tumours had the worst prognosis22. There appears to 
be an association between obesity and the EC integrated clusters: women with 
CNL tumours have the highest median BMI whereas women with POLE mutated 
tumours have the lowest BMI23. Furthermore, oestrogen receptors (ER) were 
found evenly expressed (50-75%) across all four subtypes, offering a potential 
pathway for sex hormones to mediate obesity-related cancer tumorigenesis in all 
four subtypes and therefore potentially explaining the link between increased BMI 
and risk for both type I and II EC24. 
EC carcinogenesis
During the development of EC, there is an imbalance between oestrogens and 
progestogens. Oestrogens are the primary female sex hormones responsible 
for endometrial proliferation25. Progestogens on the other hand counteract 
the oestrogen-induced endometrial growth, and induce differentiation into the 
secretory phase of the endometrium26. High levels of oestrogens unopposed by 
progesterone, as frequently observed in obese women, can therefore lead to 
endometrial hyperplasia, and subsequently develop into early-stage EC27. 
Carcinogenesis is a multistep process, starting from the initial carcinogenic 
stimulus, followed by changes at the cellular level with abnormal cell division, to 
the final manifestation of cancer. Although uncontrolled growth is a fundamental 
characteristic of cancer cells, these cells also require a proper microenvironment 
to survive, develop and progress28. The tumour microenvironment (TME) consists 
of extracellular matrix including myofibroblasts and cellular players, such as 
fibroblasts, neuroendocrine cells, blood and lymphatic vascular networks, immune-
inflammatory cells and adipose cells29. Adipose cells play an important role in EC 
microenvironment because they establish a proinflammatory microenvironment, 
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which is more likely to breed tumours30. In addition, adipose cells secrete more 
than 50 different cytokines, chemokines, and hormone-like factors, which may be 
accomplices in tumour initiation (Figure 2)31,32.
Figure 2. Obesity is associated with metabolically active adipose tissue, leading to inflammation 
and altered cytokine/adipokine secretion. These changes contribute to and interact with 
alterations in systemic physiology that reflect the insulin resistance and metabolic syndrome. 
Adipose tissue can impact cancer directly by activating the signalling pathway and altering 
cellular metabolism but also indirectly on the tumour microenvironment to promote proliferation, 
angiogenesis and invasion.
Whereas TME  is seen as the local interaction between the cellular elements 
of a tumour, the tumour’s macroenvironment can be described as the systemic 
interaction between the tumour microenvironment with other organs and systems 
in the body (Figure 3)33. 
Tumour-induced angiogenesis supports tumour growth, however the newly 
formed network of blood vessels are leaky, resulting in an accumulation and/
or release of soluble factors from the TME into the circulation33. This leads to 
pathological endocrine effects and interaction between the TME and the patient’s 
organs and systems, resulting in the development of cancer-associated systemic 
syndromes in the tumour macroenvironment33. 
The major influence of the tumour on the macroenvironment appears to be related 
to excess of cytokines in the serum, which are responsible for promoting degradative 
14
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pathways in skeletal muscle and adipose tissue34. The most well-known systemic, 
multi-factorial syndrome is cancer cachexia, which is characterised by progressive 
loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully 
reversed by conventional nutritional support and leads to progressive functional 
impairment35. Cancer cachexia links regulation of the macroenvironment of 
tumours to the entire individual. 
Figure 3. The tumour micro- and macroenvironment concept.
Obesity and EC
The rising incidence of EC has been attributed to the increased prevalence of 
obesity in developed countries for both type I and type II EC36–40. Obesity is also 
an important contributor for morbidity and mortality from several diseases such 
as cardiovascular disease, diabetes and different cancer types including EC41. 
Over the past 10 years, the World Health Organization (WHO) has recognised 
the increased number of people who are overweight or obese, and attention is 
now being given to the global implications associated with this trend42. Since 
obesity is a multifactorial problem, understanding and addressing obesity requires 
recognising and appreciating biology including mechanistic background, behaviour, 
environment and culture. 
Individual, environmental, socioeconomic and genetic factors are all linked to the 
increase in obesity in developed countries43. The individual factors for obesity 
consist of diet, physical activity, sedentary behaviour and sleep43. Socioeconomic 
status (SES), which is based on income, education and occupation, is associated 
with obesity, in which obesity is more frequently seen in individuals with low 
SES44,45. Individuals of lower SES tend to be less physically active and have 
unhealthier food habits, contributing to poorer health status46,47. Low SES is 
associated with increased morbidity including DM and cardiovascular disease and 
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all-cause mortality including cancer-related mortality48–50. There seems evidence 
of a relationship between socioeconomic deprivation and survival in EC, however 
the exact link including the relationship with obesity is unclear. 
The pathogenetic mechanisms for endometrial tumorigenesis in relation to obesity 
is explained by a variety of mechanisms and relevant in both type I and type II 
EC. In adipose tissue, both adipocytes and stromal cells express aromatase, an 
enzyme which converts circulating androgens (androstenedione and testosterone) 
to oestrone (E1) and oestradiol (E2), respectively51–58. The excess oestrogen 
produced by adipose tissue provides a growth signal for the endometrium that 
is unopposed by progesterone, leading to an increased risk of EC. Furthermore, 
like in most cancers, the TME also plays an essential role in EC progression59. 
Mutations in PTEN, KRAS, p53, and microsatellite instability initiate EC lesions, 
but this does not lead to high-grade cancer or metastasis unless supported by 
the microenvironment59. Furthermore, in obese women, the paracrine signalling 
from visceral adipocytes is associated with chronic inflammation mediated by 
proinflammatory adipokines leading to hyperinsulinemia, increases in insulin-
like growth factor 1 (IGF1) and hyperglycaemia, which in turn also stimulates 
endometrial proliferation61. In addition, sex hormone-binding globulin (SHBG) 
levels decrease with increasing adiposity, thereby increasing the pool of bioactive 
oestrogen60.
Obesity and body composition in EC
BMI is the most frequent used measurement to class individuals into underweight, 
normal weight, overweight and obese. However, BMI has limitations as a measure 
of obesity as it does not provide an appropriate assessment of body composition 
including differentiation between muscle and fat mass62,63. Therefore, attention 
has shifted towards the usage of body composition measurements. Body fat can 
be distributed into subcutaneous adipose tissue and visceral adipose tissue, which 
is defined as fat around the viscera and inside the intra-abdominal parenchymal 
organs. High percentages of visceral fat are associated with worse outcomes in 
several cancers sites such as breast and ovarian cancer64,65. In addition, visceral fat 
is associated with an increased cardiometabolic risk66. Furthermore, sarcopenia, 
described as a pathological decrease in muscle mass, is an objective measure 
of frailty and is associated with poor outcomes including survival for several 
cancer types67,68. The relationship between body composition and outcomes in 
EC patients, is unclear. Understanding these underlying mechanisms could aid in 
understanding the obesity-related EC carcinogenesis.
Obesity and haematological parameters in EC
The chronic low-grade inflammation state of obese patients is characterised 
by elevated levels of  circulating pro-inflammatory cytokines and acute phase 
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proteins69. This inflammatory state generates a pro-tumorigenic environment 
promoting angiogenesis70. In addition, excessive cytokine production stimulates 
the release of young and large platelets from bone marrow to the peripheral blood, 
which cause changes in haematological parameters71. Due to their angiogenic, 
metastatic, and proteolytic activities, platelets have a major role in the background 
of inflammation and are an important part of the TME72,73. Pre-treatment 
thrombocytosis, often defined as platelet count higher than 400 x 109/L, has been 
associated with adverse prognosis in EC74. Furthermore, an inverse relationship 
between haemoglobin and thrombocyte levels is seen, and anaemia is thought 
to be a marker of tumour burden or biologically more aggressive disease75. In 
addition, preoperative leucocytosis, which is more often seen in obese patients, is 
associated with increasing tumour size and increased risk of death in EC76,77. It has 
been hypothesised that leucocytosis is also linked to the presence of comorbid 
conditions, however this association is unclear in EC. 
Obesity and miRNA in EC
To fully understand the link between EC and its major risk factor, obesity, new 
insights into the pathogenetic and molecular mechanisms for obesity-related 
endometrial tumorigenesis are needed.
MicroRNAs (miRNAs) are a novel group of non-coding RNAs that have emerged 
as important regulators of mRNA expression78. Recent findings indicate that 
miRNAs play crucial roles in biological processes including cellular differentiation, 
proliferation and apoptosis78,79. Alterations in miRNA expression are described 
in a wide range of human diseases such as metabolic-, neurodevelopmental-, 
inflammatory-, cardiovascular- and liver diseases80,81. In addition, miRNAs have 
emerged as key regulators of lipid and glucose metabolism and play pivotal roles in 
the onset of obesity and obesity-related diseases by affecting status and functions 
of the adipose tissue, pancreas, liver and muscle82. 
Although the associations of obesity with EC and of miRNAs with EC are well 
documented, there is a scarcity of data concerning the role of miRNAs as a potential 
link between obesity and EC. Gaining a better understanding of the relationship 
between obesity and EC can provide new insights in obesity-related endometrial 
tumorigenesis. 
Diagnosis of EC: miRNA as diagnostic biomarker
Since abnormal expression of miRNAs can contribute to the development of cancer 
including gynaecological cancer, they can be a candidate in either detecting or 
monitoring cancer treatment  81,83–87. Currently, EC diagnosis is made by endometrial 
biopsy, which is an invasive and often uncomfortable procedure88,89. In addition, 
there is a large discordancy between pre- and postoperative tumour classification 
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following endometrial biopsy90. This can lead to either undertreatment or 
overtreatment with unnecessary surgical procedures and associated complications. 
Therefore, to improve correct preoperative classification, the identification of 
a novel diagnostic biomarker is needed. Novel diagnostic biomarkers should be 
non-invasive to improve management, patient care and acceptability of women 
presenting with abnormal bleeding.
MiRNAs are detectable and stable in a huge variety of bodily fluids including 
serum, urine, saliva and Pap smear91. Therefore, miRNAs are promising as non-
invasive diagnostic biomarkers92,93. However, the diagnostic value of miRNA for 
EC is unknown. 
Aims of this thesis
To improve understanding of the obesity-related endometrial carcinogenesis and 
prevent further excessive rise in the incidence of EC. Therefore, we aim to study:
 − The relationship between adiposity distribution (body composition) in relation 
to outcomes in endometrial cancer
 − The association between socioeconomic deprivation, obesity and survival in 
endometrial cancer 
 − The value of haematological parameters as indicators for comorbidity and 
body composition in endometrial cancer 
 − The link between miRNA expression levels and obesity in endometrial cancer
 − The diagnostic value of miRNA expression in endometrial cancer
Outline of this thesis
In Chapter 2, body fat measurements are assessed with CT-scan and analysed in 
relationship to mortality in endometrial cancer. 
In Chapter 3, the relationship between sarcopenia, obesity and outcomes in 
endometrial cancer is explored.
In Chapter 4, the association between socioeconomic deprivation and survival in 
endometrial cancer patients is outlined.
In Chapter 5, the link between socioeconomic deprivation, BMI and mortality in 
endometrial cancer is investigated.
18
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In Chapter 6, haematological parameters as indicators for comorbidity and body 
composition in endometrial cancer are described and their relationship with 
survival is analysed.
In Chapter 7, the diagnostic value of miRNA expression in endometrial cancer is 
reviewed.
In Chapter 8, the miRNA expression patterns in tissue samples of endometrial 
cancer patients are determined and compared to benign endometrial tissue.
In Chapter 9, the diagnostic value of urinary miRNA expression in endometrial 
cancer is examined and the relationship between urinary miRNA expression and 
obesity is described.
In Chapter 10, findings are reviewed and future perspectives including impact on 
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Abstract
Background
Obesity is an important risk factor for the development of endometrial cancer (EC). 
Recent data showed that body fat distribution might be more relevant than Body 
Mass Index (BMI). High visceral fat percentage was shown to be an independent 
predictor for survival in EC, but mainly included grade 1-2 EC. 
Objective
To evaluate body fat distribution and its relation to outcome in high-grade EC.
Methods
Retrospective study in women diagnosed with high-grade EC between February 
2006 and August 2017 at the Royal Cornwall Hospital who had abdominal CT-scan 
as part of routine diagnostic work-up. Subcutaneous abdominal fat volumes and 
visceral abdominal fat volumes were quantified based on CT-scan measurements, 
and visceral fat percentage calculated. 
Results
A total of 176 patients with high-grade EC were included. The median age was 
70 years and median BMI was 29.4 kg/m2. The majority of patients had non-
endometrioid endometrial cancer (NEEC; 62%). High visceral fat percentage was 
associated with poor overall- and disease-specific survival (p = 0.006 and p = 0.026, 
respectively) in NEEC patients, but not in high-grade endometrioid EC (EEC). The 
most frequent obesity comorbidities hypertension and diabetes mellitus were 
significantly associated with high BMI and high visceral fat percentage.
Conclusion
In high-grade EC, high visceral fat percentage was an independent predictor of poor 
survival only in NEEC. The strong correlation between high visceral fat and obesity-




In the United Kingdom (UK), 62% of women are either overweight or obese, with 
an increasing prevalence of obesity ranging from 15% in 1993 to 29% in 20191. 
Obesity is strongly associated with the development of several serious medical 
conditions such as cardiovascular disease, type-2 diabetes and cancer including 
endometrial cancer (EC)2. Several mechanisms have been proposed to explain links 
between adiposity and EC including excess of endogenous sex steroid hormones, 
insulin resistance and chronic inflammation3,4. Although these mechanisms have 
been mainly attributed to endometrioid type EC (EEC), recent data illustrate that 
this is also relevant in non-endometrioid type EC (NEEC)5.
Body Mass Index (BMI) is a well-recognised and widely used measure to classify 
adults into categories of underweight, normal weight, overweight and obese. 
However, there are limitations to the suitability of BMI as a measure of obesity 
as it does not incorporate metrics reflecting body composition6,7. Body fat is 
distributed into two main compartments with different metabolic characteristics: 
subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT)8. The 
accumulation of visceral fat, defined as fat around the viscera and inside the intra-
abdominal parenchymal organs, is an independent risk factor in cardiovascular 
disease and is linked to poor outcomes in breast and ovarian cancer9,10. The gold 
standard for quantitative assessment of intra-abdominal adipose tissue is either by 
Computerized Tomography (CT) or Magnetic Resonance Imaging (MRI)11,12. 
The impact of obesity on survival in EC has been studied considerably, with 
studies suggesting worse outcomes in women with increased BMI, however 
the link between BMI and survival has not fully been established17,18. Therefore, 
accurate measures of body fat distribution in overweight and obese women would 
potentially allow us to assess the influence of obesity on survival and other health 
outcomes.  
Evidence is scarce regarding the association between body fat distribution and 
outcomes including mortality, recurrence rates and surgical outcomes in EC. It has 
been hypothesised that high visceral fat rates are associated with worse outcomes, 
however previous studies have yielded conflicting results19–21. Furthermore, the 
largest study to date mainly included grade 1 or 2 EC19. 
Therefore, the aim of this study is to investigate the relationship between body fat 
distribution assessed by CT-scan in relation to overall and disease-specific survival 
in high-grade (grade 3) EC. 
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Materials and methods
Patients
Women diagnosed with high-grade primary EC between February 2006 and August 
2017 at Royal Cornwall Hospital Trust (RCHT) Truro, Cornwall, United Kingdom 
were considered eligible for inclusion in this retrospective study. Inclusion criteria 
were women with grade 3 EEC or NEEC diagnosis who had CT-scan as part of 
standard management and exclusion criteria were women with grade 1 or 2 EC.
All included women had undergone contrast-enhanced abdominal CT (n = 174) or 
non-contrast CT (n = 2). CT-scans were conducted either preoperatively (n = 146) 
or within 6 weeks after surgery (n = 30). Indications for CT-scan postoperatively 
where either due to postoperative symptoms and/or complications or to establish 
baseline values for adjuvant treatment. 
Women underwent standard treatment which included hysterectomy and 
bilateral salpingo-oophorectomy, when indicated followed by adjuvant therapy 
(radiotherapy and/or chemotherapy). Individualised management was given to 
women unfit for surgery or women who preferred non-surgical options, which 
included hormonal therapy, radiotherapy or chemotherapy. The majority of 
patients (84%) underwent surgical staging using the International Federation of 
Gynecology and Obstetrics (FIGO) staging criteria, accompanied by CT-scan as per 
local protocol22. For the 26 (15%) patients who did not undergo surgery, the FIGO 
stage was based on clinical examination and imaging results, and surgery was 
omitted due to advanced stage disease or patient preference. These patients were 
older and had more comorbidities when compared to the patients that underwent 
surgery. As the overall data were not affected, patients were included for analysis. 
Only 37 patients (21%) received either pelvic or para-aortic lymphadenectomy, 
since lymphadenectomy was only performed in high-risk EC patients with enlarged 
lymph nodes on imaging (CT-scan) as per British Gynaecological Cancer Society 
guidelines following the ASTEC trial23,24.
Baseline characteristics were extracted from medical records, including patient- 
and tumour characteristics and CT report. BMI (weight in kg divided by height in 
meters squared) was based on measured weight and height during clinical visits 
within six weeks prior to surgery. Follow-up time varied from 27 months to 166 
months, and patients were followed from the date of diagnosis until October 29th 
2019, or death. Ethical and institutional approval was obtained for the study in 
accordance with the Declaration of Helsinki and was approved by the Health 




Abdominal CT images were analysed at the Mohn Medical Imaging and 
Visualization Centre (MMIV), Haukeland University Hospital, Bergen, Norway, 
using a semi-automated method for volumetric quantification of abdominal fat 
(iNtuition software program, TeraRecon Inc., San Mateo, CA, USA). Cross-sectional 
images were analysed consecutively from the upper right diaphragm to the level 
of vertebral body L5/S1, segmenting pixels with Hounsfield unit (HU) values 
corresponding to fat tissue (-195 to -45 HU), using a validated and reproducible 
method as previously described26–29. 
The segmented subcutaneous abdominal fat volume (SAV) and visceral abdominal 
fat volume (VAV) were visually verified by the operator (HD) and manually adjusted 
if necessary (illustrated in Figure 1). 
Figure 1. Cross-sectional abdominal CT image with segmentation of subcutanous (blue) 
and visceral (green) body fat for measurements of body fat distribution in two endometrial 
cancer patients. 
Left: 70-year old patient (FIGO stage 1B, endometrioid subtype, BMI 39.1) with high SAV and 
low VAV%. Survival time 87 months (still alive)
Right: 81-year old patient (FIGO stage IIIA, endometrioid subtype, BMI 26.5) with high VAV and 
high VAV%. Survival time 23 months (deceased)
Internal validation was performed by a second operator (IH). VAV (cm3) and SAV 
(cm3) were estimated and the sum was considered to comprise the total abdominal 
fat volume (TAV, cm3). The percentage of visceral out of total abdominal fat volume 
([VAV/TAV]x100; VAV%) was also calculated. Waist circumference (cm) was 
measured at the level of vertebral body L3/L4.
Statistical analysis
For normally distributed variables, continuous variables were presented as medians 
and range and categorical variables presented as frequencies and proportions. 
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Nonparametric continuous data was compared using the Kruskal-Wallis test or 
Mann-Whitney U test, and Pearson Chi-square test was used for categorical data. 
Survival analysis were conducted using Kaplan-Meier curves and Cox Regression 
models while controlling for possible confounders (histology, FIGO stage, VAV%, 
BMI, age, hypertension and diabetes mellitus). The statistical significance of 
differences in outcome between the groups was assessed with the log-rank 
test. P-values less than 0.05 were considered significant for all tests. Data were 
analysed with IBM SPSS statistics version 26.0.
Results
Patient characteristics
In total, 176 women were included in this study. Median patient age was 70 
years and median BMI was 29.4 kg/m2 (Table 1). The majority of women had 
endometrioid subtype EC (38%), followed by serous (22%) and carcinosarcoma 
(20%). In total, 51% of women presented with FIGO stage I. Nearly the entire 
population was Caucasian (98%). 
Table 1. Patient characteristics
Characteristics Value
No. of patients 176
Age (years), median (range) 70 (58)
BMI (kg/m2), median (range) 29.4 (39.4)
Overall survival (months), median (range) 42 (167)
BMI groups (%)
    < 25
     25 – 30
     > 30






    Caucasian
    Any other ethnic group





    Yes
    No
    Ex-smoker






    None
    One
    Two or more






    Yes




    Yes








   0
   1
   ≥2






    Endometrioid
    Serous
    Carcinosarcoma 
    Clear cell
    Mixed tumours








    I
    II
    III
    IV







    Laparoscopic hysterectomy + BSO
    Laparotomy hysterectomy + BSO
    Other type surgery
    No surgery







    Yes
    No





    Yes
    No





    Yes
    No





    No
    Yes





    Yes
    No
    Progression despite treatment






    No
    Yes
80 (45)
96 (55)
Cause of death (%)
    Endometrial cancer
    Other




Abbreviations: BMI = Body Mass Index, ECOG = Eastern Cooperative Oncology Group, FIGO = 
International Federation of Gynecology and Obstetrics
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The association between BMI and CT-assessed obesity parameters and 
clinicopathological factors is shown in Table 2. Subtype EC (endometrioid versus 
non-endometrioid) was not associated with obesity parameters. However, 
patients with early FIGO stage had higher BMI (p = 0.036) than patients with 
advanced FIGO stage. Furthermore, elderly patients (aged ≥ 70 years) had higher 
VAV% compared to patients aged < 70 (p = 0.001). Two or more comorbidities 
were associated with all obesity parameters except for VAV. 
Fat distribution and clinicopathological outcomes
Conversion from laparoscopy to laparotomy was more frequent in patients with 
high BMI (p = 0.004). In univariate analysis, none of the obesity parameters were 
associated with intraoperative complication rate. However, high WC (p = 0.027) 
and high VAV (p = 0.013) were associated with higher postoperative complication 
rates. In multivariate analysis, VAV (p = 0.039) was significantly associated with 
higher number of postoperative complications, but WC (p = 0.091) was not, data 
not shown (model adjusted for histological subtype, FIGO stage, age, hypertension 
and diabetes mellitus).
All obesity parameters were associated with the presence of hypertension and 
all obesity parameters with the exception of SAV were associated with diabetes 
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Table 3. Association of obesity parameters with obesity related comorbidities.
BMI WC VAV SAV TAV VAV%
DM
Yes (N = 22)





















Yes (N = 90)





















Yes (N = 17)




















Abbreviations: BMI = Body Mass Index, DM = Diabetes Mellitus, SAV = subcutaneous abdominal fat 
volume, TAV = total abdominal fat volume, VAV = visceral abdominal fat volume, VAV% = percentage of 
visceral out of total abdominal fat volume, WC = waist circumference
* Significant at p < 0.05 level
Values are presented as medians
Fat distribution and survival
High VAV% was significantly associated with reduced OS (p = 0.002) and DFS (p = 
0.041) in the univariable Cox-model (Table 4).
Table 4. Univariate hazard ratios for OS and DSS and obesity parameters
Overall survival Disease-specific survival
N Unadjusted 
HR





BMI 170 1.02 0.99 – 1.05 0.22 170 1.00 0.99 – 
1.06
0.19
WC 176 1.00 0.99 – 10.2 0.33 176 1.00 0.99 – 
1.02
0.46
TAV 176 1.00 1.00 – 1.00 0.78 176 1.00 1.00 – 
1.00
0.84
VAV 176 1.00 1.00 – 1.00 0.10 176 1.00 1.00 – 
1.00
0.29
SAV 176 1.00 1.00 – 1.00 0.64 176 1.00 1.00 – 
1.00
0.78
VAV% 176 1.04 1.01 – 1.06 0.002* 176 1.03 1.00 – 
1.06
0.041*
Abbreviations: HR = hazard ratio, BMI = Body Mass Index, WC = waist circumference, TAV = total 
abdominal fat volume, VAV = visceral abdominal fat volume, SAV = subcutaneous abdominal fat volume, 
VAV% = percentage of visceral out of total abdominal fat volume. 
* Significant at p < 0.05 level
Survival curves are visualised in the Kaplan-Meier plots where patients with VAV% 
above median (34.1%) had significantly reduced OS (p = 0.024) but not DSS (p = 
37
2
0.35) (Figure 2A and B). Mean overall survival time for patients with low VAV% 
was 88 months compared to 73 months for patients with high VAV% and mean 
DSS time was 96 months with low VAV% compared to 98 months in patients with 
high VAV%. Patients with higher VAV% did not have a higher risk for recurrent 
disease (p = 0.91). 
Figure 2. High VAV% is associated with worse overall survival, but not disease specific 
survival
A. Kaplan Meier curve showing reduced OS in patients with high VAV% (median cut-off: 34.1%)
B. Kaplan Meier curve showing no difference in DSS in patients with high VAV%
In multivariate Cox Proportional Hazards Regression model, histological subtype 
(p = 0.031), FIGO stage (p < 0.001), BMI (p = 0.007) and age (p = 0.006) were 
associated with OS after adjusting for confounders, but VAV% did not remain 
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stage (p < 0.001) and BMI (p = 0.017) were associated with DSS in multivariate 
analysis, but VAV% was not (p = 0.11). 











176 0.59 0.38 – 0.92 0.018* 0.59 0.36 – 0.95 0.031*
FIGO stage 168 1.69 1.42 – 2.00 <0.001* 1.76 1.47 – 2.10 <0.001*
VAV% 176 1.04 1.01 – 1.06 0.002* 1.03 1.00 – 1.06 0.10
BMI 170 1.02 0.99 – 1.05 0.22 1.05 1.01 – 1.08 0.007*
Age 176 1.05 1.03 – 1.07 <0.001* 1.03 1.01 – 1.06 0.006*
Hypertension 176 1.65 1.09 – 2.48 0.017* 0.98 0.60 – 1.59 0.92





176 0.52 0.31 – 0.88 0.015* 0.52 0.29 – 0.92 0.025*
FIGO stage 168 1.95 1.59 – 2.39 <0.001* 2.05 1.66 – 2.53 <0.001*
VAV% 176 1.03 1.01 – 1.06 0.041* 1.03 0.99 – 1.07 0.11
BMI 170 1.02 0.99 – 1.06 0.19 1.05 1.01 – 1.09 0.017*
Age 176 1.02 1.00 – 1.04 0.05 1.01 0.99 – 1.04 0.42
Hypertension 176 1.59 0.99 – 2.57 0.06 0.95 0.54 – 1.68 0.86
DM 176 1.32 0.68 – 2.59 0.42 0.97 0.45 – 2.08 0.94
Abbreviations: BMI = Body Mass Index, CI = Confidence Interval, EEC = endometrioid endometrial 
cancer, FIGO = International federation of Gynecology and obstetrics, HR = Hazard ratio, NEEC = non-
endometrioid endometrial cancer, VAV% = Visceral fat percentage, DM = Diabetes Mellitus.
* Significant at p < 0.05 level
Model adjusted for histology, FIGO stage, VAV%, BMI, age, hypertension and Diabetes Mellitus
However, sub-analysis in non-endometrioid endometrial cancer (NEEC) patients 
showed a significant correlation between high VAV% and OS (p = 0.006) and DSS 
(p = 0.026) in multivariate analysis (Table 6). 
Survival curves are visualised in the Kaplan-Meier plots where NEEC patients with 
VAV% above median had significantly reduced OS (p = 0.009) but not DSS (p = 0.22) 
(Figure 3A and B). Moreover, BMI was associated with both OS (p = 0.002) and DSS (p 
= 0.026) and FIGO stage was also associated with OS (p < 0.001) and DSS (p < 0.001). 
In endometrioid endometrial cancer (EEC) patients, only FIGO stage (p < 0.001 for 
OS and p < 0.001 for DSS) and age (p = 0.012 for OS and p = 0.048 for DSS) was 
associated with poorer survival and no association between survival and VAV% 
was seen (Table 7). Kaplan-Meier curves (Figure 3C and D) show no difference in 
survival for EEC patients with high VAV%.
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FIGO stage 107 1.81 1.47 – 2.24 <0.001* 1.83 1.46 – 2.29 <0.001*
VAV% 110 1.04 1.01 – 1.07 0.003 1.06 1.01 – 1.10 0.006*
BMI 105 1.03 0.99 – 1.07 0.13 1.06 1.02 – 1.10 0.002*
Age 110 1.04 1.02 – 1.07 0.001* 1.01 0.98 – 1.04 0.41
Hypertension 110 1.44 0.88 – 2.37 0.15 0.80 0.46 – 1.41 0.44
DM 110 1.25 0.64 – 2.46 0.51 0.80 0.36 – 1.75 0.57
Disease specific survival
FIGO stage 107 2.02 1.58 – 2.58 <0.001* 2.13 1.63 – 2.78 <0.001*
VAV% 110 1.03 1.00 – 1.06 0.09 1.05 1.01 – 1.10 0.026*
BMI 105 1.03 0.98 – 1.07 0.24 1.05 1.01 – 1.11 0.026*
Age 110 1.02 0.99 – 1.05 0.22 0.99 0.96 – 1.02 0.51
Hypertension 110 1.09 0.49 – 2.43 0.83 0.72 0.38 – 1.37 0.31
DM 110 1.32 0.75 – 2.31 0.34 0.88 0.35 – 2.22 0.78
Abbreviations: BMI = Body Mass Index, CI = Confidence Interval, FIGO = International federation of 
Gynecology and obstetrics, HR = Hazard ratio, VAV% = Visceral fat percentage, DM = Diabetes Mellitus.
* Significant at p < 0.05 level
Model adjusted for FIGO stage, VAV%, BMI, age, hypertension and Diabetes Mellitus
 
Table 7. Prognostic impact of VAV% on OS and DSS in endometrioid endometrial cancer 
N Unad-
justed HR




FIGO stage 61 1.57 1.15 – 2.14 0.004* 1.95 1.34 – 2.83 <0.001*
VAV% 66 1.01 0.97 – 1.06 0.56 1.00 0.94 – 1.06 0.93
BMI 65 1.00 0.95 – 1.06 0.88 1.02 0.94 – 1.11 0.68
Age 66 1.05 1.02 – 1.09 0.003* 1.05 1.01 – 1.10 0.012*
Hypertension 66 2.04 0.82 – 5.07 0.13 1.72 0.54 – 5.52 0.36
DM 66 1.74 0.51 – 5.97 0.38 0.85 0.24 – 2.98 0.80
Disease specific survival
FIGO stage 61 1.95 1.32 – 2.87 0.001* 2.62 1.64 – 4.20 <0.001*
VAV% 66 1.02 0.96 – 1.08 0.54 1.01 0.94 – 1.09 0.78
BMI 65 1.02 0.96 – 1.09 0.52 1.06 0.96 – 1.16 0.27
Age 66 1.03 0.99 – 1.07 0.15 1.05 1.00 – 1.11 0.048*
Hypertension 66 2.04 0.82 – 5.07 0.13 1.87 0.50 – 6.97 0.35
DM 66 1.74 0.51 – 5.97 0.38 0.77 0.19 – 3.40 0.77
Abbreviations: BMI = Body Mass Index, CI = Confidence Interval, FIGO = International federation of 
Gynecology and obstetrics, HR = Hazard ratio, VAV% = Visceral fat percentage, DM = Diabetes Mellitus.
* Significant at p < 0.05 level
Model adjusted for FIGO stage, VAV%, BMI, age, hypertension and Diabetes Mellitus
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Figure 3. Differences in survival according to histological subtype
A. Kaplan Meier curve showing reduced OS in non-endometroid patients with high VAV% 
B. Kaplan Meier curve showing no difference in DSS in non-endometrioid patients with 
high VAV%
C. Kaplan Meier curve showing no difference in OS in endometrioid patients with high 
VAV%
D. Kaplan Meier curve showing no difference in DSS in endometrioid patients with high 
VAV%
Discussion
To our knowledge, this is the largest study investigating body fat measurements 
on CT-scans in women with high-grade EC. In this study we found a relationship 
between high VAV% and poor OS and DSS specifically in NEEC. A study by 
Mauland et al. showed poor DSS in patients with higher VAV%, however included 
limited number of high-grade EC (32%); with 32 grade 3 endometrioid and 41 
non-endometrioid19. They also found that increasing VAV% in EC patients was 
associated with older age, which is a well-known unfavourable prognostic factor in 
EC19,30. Furthermore, a smaller study by Nattenmüller in 54 EC patients showed no 
impact of VAV% on overall survival, however grade or subtype were not specified20. 
Previous literature has shown high VAV% to be associated with decreased OS in 
other cancer sites such as epithelial ovarian, oesophageal and pancreatic cancer, 
further supporting that increased visceral fat facilitates cancer progression due to 
obesity-induced inflammation and associated neutrophil infiltration which lead to 
the proliferation of adjacent tissues in the tumour microenvironment rather than 
reflecting an aggressive cancer phenotype10,31,32. 
D
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The association found in this study between poor survival and high VAV% in NEEC 
patients is an interesting finding and supports the theory that not only EEC is 
related to obesity and outcome, but NEEC is also linked to obesity as supported 
by the data of Setiawan5. This is further highlighted by the fact that median BMI 
was similarly high for endometrioid patients versus non-endometrioid patients in 
our study.
It has been shown that with increasing age, fat distribution patterns change 
from a peripheral to a central fat deposition, although exact etiological pathways 
are unknown33. Our study has confirmed these results, finding higher VAV% in 
elderly patients, and even after adjusting for age, high VAV% was an independent 
predictor of poor survival in NEEC patients. 
It is increasingly recognised that cancer progression and cancer-specific survival 
is not solely determined by the intrinsic characteristics of the tumour but also by 
host characteristics and in particular the systemic inflammatory response34. 
Furthermore, ageing is associated with an increase in systemic low-grade chronic 
inflammation as seen by raised levels of inflammatory markers such as IL-1 and 
C-reactive protein, which has been shown to contribute to morbidities and 
mortalities35–37. This can in turn lead to tissue degeneration and is associated 
with cancer induction and progression34. In addition, other age-related changes, 
obesity, comorbidities and tissue degradation also seem to drive the inflammatory 
response38. It has been hypothesised that systemic inflammatory response and 
hyperinsulinemia influence metabolic conditions such as diabetes and pre-
existing comorbid disease as well as cancer in women with EC39. Therefore, the 
interrelationship between the host factors of age, BMI, comorbidities and the 
systemic inflammatory response are complex. In our study, we found a strong 
relationship between VAV% and the obesity-related comorbidities hypertension 
and diabetes mellitus, further supporting the concept that those comorbid 
conditions reflect an unhealthy macroenvironment. Patients with diabetes mellitus 
and/or hypertension are at increased risk for cancer progression which should be 
monitored in EC patients in order to reduce morbidity and mortality40,41. 
Previous trials have shown that EC patients with high BMI have unfavourable 
surgical outcomes17. In addition, in gastric and rectal cancer, patients with 
more visceral fat are more likely to develop postoperative complications42–44. In 
addition, Palomba et al. showed an association between increased visceral fat 
and greater risk of conversion to laparotomy in obese EC patients46. In this study, 
there was an increased risk of postoperative complications in patients with high 
visceral fat volumes. Furthermore, conversion from laparoscopy to laparotomy 
was more frequent in patients with high BMI, but there was no association with 
43
2
fat distribution parameters. In our study, obesity parameters were not associated 
with increased risk of intraoperative complications, this is probably due to low rate 
of intraoperative complications (7%).
This study underlines the importance of adiposity and its impact on survival 
and outcomes in EC survivors. To improve visceral adiposity, several treatment 
programs have been suggested. Lifestyle interventions including calorie restriction 
and physical activities are described most frequently47. Specifically high intensity 
resistance training can slow the loss of muscle, while nutrition therapy improves 
visceral adiposity, as there is a strong association between energy intake and 
visceral fat accumulation48. Kwon et al. showed the effectiveness of a combined 
exercise regime to significantly reduce VAV, SAV and VAV% in healthy female 
adults49. Exercise interventions should however be individualised for EC patients 
because of age, comorbidities and disabilities. 
This study has shown the importance of visceral fat (VAV%) as a potential 
obesity marker as a supplement to BMI in NEEC patients. CT based quantitative 
measurements of VAV using semi-automated software appears simple, accurate 
and minimally time-consuming, thus representing a feasible supplement to BMI 
for better prognostication by incorporating image-based obesity markers in EC 
patients. We propose this may be considered for inclusion in the future as part of 
standard work-up for patients newly diagnosed with high-grade EC. 
Strengths and limitations
Strengths of our study include the large sample size of body fat measurements 
on CT-scans in high-grade EC patients. Furthermore, a highly reproducible 
and quantitative analysis of SAV and VAV could be performed due to usage of 
standardised fat measurements. Additionally, this study had a long follow-up time 
of over 10 years, in which a relatively high number of events (n = 96) was found. 
This study has limitations due to its retrospective design including completeness of 
previously recorded data. Furthermore, BMI calculations (measured at clinical visit) 
and all CT-based estimates were only measured at one particular time-point and 
no data regarding possible changes in BMI and/or fat distribution were collected 
that could be taken into account. In addition, the field of view (FOV) for the CT-
scans were set to assess intraabdominal tumour spread and therefore in some of 
the very obese patients, the entire SAV was not completely visualised, therefore 
potentially slightly underestimating the measured SAV in these patients. However, 
this was only the case in a very small percentage of the patients (5%) and in these 
it was perceived that the effect on the total SAV-measures was minimal; thus, 
this limitation seems to have only minimally influenced the findings in this study. 
Furthermore, only 21% of the patients underwent full staging procedure including 
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lymphadenectomy. However, the recurrence and survival rate of patients that 
underwent a complete surgical staging was comparable to those that were not 
properly staged, therefore we presume that this has not affected our results. In 
addition, there was no difference in EEC and NEEC with respect to surgical staging. 
Conclusions and clinical implications
Obesity with increased visceral fat is important in predicting survival in NEEC 
patients. High visceral fat percentage was specifically associated with reduced 
overall and disease-specific survival in NEEC patients, but not in high-grade 
EEC patients. Clinicians need to be aware of those patients with obesity-
related comorbidities, increased risk of postoperative complications and cancer 
progression. Specialised rehabilitation with training programs and nutritional 
therapy aiming at reducing their visceral fat volumes might be an important step 
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Abstract
Objective
To investigate the relationship between obesity and sarcopenia in relation to 
overall (OS) and disease-specific survival (DSS) in high-grade endometrial cancer 
(EC).
Methods
Retrospective study in women diagnosed with high-grade EC between February 
2006 and August 2017 in the Royal Cornwall Hospital who had abdominal CT-scan 
as part of routine staging work-up. Sarcopenia was assessed by measuring psoas-, 
paraspinal- and abdominal wall muscles on CT and defined by skeletal muscle 
index ≤ 41 cm2/m2. Sarcopenic obesity was defined as sarcopenia combined with 
Body Mass Index (BMI) ≥ 30 kg/m2.
Results
A total of 176 patients with median age of 70 years and median BMI of 29.4 kg/
m2 were included in the study. The majority of patients (38%) had endometrioid 
type histology. Sarcopenia was not associated with OS (p = 0.95) or DSS (p = 0.55). 
However, in multivariate analysis, sarcopenic obesity was associated with reduced 
OS in endometrioid endometrial cancer (EEC) patients (p = 0.048). 
Conclusion
Sarcopenic obesity is associated with OS in high-grade EEC patients, while 
sarcopenia without obesity is not related to OS or DSS in high-grade EC.  In NEEC, 




Endometrial cancer (EC) is the sixth most commonly occurring cancer in women 
worldwide, with over 380,000 new cases and nearly 90,000 deaths in 20181. EC 
patients are often elderly with multiple comorbidities including obesity2,3. Due to 
the rise in obesity during the last decade, the incidence of EC has increased4,5. 
Although obesity in the general population is associated with an increased risk of 
death, there are conflicting reports about the relationship between obesity and 
mortality among individuals with cancer. In some studies, a survival benefit for 
overweight or even obese individuals has been demonstrated6–10. Furthermore, 
in EC, high Body Mass Index (BMI) and obesity is associated with low-grade, i.e. 
grade 1-2 endometrioid endometrial cancer (EEC), with relatively good overall 
survival11. This positive effect of high BMI on outcome is called the ‘’obesity 
paradox’’, which suggests a potential protective effect of overweight or obesity. 
However, this reflects a complex relationship between obesity and EC. It has been 
hypothesised that reduced survival for people with normal BMI, compared with 
overweight, might be explained by loss of muscle mass12. 
Although BMI is a well-recognised and widely used measure to classify adults into 
categories of underweight, normal weight, overweight and obese, one major flaw 
and limitation is its inability to differentiate fat and muscle mass13,14. Some studies 
have therefore used waist-to-hip ratio (WHR) or waist circumference (WC); 
however these measures seem to lack the ability to differentiate subcutaneous 
from visceral fat deposition15. Therefore, in addition to BMI, there is a clear need 
for further specifying body composition incorporating muscle measurements. 
Currently, the gold standard for assessing body composition is Computerized 
Tomography (CT) or Magnetic Resonance Imaging (MRI)16–18.
Since the median age group of women with EC is 61 years with 75-80% being 
postmenopausal, it is important to recognise that age is associated with alterations 
in body composition, with a decrease in muscle mass and strength19,20. Sarcopenia, 
a pathological decrease in muscle mass, is an objective measure of frailty that is 
associated with functional impairment and disability21. Furthermore, sarcopenia 
is associated with higher risk of cancer recurrence, reduced overall- and cancer-
specific mortality, surgical complications and treatment-related toxicities22. 
Sarcopenia has been shown to have a strong mortality risk in all BMI groups, but 
mainly in obesity23. This is a condition called sarcopenic obesity and is associated 
with worse prognosis in several chronic diseases and various cancers24–26.
The relationship between sarcopenia, obesity and outcome in EC patients is 
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unclear. Previous studies have shown sarcopenia to impact recurrence-free 
survival, but not overall survival in EC27,28. However, the interaction of obesity and 
sarcopenia in EC has not yet been studied. Furthermore, the largest study to date 
mainly included grade 1-2 EEC28.
Therefore, the aim of this study is to investigate the relationship between obesity 
and sarcopenia in relation to overall- and disease-specific survival as measured by 
CT in high-grade EC patients. 
Materials and methods
In this retrospective study, women diagnosed with primary EC between February 
2006 and August 2017 at Royal Cornwall Hospital Trust (RCHT) Truro, Cornwall, 
United Kingdom were considered eligible for inclusion. Inclusion criteria were 
women diagnosed with primary EC, histology either endometrioid grade 3 or 
non-endometrioid carcinoma and ≥ 18 years of age, who had CT-scan as part of 
standard staging workup. Exclusion criteria were women with grade 1 or 2 EEC.
In total, 176 women were included, and all included women had undergone 
contrast-enhanced abdominal CT (n = 174) or non-contrast CT (n = 2). CT-scans 
were conducted either preoperatively or at time of diagnosis (n = 146) or within 6 
weeks after surgery (n = 30). Indications for CT-scan postoperatively were either 
due to postoperative symptoms or complications or to establish baseline staging 
parameters before adjuvant treatment. 
Women underwent standard treatment which included hysterectomy and bilateral 
salpingo-oophorectomy (BSO), followed by adjuvant therapy (radiotherapy and/or 
chemotherapy) when indicated. Individualised management was given to women 
unfit for surgery or women who preferred non-surgical options, which included 
hormonal therapy, radiotherapy or chemotherapy. The majority of patients (84%) 
underwent surgical staging using the International Federation of Gynecology and 
Obstetrics (FIGO) staging criteria, accompanied by CT-scan as per local protocol29. 
Staging procedure included para-aortic and/or pelvic lymph node dissection 
performed by gynaecological oncologist. For the 26 (15%) patients who did not 
undergo surgery, the FIGO stage was based on clinical examination and imaging 
results. Reasons surgery was omitted included advanced stage disease, patient 
unfit for surgery or patient preference. These patients were older and had more 
comorbidities when compared to the patients that underwent surgery; however, 
as the overall data were not affected, patients were included for analysis. Following 
the ASTEC trial, in most UK centres lymphadenectomy is exclusively performed in 
high-risk EC patients with enlarged lymph nodes on imaging by CT-scan30. Therefore, 
only 37 patients (21%) underwent either pelvic or para-aortic lymphadenectomy.
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For every case, a formal review of the pathology slides was performed at the 
Multidisciplinary Team Meeting (MDT). This allows for two pathologist to review 
slides independently of each other. 
Ethical and institutional approval was obtained for the study in accordance with 
the Declaration of Helsinki and was approved by the Health Research Authority 
(HRA) with reference number 19/SW/0111. It was deemed informed consent was 
not needed due to the retrospective nature of this study.
Baseline characteristics were obtained from patient records, including patient- and 
tumour characteristics. BMI (weight in kg divided by height in meters squared) was 
based on measured weight and height during clinical visits within six weeks prior 
to surgery. Follow-up time varied from 27 months to 166 months and patients 
were followed from the date of diagnosis until October 29th 2019 or death. 
Abdominal CT images were analysed at the Mohn Medical Imaging and 
Visualization Centre (MMIV), Haukeland University Hospital, Bergen, Norway, 
using a semi-automated method for volumetric quantification of abdominal fat 
(iNtuition software program, TeraRecon Inc., San Mateo, CA, USA). 
Sarcopenia markers were measured on cross-sectional image on which both 
vertebral transverse processes of the third lumbar vertebra (L3) were most 
clearly depicted. L3 was chosen as the standard landmark according to previously 
published studies16,31. The selected image had to be of sufficient quality for valid 
muscle segmentation analysis, meaning no imaging artefacts inducing difficulties 
in valid muscle segmentation32. Based on these criteria, no patients were excluded 
for analysis. The relevant muscles were identified based on anatomical localisation 
and comprised the psoas, paraspinal and abdominal wall muscles, which have 
been previously used to determine muscle mass and sarcopenia16. The iNtuition 
software was used to manually delineate muscular tissue using threshold values of 
HU units of -29 to + 150 by the operator (HD) (Figure 1)32. 
Internal validation was performed by a second operator (IH). The software 
program computed skeletal muscle area (SMA; cm2) by summing cross-sectional 
muscle areas. Skeletal muscle index (SMI; cm2/m2) was calculated by correcting 
SMA for height: SMA (cm2)/height (m)2. Sarcopenia was defined as SMI < 41 cm2/
m2 according to threshold values described previously33. Sarcopenic obesity was 
defined as sarcopenia plus BMI ≥ 30 kg/m2.
With a background prevalence of sarcopenic obesity of 7% in the general 
population and 15% in cancer patients, we performed a sample size calculation (α 
= 0.05 and power of 80%). The sample size was calculated to be 100 patients34–36.
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Figure 1. Cross-sectional abdominal CT image at the level of the vertebral transverse 
processes of L3 with segmentation of skeletal muscles (blue), viscera in green.
Left: 72-year old patient (FIGO stage 2, serous subtype, BMI 38) with low skeletal muscle area 
indicating sarcopenia. Survival time 11 months (deceased)
Right: 77-year old patient (FIGO stage IA, endometrioid subtype, BMI 22) with high skeletal 
muscle area. Survival time 62 months (still alive)
For variables having normal distribution, continuous variables were presented 
as medians and range and categorical variables presented as frequencies and 
proportions. Nonparametric continuous data was compared using the Kruskal-
Wallis test or Mann-Whitney U test, and Pearson Chi-square test was used for 
categorical data. Survival data was analysed using Kaplan-Meier curves and Cox 
Regression models while controlling for possible confounders. The statistical 
significance of differences in outcome between the groups was assessed with the 
log-rank test. P-values less than 0.05 were considered significant for all tests. Data 
were analysed with IBM SPSS statistics version 26.0.
Results
In total, 176 women were included in this study. Median patient age was 70 years 
and median BMI was 29.4 kg/m2 (Table 1). The majority of women had endometrioid 
subtype EC (38%), followed by serous carcinoma (22%) and carcinosarcoma (20%). 
Nearly the entire population was Caucasian (98%). Out of these 176 women, 61 
(35%) were sarcopenic and 17 (10%) met the criteria for sarcopenic obesity.
Sarcopenic patients had similar age as patients without sarcopenia but sarcopenic 
patients had lower BMI (p = 0.002) and higher FIGO stage at diagnosis (p = 0.031) 
(Table 2). However, sarcopenia was not associated with disease recurrence (p = 
0.27) or overall mortality (p = 0.76). 
57
3





No. of patients 176 61 17
Age (years), median (range) 70 (58) 72 (49) 72 (23)
BMI (kg/m2), median (range) 29.4 (39.4) 25.7 (22.2) 32.6 (11.4)
Overall survival (months), median 
(range)
42 (167) 51 (131) 40 (90)
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Abbreviations: BMI = Body Mass Index, BSO = bilateral salpingo-oophorectomy, ECOG = Eastern 
Cooperative Oncology Group, FIGO = International Federation of Gynecology and Obstetrics
Sarcopenic obesity patients had similar baseline characteristics compared to 
patients without sarcopenic obesity, with the exception of BMI (median BMI 32.6 
for sarcopenic obese patients and 28.3 for non-sarcopenic obese patients, p < 
0.001, Supplementary Table 1).
Sarcopenia was not associated with OS (p = 0.95) or DSS (p = 0.55) in EC patients 
(Figure 2), with median overall survival time 69 months (95% CI 44 – 95 months) 




Table 2. Differences in clinicopathological factors between patients with and without 
sarcopenia (univariate analysis)
Patient characteristics Sarcopenia




Age, median (IQR) 72 (15) 69 (16) 0.37
BMI, median (IQR) 25.7 (6.0) 31.4 (8.9) 0.002*
Histology (%)
    Endometrioid
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Cause of death (%)
    Endometrial cancer






Abbreviations: BMI = Body Mass Index, ECOG = Eastern Cooperative Oncology Group, IQR = interquartile 
range, SMI = skeletal muscle index
Numbers don’t add up due to missing values 
* Significant at p < 0.05 level
In multivariate analysis, sarcopenic obesity (p = 0.048), FIGO stage (p = 0.005) 
and age (p = 0.015) were associated with OS in high-grade EEC patients (Table 3). 
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Figure 2. Sarcopenia is not associated with survival in high-grade endometrial cancer
A. Kaplan Meier curve showing similar OS for patients with sarcopenia
B. Kaplan Meier curve showing similar DSS for patients with sarcopenia
In NEEC patients, FIGO stage (p < 0.001), BMI (p = 0.007) and age (p = 0.024) were 
associated with OS (Supplementary Table 2). For DSS, only FIGO stage (p < 0.001) 
and BMI (p = 0.042) remained significantly associated. 
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FIGO stage 61 1.57 1.15 – 2.14 0.004* 1.69 1.17 – 2.43 0.005*
BMI 66 1.00 0.95 – 1.06 0.88 1.01 0.93 – 1.10 0.76
Age 65 1.05 1.02 – 1.09 0.003* 1.06 1.01 – 1.12 0.015*
Comorbidities (2+) 66 3.24 1.38 – 7.60 0.007* 1.22 0.35 – 4.24 0.78
Sarcopenic obesity 65 3.09 0.93 – 10.3 0.07 4.22 1.02 – 17.6 0.048*
Disease specific survival
FIGO stage 61 1.95 1.32 – 2.87 <0.001* 2.17 1.34 – 3.50 0.002*
BMI 65 1.02 0.96 – 1.09 0.52 1.05 0.94 – 1.16 0.41
Age 66 1.03 0.99 – 1.07 0.15 1.06 0.99 – 1.13 0.10
Comorbidities (2+) 66 3.71 1.23 – 11.20 0.020* 1.56 0.30 – 8.14 0.60
Sarcopenic obesity 65 4.75 1.37 – 16.5 0.014* 3.15 0.67 – 14.78 0.15
Abbreviations: BMI = Body Mass Index, CI = Confidence Interval, FIGO = International federation of 
Gynecology and obstetrics, HR = Hazard ratio.
* Significant at p < 0.05 level
Discussion
To our knowledge, this is the first study assessing sarcopenia and sarcopenic 
obesity in high-grade EC. We showed no association between sarcopenia and OS 
or DSS in high-grade EC. However, an association was found between sarcopenic 
obesity and OS in high-grade EEC. 
Previously, a study by Kuroki et al. showed sarcopenia to have a negative impact on 
recurrence-free survival, but not on overall survival in 122 EC patients28. However, 
they only included 49 patients with grade 3 disease and only 10% of women had 
NEEC tumours. Furthermore, a study by Nattenmüller et al. in 54 EC patients 
showed no impact of sarcopenia on OS27. Grade or subtype was not specified in 
this study. However, in both studies, obesity was not taken into account.
Increased mortality in sarcopenic patients has been reported for all BMI categories 
but is predominantly strong in obese patients23. The prevalence of sarcopenic 
obesity is increasing in elderly adults including adults with cancer26,34. Prado et 
al. showed sarcopenic obesity to be associated with poorer functional status 
and to be an independent predictor of survival in patients with respiratory- and 
gastrointestinal tumours25. 
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Multiple factors are responsible for body composition alterations occurring 
during ageing. Body fat increases with age, peaking at about 60-75 years of age 
and thereafter decreasing35,36. Furthermore, muscle mass and strength start to 
decline progressively around the age of 30 years with a more pronounced loss 
after the age of 6037. In addition, visceral fat tends to increase, while subcutaneous 
fat declines38. Furthermore, fatty infiltration of skeletal muscle (myosteatosis) is 
an important component of aging and frailty39. The increase in body weight and 
fat are due to a progressive decline in total energy expenditure resulting from 
decreased physical activity levels and reduced basal metabolic rate40. Moreover, 
aging is associated with hormonal changes, a pro-inflammatory state, malnutrition 
and loss of alpha-motor units in the central nervous system, all accelerating the 
loss of muscle mass and strength41,42. These hormonal changes are mainly seen 
during and after menopause, in which lack of oestrogen is responsible for a decline 
in muscle mass. Oestrogens are necessary for satellite cell maintenance and 
function, which are essential for skeletal muscle regeneration43,44. 
Although it is generally believed that EEC is highly linked to obesity and NEEC 
have a different mechanistic background, recent data illustrate that NEEC are also 
linked to obesity45. In this study we found evidence for an association between 
poor survival and sarcopenic obesity in high-grade EEC, whereas no association 
was seen in NEEC. This raises questions about the different pathophysiology 
between high-grade EEC and NEEC and further emphasises the current incomplete 
understanding of the obesity-related endometrial carcinogenesis.  
This study underlines the importance of adiposity and muscle loss and its impact on 
survival in EC patients. Several treatment programs have been described to improve 
adiposity and sarcopenia including life style changes with calorie restrictions and 
physical activities34. High intensity resistance training can slow the loss of muscle 
and can be valuable for posttreatment rehabilitation46. Dieli-Conwright et al. 
showed combined resistance and aerobic exercises effectively reduced sarcopenic 
obesity and features of metabolic syndrome in overweight and obese breast 
cancer survivors47. A recent systematic review in adults with sarcopenic obesity 
showed the importance of resistance exercise, while nutritional intervention with 
low-calorie high-protein diet decreased fat mass but did not improve physical 
performance48. Exercise treatments should however be individualised for EC 
patients with sarcopenic obesity because of age, comorbidities and disabilities. 
This study has shown the importance of sarcopenia as a poor prognostic factor in 
high-grade EEC. CT based quantitative measurements of muscle mass using semi-
automated software appears simple, accurate and minimally time-consuming and 




Strengths of our study include the largest study to date of sarcopenia measurements 
on CT-scans in EC patients. In addition, this study included a heterogenous group 
of EC patients with different histology and FIGO stage. Additionally, this study had 
a long follow-up time of over 10 years, in which a relatively high number of events 
(n = 96) was found. 
The main limitation of this study was BMI calculations and all CT-based estimates 
were only measured at one particular time-point and no data regarding possible 
changes in BMI were collected. Furthermore, only 21% of the patients underwent 
full staging procedure including lymphadenectomy. However, the recurrence- 
and survival rate of patients that underwent a complete surgical staging was 
comparable to those that were not fully surgically staged, therefore we believe 
that this has not affected our results. In addition, there was no difference in EEC 
and NEEC with respect to surgical staging.
Conclusion
In our study, sarcopenia was not associated with survival in high-grade EC, 
however sarcopenic obesity seems an independent negative prognostic factor in 
high-grade EEC. Further studies are needed to investigate the role of sarcopenia in 
EC. Specialised rehabilitation with training programs aiming at increasing muscle 
mass could be an important step to improve outcome in these patients. 
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Supplementary Table 1. Differences in clinicopathological factors between patients with 
and without sarcopenic obesity (univariate analysis)
Patient characteristics Sarcopenic obesity 
(N = 17)
No sarcopenic 
obesity (N = 151)
p-value
Age, median (IQR) 72 (9) 70 (17) 0.80
BMI, median (IQR) 32.6 (4.7) 28.3 (8.5) < 0.001*
Histology (%)
    Endometrioid
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    Yes







    Yes






Cause of death (%)
    Endometrial cancer






Abbreviations: BMI = Body Mass Index, IQR = interquartile range.
Numbers don’t add up due to missing values 
* Significant at p < 0.05 level
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95% CI p-value Adjust-
ed HR
95% CI p-value
FIGO stage 107 1.81 1.47 – 2.24 < 0.001* 1.70 1.36 – 2.14 < 0.001*
BMI 105 1.03 0.99 – 1.07 0.13 1.05 1.01 – 1.09 0.007*
Age 110 1.04 1.02 – 1.07 0.001 1.03 1.00 – 1.06 0.024*
Comorbidities 
(2+)
110 1.00 1.00 – 1.00 < 0.001* 0.73 0.40 – 1.33 0.30
Sarcopenic 
obesity
103 0.68 0.29 – 1.58 0.37 0.78 0.32 – 1.89 0.58
Disease specific survival
FIGO stage 107 2.02 1.58 – 2.58 < 0.001* 2.01 1.54 – 2.62 < 0.001*
BMI 105 1.03 0.98 – 1.07 0.24 1.05 1.00 – 1.09 0.042*
Age 110 1.02 0.99 – 1.05 0.22 1.01 0.98 – 1.04 0.57
Comorbidities 
(2+)
110 1.00 1.00 – 1.00 < 0.001* 0.53 0.28 – 1.08 0.08
Sarcopenic 
obesity
103 0.77 0.30 – 1.96 0.59 1.23 0.45 – 3.35 0.68
Abbreviations: BMI = Body Mass Index, CI = Confidence Interval,  FIGO = International federation of 
Gynecology and obstetrics, HR = Hazard ratio.
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Abstract
Purpose
The primary objectives in this review were to (1) assess the association between 
socioeconomic deprivation and survival in endometrial cancer (EC) (2) investigate 
if there is an association between socioeconomic deprivation and peri-operative 
morbidity in EC.
Methods
We performed a systematic review using Medline (1946-2018), Embase (1980-
2018), Cinhal (1981-2018) and the Cochrane Controlled Register of Trials 
to identify studies that reported on the association between socioeconomic 
deprivation and survival or peri-operative outcomes in EC. Included were adult 
women (age ≥ 18 years) diagnosed with primary EC. Two reviewers independently 
selected studies and assessed bias using the Newcastle-Ottawa assessment scale. 
Data extraction was completed using pre-determined forms, and summary tables 
of evidences from the included studies were created.
Results
Nine studies were included in this review with a total number of 369,900 
patients. Eight studies investigated survival and socioeconomic deprivation, and 
the majority showed that socioeconomic deprivation is associated with poorer 
survival in EC. One study assessed the association between deprivation and peri-
operative morbidity and found no difference in 30-day postoperative mortality.
Conclusions
Socioeconomic deprivation seems to be associated with worse survival in EC, 
even after adjusting for stage at diagnosis. However, the impact of important 
confounders such as BMI, smoking and comorbidities is unclear and should 
be assessed. The relationship between socioeconomic deprivation and peri-
operative morbidity is unclear, and further research is needed to evaluate this 
aspect. A standardised measure for socioeconomic deprivation is needed in order 




Endometrial cancer (EC) is the sixth most commonly occurring cancer in women, 
with over 380,000 estimated new cases worldwide and nearly 90,000 estimated 
deaths in 20181. Both incidence and mortality rates have increased over the last 
decades, with obesity being one of the main risk factors2. The increase in obesity 
has multiple underlying factors including socioeconomical factors, with a strong 
association between obesity and lower socioeconomic status (SES) in EC and in 
the general population3,4.
 
Socioeconomic status (SES) is a measure of an individual’s economic and 
sociological standing and is based on income, education and occupation5. SES 
is considered to be an important predictor of health due to health inequalities6; 
however, the relationship between socioeconomic deprivation and cancer is 
complex and multifaceted. The incidence of various cancers including EC is higher 
in deprived groups7. Furthermore, death rates are examined extensively and are 
shown to be higher among the most deprived for most types of cancer8. However, 
the relationship between socioeconomic deprivation and survival in EC patients is 
not fully established. 
Whilst Body Mass Index (BMI) is related to SES and obesity is associated with an 
increased risk of surgical morbidity in EC9, the relationship between socioeconomic 
deprivation and peri-operative morbidity is unclear.
In this systematic review, our aim is to establish the relationship between 
socioeconomic deprivation and survival in EC. In addition, we aim to investigate 
the correlation between socioeconomic deprivation and peri-operative morbidity. 
Objectives
 − To evaluate the association between socioeconomic deprivation and survival 
in EC.
 − To assess the correlation between socioeconomic deprivation and peri-
operative morbidity in EC.
Methods
Study design
We conducted a systematic review of the literature to address the subject of 
socioeconomic deprivation and survival in EC. 
Eligibility criteria
We have used the following definition by Peter Townsend, sociologist, of 
socioeconomic deprivation: a lack of social and economic benefits which are 
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considered to be basic necessities in a society10. We have included studies with 
individual, area-based or both types of measures of socioeconomic deprivation in 
this review.
The following criteria were used to exclude articles from further consideration: 
not in English, contained no original data, meeting abstract only (no full article for 
review) or article did not apply to any of the review questions. We furthermore 
excluded articles that used indirect measures of socioeconomic deprivation such 
as marriage or insurance status only.
Types of studies
We included all study designs evaluating the association between socioeconomic 
status and survival or peri-operative outcomes in EC as a primary outcome. 
Types of participants
Adult women (age ≥ 18 years) diagnosed with primary EC.
Search strategy and selection criteria
This review was performed according to Preferred Reporting Items for Systematic 
reviews and Meta-Analyses (PRISMA) guidelines, and in accordance with the 
principles outlined in the Cochrane Handbook11. We performed systematic 
searches in Medline (1946 until May 2018), Embase (1980 until May 2018) and 
Cinahl (1981 until May 2018) and the Cochrane Controlled Register of Trials. Search 
strategies were adapted accordingly to each database. The used search strategies 
are presented in Appendix 1. In addition, we searched grey literature including 
abstracts of scientific meetings as well as manually checking the reference lists of 
eligible studies to identify any additional studies to include in this review. 
Types of outcome measures
Primary outcomes: Survival including overall survival (OS), cause-specific survival 
(CSS) and recurrence-free survival (RFS).
Secondary outcomes: Peri-operative morbidity in terms of peri-operative 
complications (intra-operative complications including nerve injury, bowel injury, 
bladder injury, ureter injury and vascular injury and post-operative complications 
including wound problems, fascia dehiscence, ileus, urinary tract infection, 
haemorrhage, pneumonia, pelvic abscess, haematoma, venous thromboembolism, 
sepsis, renal complications, cardiac complication and organ failure) and 30-day 
mortality.
Study selection
Two reviewers (HD and KG) independently assessed titles and abstracts of all 
75
4
identified studies. Those studies that clearly did not meet the inclusion criteria 
were excluded. Potentially relevant studies were retrieved in full text and were 
further reviewed for eligibility by both reviewers. 
Data extraction 
Data extraction was completed by two of the authors (HD and KG) using pre-
determined forms which included study author names, publication dates, study 
designs, sample sizes, measures of socioeconomic deprivation, results of univariate 
analyses testing for zero-order association between socioeconomic deprivation 
and survival or peri-operative outcomes and the results of the multivariate analyses 
testing for association between socioeconomic deprivation and survival or peri-
operative outcomes adjusting for control variables. Differences were resolved by 
consensus.
Assessment of risk bias
The risk of bias included in studies was assessed by two authors (HD and KG) 
independently using the Newcastle-Ottawa Quality Assessment Form for Cohort 
Studies which includes selection, comparability and outcome12. Differences were 
resolved by consensus.
Data synthesis
We were unable to conduct a meta-analysis because of the heterogeneity in the 
included studies. However, we created summary tables of evidence from the 
included studies and then examined the relationship between various measures of 




The search strategy identified 127 references in Medline, 183 in Embase and 35 
in Cinahl. Search results were merged, and duplicates were removed, resulting in 
247 unique studies. After screening title and abstract, 16 articles were retrieved 
in full text and were further assessed for eligibility. Subsequently seven studies 
were considered eligible for this review, and a further search of the grey literature 
identified two articles, resulting in the inclusion of nine articles in this review 
(Figure 1).
Study characteristics
The characteristics of the nine studies included in this review are illustrated in 
Table 1. All studies combined resulted in a total of 369,900 EC patients, and all 
studies were of retrospective design. Eight studies included all FIGO stages and 
subtypes of EC, whereas one study only included FIGO stages I to II endometrioid 
endometrial carcinoma (EEC). 
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combined resulted in a total of 369,900 EC patients, and all studies were of retrospective design. Eight 
studies included all FIGO stages and subtypes of EC, whereas one study only included FIGO stages I to 
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n Additional records identified 
through other sources 
(n = 2) 
Full-text articles assessed 
for eligibility 
(n = 16) 
Full-text articles excluded, 
not eligible 
(n = 7) 
Studies eligible for review 
and included in analysis 
(n = 9) 
Records after duplicates removed 
(n = 249) 
Records screened 
(n = 249) 
Records excluded 
(n = 233) 
Figure 1. PRISMA flow diagram
Different measures of socioeconomic deprivation were used: income, level of 
educati n, unemployment, social class, housing tenure and insurance status. 
Furthermore, two studies used the Income Domain of the English Indices of 
Multiple Deprivation (IMD), which are published by the UK Department for 
Communities and Local Govern ent and measure a spectrum of deprivation13.
Risk of bias of included studies
We have assessed the risk of bias with the Newcastle-Ottawa scale. Two studies 
were of poor quality and seven studies were of good quality (Figure 2).
Synthesis of results
Socioeconomic deprivation and survival
Eight studies with 331,568 EC patients assessed survival and socioeconomic 
deprivation (Table 1). A study done by The National Cancer Intelligence Network 
(NCIN) used the income domain of IMD and showed a relationship between 
deprivation and mortality in England, with a higher mortality rate in the more 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Furthermore, three studies15–17 used the median household income as measure of 
SES of which two studies (Madison et al. and Robbins et al.) found an association 
between mortality and deprivation, with a higher income being associated with a 
decreased risk of death15,16. However, in multivariate analysis Robbins et al. did not 
identify SES as a significant predictor of patient outcome, while in the study done 
by Madison et al. the significance remains after adjusting for stage. The third study 
done by Fader et al. found no difference in overall- or recurrence-free survival 
within the different income groups or educational levels, even after adjusting for 
stage17. 
Selection Comparability Outcome/exposure
NCIN, 2013 * * * - * * *
Madison, 2004 * * * * * * *
Robbins, 2013 * * * * * * *
Fader, 2016 * * * * * * *
Cheung, 2013 * * * - * * *
Ueda, 2006 * * * * * * *
Jensen, 2008 * * * * * * *
Figure 2. Risk of bias (Newcastle-Ottawa Scale)
The study done by Cheung et al. looked at county-level family income and found 
a decreased survival in patients living in low-income neighbourhood18, which 
did not remain significant in multivariate analysis, while a study done by Ueda 
et al. used municipality-based SES and found poorer 5-year survival in the low 
unemployment and education municipalities, even after adjusting for stage19. The 
study done by Jensen et al. used six different socioeconomic indicators and found 
no strong association between socioeconomic variables and survival, but survival 
tended to be better for women with higher education and more disposable 
income, however they did not correct for confounders20. Lastly, a study done by 
Seidelin et al. showed education to be associated with higher hazard ratio (HR) for 
death, even after adjusting for confounders such as stage at diagnosis, BMI and 
comorbidities21.
Socioeconomic deprivation and peri-operative morbidity
A study done by Gildea et al. used the income domain of the English IMD to 
assess the relationship between postoperative mortality and deprivation in EC, 
and found no association between income deprivation and 30-day postoperative 
mortality22. No other articles were found, which investigated the association 
between deprivation and peri-operative morbidity in EC.
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Discussion 
This review summarises the current literature about the association between 
socioeconomic deprivation and survival in EC. The results of this systematic review 
suggest a worse survival for more socioeconomically deprived patients, with 
six studies showing low SES being associated with worse survival in univariate 
analysis, and three studies confirming poor outcome in multivariate analysis. 
However, two studies did not show an association.
Previous research has looked at possible explanations for the differences in cancer 
survival within different groups of deprivation, with stage at diagnosis being one 
of the most important factors23. In cervical-, breast- and colorectal cancer, these 
survival differences are related to the differences in participation rate in cancer 
screening programmes, in which women with lower SES and women living in urban 
areas are less likely to participate24. For EC there is no routine screening; however, 
since patients present early with bleeding problems, it is usually diagnosed at an early 
stage, which leads to high survival rates14. This suggests that SES impacts survival in 
EC through other factors which may include BMI, age, smoking and comorbidities.
For EC, factors that are associated with advanced stage at diagnosis include high-
grade lesions, serous histologic subtype, older age and low SES21,25,26. Patients with 
higher socioeconomic position might be more aware of symptoms and present 
quicker to a general practitioner or medical specialist, while low SES patients tend 
to ignore early symptoms of disease such as postmenopausal bleeding21. This 
could partially explain the differences in survival, however most studies included 
in this review with the exception of two (Jensen et al. and NCIN) corrected for 
stage at diagnosis in their analyses. Therefore, it seems that regardless of stage at 
diagnosis, socioeconomic deprivation affects survival in EC. 
Other important factors in cancer survival in general and in EC include BMI, with 
normal-weight women having better survival than obese patients23,27. One of 
the mechanisms that has been suggested to explain the differences in survival 
is the fact that obesity is associated with an increased risk of surgical morbidity9; 
however some studies have shown that it is not an independent predictor but 
likely related to other comorbid conditions28. Since there is a strong relationship 
between obesity and socioeconomic deprivation in EC4, this could potentially be 
an important factor affecting survival in deprived patients; however the articles 
included in this review, with the exception of Seidelin et al., did not include or 
correct for BMI.  
A third factor in cancer survival is comorbidity, previous research has shown a 
decreased survival for EC patients with multiple comorbidities29. Different reasons 
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are reported such as delayed diagnosis, higher rate of postoperative complications, 
a reduction of the possibility of surgery and a lower tolerance of oncological 
treatment30. Since the prevalence of comorbidity tend to be higher among EC 
patients with higher levels of deprivation31, this could also affect survival. Of the 
articles included in this review, only Seidelin et al. corrected for comorbidity and 
found no difference in the odds ratio for death.
Furthermore, age at diagnosis is an important factor in EC survival32. Elderly 
patients often have more aggressive histology and are less likely to receive surgical 
treatment or adjuvant therapy leading to under treatment33. Furthermore, an 
article by Poupon et al. showed 3-year OS rates to be lower than cancer specific 
survival rate, indicating that death in elderly is often a combination of death due to 
cancer as well as to causes other than cancer33. All studies included in this review 
have adjusted for age at diagnosis with the exemption of Cheung et al18. 
Another element in survival in EC is treatment received by patients34. This is 
often influenced by patient characteristics such as age, comorbidities and patient 
preference. Furthermore, the type of treatment centre (cancer centre or smaller 
hospital) also influences the type of treatment offered to patients and influences 
survival in EC35,36. Patients with low SES are less likely to afford travel costs to 
cancer centres, especially if they reside in rural counties. Only half of the studies 
included in this review have taken treatment into account.   
Lastly, smoking status is an important aspect in survival in EC, in which smokers 
show worse survival compared to non-smokers37, although some of the overall 
survival differences may be more attributable to associated co-morbid conditions 
in smokers. None of the studies in this review have corrected for smoking status 
in their analysis. 
BMI, comorbidities and smoking not only affect survival, but are also risk factors 
for peri-operative morbidity in EC9,38,39. Because of the correlation of SES with 
BMI, comorbidities and smoking status, we have tried to investigate if there is 
a relationship between socioeconomic deprivation and peri-operative morbidity, 
however the current literature is scarce and only one study was identified 
which did not show an association between income deprivation and 30-day 
postoperative mortality22. Further research is needed to establish any relationship 
between socioeconomic deprivation and peri-operative morbidity including 30-
day mortality in EC. 
The studies in this review have used different measures of mortality (age-
standardised mortality rate, survival time, disease-specific survival, overall 
survival, 1- and 5-year survival etc.), which is an important issue when comparing 
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results. EC has a relatively high survival rate; however, the 1-year survival will 
be very different to mortality rates and may reflect the individual’s underlying 
comorbidities which may lead to earlier demise. Therefore, it is difficult to compare 
all different measures of mortality.
Despite increasing recognition of the impact of socioeconomic deprivation on 
survival of EC, questions about the strength of its impact and relationship with 
other prognostic factors remain. To address these questions, more studies are 
needed which measure socioeconomic deprivation with a standardised measure 
and also correct for other prognostic variables including BMI, comorbidities and 
smoking status. From this knowledge, interventions to improve survival in lower 
SES patients can then be introduced.
Overall completeness and applicability of evidence 
The majority of women were diagnosed with stage I disease, consistent with 
reported incidence rates40. Literature was scarce about the correlation between 
socioeconomic deprivation and peri-operative morbidity and we only found one 
study that evaluated peri-operative outcomes and SES in EC.
Quality of evidence
The studies included were of a high degree of heterogeneity in study design and 
evaluated a variety of socioeconomic status measures, which lacked in uniformity. 
Different measures were used, each capturing a distinct aspect of SES, which may 
be correlated with other measures, but are not interchangeable41. Furthermore, 
individual SES measures such as income and occupation differ from environmental 
SES measures, which are area-based, and these two measures often do not correlate 
well42. These different measures can all impact results. Area-based measures may 
not accurately represent a patient’s socioeconomic deprivation status, since not 
all people living in a poor area are poor themselves. Furthermore, there is a large 
variety in definitions of socioeconomic deprivation: the definition of a deprived 
person living in the United States might be different from a deprived person living 
in Japan. In addition, in some studies only one indicator of SES was used, while 
others used multiple measures. Furthermore, most studies have not adjusted for 
important confounders. Therefore, it is difficult to draw hard conclusions about 
the strength of the evidence. 
Potential biases in review process
A comprehensive search of the literature with aid of librarian was performed by 
two reviewers independently, including a search of the grey literature. Reviewers 




Comparison with existing literature
A previous review done by Kogevinas et al. about socioeconomic differences in 
cancer survival included six studies about EC and showed survival was poorest 
in low socioeconomic groups in five studies; in three of those studies differences 
were statistically significant. However, the reverse pattern was seen in one study8. 
The association of inequality in survival is supported by several studies that have 
assessed the association between SES and cancer survival in general and that also 
included EC patients43,44,53,45–52, even though several other studies did not find an 
association between deprivation and mortality54–58. 
Conclusion
Socioeconomic deprivation seems to be associated with poorer survival in EC, 
regardless of their stage at diagnosis. However, important confounders such 
as BMI, comorbidities and smoking status should be taken into account. The 
relationship between peri-operative morbidity and socioeconomic deprivation in 
EC is not clear.
Implications for clinical practice
 − Socioeconomic deprivation status should be included in the initial evaluation 
of new patients diagnosed with endometrial cancer 
 − Early and non-invasive diagnostic testing is needed in the community to 
improve access to health care in deprived groups
 − Early referral to cancer support teams is recommended
Implications for research 
 − Further research should be directed to establish any relationship between 
socioeconomic deprivation and peri-operative morbidity in endometrial 
cancer 
 − Furthermore, a standardised measure for socioeconomic deprivation is 
needed in order to establish adequate comparison between studies
 − Further studies should adjust for important confounders such as BMI, 
comorbidities and smoking to assess the true extent of socioeconomic 
deprivation on survival in endometrial cancer 
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Appendix 1. Search strategy
1. endometr* adj2(neoplas* OR carcinom* OR cancer* or tumour* OR tumour)
2. exp endometrial neoplasms/
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Chapter 5. Socioeconomic deprivation and survival in endometrial cancer: The effect of BMI
Abstract
Objectives
 − To determine the association between survival and socioeconomic deprivation 
in endometrial cancer (EC).
 − To evaluate and quantify the effect of socioeconomic deprivation on peri-
operative morbidity and mortality in EC.
Methods
This is a retrospective study of surgically managed EC patients in the Royal Cornwall 
Hospital Truro between January 2006 and August 2017. Patient characteristics, 
overall survival, recurrence-free survival and intra- and postoperative outcomes 
were evaluated across socioeconomic deprivation groups in which socioeconomic 
deprivation was measured with the English Indices of Multiple Deprivation (IMD).
Results
In total, we identified 831 women, of which 690 were included. The median age 
was 66 years with a median BMI of 31 kg/m2 and the majority of tumours were 
endometrioid endometrial carcinomas (EEC, 80%). In EEC, better survival was 
seen in the least deprived patients, however this was not significant in multivariate 
analysis and only age, stage and BMI remained significantly associated. For non-
endometroid endometrial carcinoma (NEEC), no association between survival and 
socioeconomic deprivation was found and only stage was significant. However, 
more affluent patients had significantly higher recurrence rates. In addition, we did 
not find evidence of an association between intra- or post-operative complication 
rates and socioeconomic deprivation.
Conclusion
Socioeconomic deprivation is associated with survival in EC, however after 
adjusting for confounders this association does not remain. Only age, stage and 
BMI are independent prognostic factors for survival. In addition, there is no 





Endometrial cancer (EC) is the most common gynaecological malignancy in 
the United Kingdom (UK), with over 9,000 women being diagnosed annually1. 
The most important risk factor for the development of EC is obesity2, which 
is associated with low socioeconomic status (SES)3,4. SES is the social standing 
or class of an individual or group and is measured as a combination of income, 
education and occupation5. Socioeconomic deprivation is considered to be an 
important predictor of health and survival with major inequalities among different 
levels of deprivation6. 
For most types of cancer, socioeconomic deprivation is associated with survival, 
with more deprived patients showing poorer survival7. A recent systematic review 
showed that socioeconomic deprivation was associated with poorer survival 
in EC, even after adjusting for stage at diagnosis8. However, not only stage at 
diagnosis is associated with worse survival, but grade of disease, obesity and 
comorbidities are also related to survival9,10. The exact interaction between these 
factors, socioeconomic deprivation and survival in EC are unclear.
More deprived patients tend to have higher Body Mass Index (BMI) and more 
comorbidities11. In addition, obesity and multiple comorbidities are associated 
with an increased risk of surgical morbidity in EC12. However, the relationship 
between socioeconomic deprivation and peri-operative morbidity in EC is unclear. 
The aim of this study was to investigate the association between survival and 
socioeconomic deprivation in EC in more detail while taking into account 
confounding factors such as BMI and comorbidities. In addition, we aim to evaluate 
and quantify the effect of socioeconomic deprivation on peri-operative morbidity 
and mortality in patients undergoing surgery for EC. 
Materials and methods
Study design and population
This is a retrospective cohort study in the Royal Cornwall Hospital Trust (RCHT) 
in Truro, UK, on women undergoing surgical treatment for EC. Women with 
histologically proven primary EC receiving surgical treatment at the RCHT between 
January 2006 and August 2017 were identified from the cancer registry of the 
South West Cancer Intelligence Service. Exclusion criteria were: less than 18 years 
of age, incomplete follow-up data and unknown address. Full ethical approval was 
obtained through Health Research Authority (HRA), No: 236426 and the study 
had full Trust approval.
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Data collection
Patient characteristics including date of diagnosis, age at diagnosis, stage, grade, 
histology, treatment modality, intra- and postoperative complications and other 
clinical characteristics were collected from the medical records. The patients postal 
code was used to identify the geographical location of residence, so that it could 
be assigned a deprivation risk using the English Indices of Multiple Deprivation 
(IMD) 201513. 
IMD are published by the UK Department for Communities and Local Government 
and measure a spectrum of deprivation, combining 38 indicators that are grouped 
into seven domains which are differently weighted (income deprivation 22.5%, 
employment deprivation 22.5%, health deprivation and disability 13.5%, education 
skills and training deprivation 13.5%, barriers to housing and services 9.3%, living 
environment 9.3% and crime 9.3%). IMD gives an overall measure of deprivation 
experienced by people living in a certain area for every Lower Layer Super Output 
Area (LSOA) in England. There are 32,844 LSOAs in England, where 1 is the most 
deprived LSOA and 32,844 is the least deprived.
Outcome measures
Primary outcome: overall survival (OS) defined as the length of time from date of 
diagnosis that patients are still alive and recurrence-free survival (RFS) defined as 
the length of time after primary treatment ends that patients survive without any 
signs or symptoms of cancer.
Secondary outcomes: surgical morbidity in terms of intra-operative complications 
(including bowel injury, bladder injury, ureter injury, vascular injury), post-
operative complications (including wound problems, fascia dehiscence, ileus, 
antibiotics usage, urinary tract infection, haemorrhage, pneumonia, pelvic abscess, 
haematoma, venous thromboembolism, sepsis, renal problems, cardiac problems, 
organ failure, relaparotomy, readmission) and other surgical outcomes such as 
hospital stay, blood loss, transfusion and 30- and 90-day mortality. 
Statistical analysis
For analysis purposes, deprivation data was grouped into 3 groups, with 1 being the 
most deprived and 3 being the least deprived. BMI was recorded and categorised 
according to national guidelines: underweight (≤ 18.5 kg/m2), normal range (18.5 
– 24.9 kg/m2), overweight (25 – 29.9 kg/m2) and obese (≥ 30 kg/m2)14.
For normal distributed data continuous outcomes were presented as means or 
medians and standard deviations, categorical data were presented as frequencies 
and proportions. Non-parametric continuous data was compared using the Kruskal-
Wallis test or Mann-Whitney U test, and Pearson Chi-square test or Fisher’s Exact 
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test for categorical data. Survival data were estimated using Kaplan-Meier curves 
and Cox Regression models were used while controlling for possible confounders. 
The statistical significance of differences in outcome between the groups was 
assessed with the log-rank test. P-values less than 0.05 were considered significant 
for all tests. Data were analysed with IBM SPSS statistics version 24.0.
Results
A total of 829 women were diagnosed with EC at the RCHT between January 
2006 and August 2017, of which 722 had undergone surgical treatment. Excluded 
were 19 women who received treatment elsewhere, 14 women with incomplete 
data on their perioperative course and one woman with an unknown postal code. 




A total of 829 women were diagnosed with EC at the RCHT between January 2006 and August 2017, of 
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The median age of included patients was 66 years (SD 10.6) with a median BMI of 31 kg/m2 (SD 7.2) (Table 
1). Majority of tumours were endometrioid tumours (8%), followed by serous (6%) and carcinosarcomas 
(5%). Most women presented with FIGO stage I disease (82%), followed by stage III (7%), stage II (7%) and 
stage IV (3%). The majority of women had two or more comorbidities (53%). Furthermore, 118 women 
(17%) died of which 67 (57%) due to EC and 42% due to other causes such as cardiac or respiratory 
diseases. In addition, 76 (11%) had recurrent disease. The median RFS time was 48.4 months.  
 
 
829 women diagnosed with 
endometrial cancer 
722 women received 
surgical treatment 
Total study population of 
688 women 
Excluded: 
- No surgical management (n = 107) 
Excluded: 
- Treatment elsewhere (n = 19) 
- Incomplete data on perioperative 
course (n = 14) 
- Unknown postal code (n= 1) 
Figure 1. Flow chart of recruitment
Baseline characteristics
The median age of included patients was 66 years (SD 10.6) with a median BMI of 
31 kg/m2 (SD 7.2) (Table 1). Majority of tumours were endometrioid tumours (8%), 
followed by serous (6%) and carcinosarcomas (5%). Most women presented with 
FIGO stage I disease (82%), followed by stage III (7%), stage II (7%) and stage IV 
(3%). The majority f w men had two or  comorbidities (53%). Furth rmore, 
118 women (17%) died of which 67 (57%) due to EC and 42% due to other causes 
such as cardiac or respiratory diseases. In addition, 76 (11%) had recurrent disease. 
The median RFS time was 48.4 months. 
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Table 1. Baseline characteristics.
Characteristics Value
No. of patients 688
Age (years), median 66
BMI (kg/m2), median 31
BMI groups (%)
    < 25 117 (17)
    25 – 30 178 (26)
    > 30 370 (54)
    Unknown 23 (3)
Ethnicity (%)
    Caucasian 679 (99)
    Any other ethnic group 6 (1)
    Unknown 3 (0)
Smoking (%)
    Yes 49 (7)
    No 562 (82)
    Ex-smoker 14 (2)
    Unknown 63 (9)
Parity (%)
     0 114 (17)
     1 110 (16)
     ≥2 388 (56)
    Unknown 76 (11)
Comorbidities (%)
    None 156 (23)
    One 162 (24)
    Two or more 365 (53)
    Unknown 5 (1)
Histology (%) 
    Endometrioid 552 (80)
    Serous 40 (6)
    Carcinosarcoma 33 (5)
    Mixed tumours 17 (3)
    Clear cell 13 (2)
    Mucinous 5 (1)
    Other 21 (3)
    Unknown 7 (1)
FIGO stage (%)
    I 564 (82)
    II 47 (7)
    III 51 (7)
    IV 20 (3)
    Unknown 6 (1)
Grade (%)
    1 257 (37)
    2 243 (35)
    3 151 (22) 
    Unknown 37 (5)
Treatment modality (%) 
    Laparoscopic hysterectomy +/- BSO 355 (52)
    Laparotomy hysterectomy +/- BSO 318 (46)





    Unknown 5 (1)
Adjuvant treatment (%)
    Neoadjuvant 13 (2)
    Adjuvant 195 (28)
    None 464 (67)
    Unknown 16 (2)
Type (neo)adjuvant treatment (%)
    Chemotherapy 89 (43)
    Radiotherapy 166 (80)
    Hormonal treatment 33 (16)
Recurrence (%)
    Yes 76 (11)
    No 596 (87)
    Progression despite treatment 11 (2)
    Unknown 5 (1)
Death (%)
    Yes 118 (17)
    No 570 (83)
Cause of death (%)
    Endometrial cancer 67 (56)
    Other 51 (43)
Deprivation groups (%)
    Most deprived 255 (37)
    Middle deprived 394 (57)
    Least deprived 37 (5)
    Unknown 2 (0)
Abbreviations: BMI = Body Mass Index, FIGO = International Federation of Gynecology and Obstetrics
Socioeconomic deprivation and survival 
Initially all types of EC combined were analysed. The worst OS was seen for the 
middle-deprived group, with similar OS for the least and most deprived groups (p 
= 0.007, Figure 2).   
The mean survival time was 123 months (95% CI 118 - 129) for the most deprived 
patients, 111 months (95% CI 106 – 117) for the middle-deprived group and 
118 (95% CI 101 – 133) for the least deprived group of patients. However, when 
performing a Cox Regression analysis in which we corrected for age at diagnosis, 
BMI, comorbidities, smoking status, histology, stage, grade and type of surgery, 
deprivation was not significantly associated with survival (p = 0.237). Only stage 
(p < 0.001, Risk Ratio (RR) 2.197), grade (p = 0.044, RR 1.381) and age at diagnosis 
(p < 0.001, RR 1.075) were significantly associated with survival. 
For further analyses we subdivided our patients into two categories; endometrioid 
endometrial carcinoma (EEC) versus non-endometrioid endometrial carcinoma 
(NEEC). In EEC, better OS for the least deprived patients was seen (p = 0.034, 
Figure 3).
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Figure 2. Kaplan-Meier plots showing overall survival for different deprivation groups in all 
endometrial cancer patients
Figure 3. Kaplan-Meier plots showing overall survival for different deprivation groups in 
EEC
The mean survival time was 127 months (95% CI 122 – 133) for the most deprived 
patients, 118 months (95% CI 113 – 124) for the middle-deprived group and 
132 (95% CI 119 – 126) for the least deprived patients. When performing a Cox 
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Regression analysis, only age at diagnosis (p < 0.001. RR 1.091), stage (p < 0.001, 
RR 2.652) and BMI (P = 0.043, RR 1.041) remained significantly associated with 
survival. 
For NEEC, least deprived patients seemed to show the poorest survival, however 
this was not statistically significant and numbers were small (p = 0.064, Figure 4). 
Figure 4. Kaplan-Meier plots showing overall survival for different deprivation groups in 
NEEC
For NEEC, multivariate Cox Regression analysis showed only stage (p = 0.003, RR 
1.796) to be associated with survival.
The overall one-year and five-year survival was 95% and 83% respectively. For 
EEC the one-year and five-year survival was 98% and 88% respectively compared 
to 82% and 61% for NEEC.
Socioeconomic deprivation and recurrence
The total recurrence rate was 11% (n = 76) with median time until recurrence of 
15.9 months (SD 22). In total, 19 patients (8%) in the most deprived group, 49 
(13%) in the middle-deprived group and 8 (22%) in the least deprived group had 
a recurrence, which is statistically significant (p = 0.015). When analysed for the 
subgroups, EEC did not show a significant association between socioeconomic 
deprivation and recurrence rates (p = 0.590), however NEEC did show a significant 
(p = 0.017) higher recurrence rate for patients with a better socioeconomic 
position.
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Socioeconomic deprivation and intra-operative complications
In total, 45 patients developed intra-operative complications, but there was no 
significant difference (p = 0.844) in incidence rates among different deprivation 
groups. No difference was found for the different types of intra-operative injuries, 
including bowel, bladder, ureter and vascular injuries (Table 2).










Yes 18 (7) 24 (6) 3 (8) 0.844
No 237 (93) 365 (92) 34 (92)
Individual complications 
Bowel injury 2 (1) 1 (0) 1 (3) 0.150
Bladder injury 1 (0) 0 (0) 0 (0) 0.428
Ureter injury 1 (0) 0 (0) 0 (0) 0.428
Vascular injury 3 (1) 10 (3) 1 (3) 0.472
Other 1 (0) 2 (1) 0 (0) 0.897
Post-operative complications
Yes 54 (21) 83 (21) 8 (22) 0.998
No 201 (79) 308 (78) 29 (78)
Individual complications
Wound 16 (6) 21 (5) 3 (8) 0.745
Fascia dehiscence 3 (1) 4 (1) 1 (3) 0.663
Ileus 5 (2) 3 (1) 0 (0) 0.307
Antibiotics use 42 (17) 55 (14) 5 (14) 0.683
UTI 10 (4) 9 (2) 1 (3) 0.489
Haemorrhage 0 (0) 2 (1) 2 (5) 0.000*
Pneumonia 6 (2) 7 (2) 0 (0) 0.601
Pelvic abscess 4 (2) 0 (0) 0 (0) 0.035*
Haematoma 4 (2) 3 (1) 0 (0) 0.502
VTE 2 (1) 1 (0) 0 (0) 0.561
Sepsis 0 (0) 2 (1) 0 (0) 0.473
Renal 3 (1) 3 (1) 0 (0) 0.725
Cardiac 5 (2) 10 (3) 1 (3) 0.873
Organ failure 1 (0) 4 (1) 0 (0) 0.568
Relaparotomy 4 (2) 5 (1) 3 (8) 0.010*
Readmission 17 (7) 23 (6) 6 (16) 0.059
30-day mortality 0 (0) 3 (1) 0 (0) 0.325
90-day mortality 1 (0) 6 (2) 0 (0) 0.304
EBL, mean (SD) 196 (190) 173 (194) 190 (366) 0.545
Transfusion 2 (1) 10 (3) 1 (3) 0.256
Hospital stay, mean (SD) 4.9 (4) 4.6 (2.9) 4.2 (2.2) 0.732
ICU requirement 15 (6) 17 (4) 1 (3) 0.556
Abbreviations: EBL = estimated blood loss, CU = intensive care unit, SD = standard deviation UTI = urinary 
tract infection, VTE =venous thromboembolism
Data are numbers of patients (%) unless stated otherwise. Numbers do not add up because of missing 
values
*: p < 0.05
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Socioeconomic deprivation and post-operative complications
In total, 145 patients developed post-operative complications, but there was no 
significant difference (p = 0.998) in incidence rates among different deprivation 
groups (Table 2). There was a significant difference in the incidence of haemorrhage 
(p < 0.001), pelvic abscess (p = 0.034) and relaparotomy (p = 0.010) among the 
different deprivation groups.
Crude 30-day postoperative mortality rates were low, with only 3 deaths, 
accounting for 0.45% of women treated surgically. 90-day postoperative mortality 
rates were similarly low, with 7 deaths reported, accounting for 1.01% of women 
treated surgically.
Discussion
The aim of this study was to determine the relationship between socioeconomic 
deprivation and survival in EC in more detail. We recently published a systematic 
review about socioeconomic deprivation and survival in EC, showing deprivation 
seems to be associated with worse survival, however the impact of important 
confounders such as BMI, smoking and comorbidities were unclear and therefore 
should be assessed8. In this study we found an association between socioeconomic 
deprivation and overall survival in EC, with better survival for the least deprived 
patients in EEC.  However, this association was not found after adjusting for 
confounders. Furthermore, socioeconomic deprivation was not associated with 
survival in NEEC. 
To our knowledge, this is the first study to assess survival and EC while looking 
at two different groups; EEC (associated with unopposed oestrogen stimulation 
and obesity) and NEEC (developing in the presence of endometrial atrophy in 
mostly elderly patients, including serous tumours, carcinosarcomas and clear cell 
tumours)15.  For EEC, age at diagnosis, stage and BMI were associated with OS 
and for NEEC, only stage was associated with survival in multivariate analysis. 
Therefore, to improve survival rates in EC, it is not only important to focus on 
early detection and diagnosis but also on obesity, mainly in endometroid tumours, 
which is the vast majority (80%) of EC.
Furthermore, this is the first study assessing the association between recurrence 
and socioeconomic deprivation in EC. We showed recurrences rates to be 
significantly higher in less deprived patients, which is an unexpected finding. We 
would expect an inverse association, since patients with lower SES more often 
ignore symptoms of disease or recurrence and are more reluctant in approaching 
the healthcare system outside of scheduled appointments when they experience 
102
Chapter 5. Socioeconomic deprivation and survival in endometrial cancer: The effect of BMI
symptoms16. Furthermore, more deprived patients tend to have more comorbidities 
and studies have shown more comorbidities to be associated with a higher risk of 
recurrence in EC17. Therefore, further research is needed to fully understand the 
link between recurrences and socioeconomic deprivation.
Finally, we investigated if there is a correlation between socioeconomic status 
and peri-operative outcomes in EC. This study showed a total intra-operative 
complication rate of 6.6% and a postoperative complication rate of 21.2%, which 
is in line with previous research18. However, we did not show a difference in 
intra-operative or postoperative complication rate in EC for different levels of 
deprivation. Only a small number of patients were identified with complications in 
all groups, which makes it difficult to draw any hard conclusions.  
Socioeconomic deprivation and 30-day postoperative mortality has been 
investigated in colorectal cancer, in which deprivation was associated with poorer 
30-day postoperative mortality even after adjusting for stage, comorbidity and 
urgency of surgical resection19. In our study, 30-day postoperative mortality for 
women with EC was low at 0.4%, which is in line with previous research20, with 
no association between socioeconomic deprivation and 30-day postoperative 
mortality. In addition, 90-day postoperative mortality was low as well at 1.0% and 
again there was no association between socioeconomic deprivation and 90-day 
postoperative mortality. Our findings are in line with a study by Gildea et al. which 
also shows no differences in postoperative mortality rates in EC for different levels 
of overall deprivation20. 
We did not find an increased length of hospital stay after surgery in more deprived 
patients. Furthermore, more deprived patients did not require more intensive care 
unit (ICU) stay than less deprived patients. This is in contrast to a study done by 
Smith et al. in colorectal cancer patients, where social deprivation was found to be 
an independent risk factor of postoperative length of stay, despite the effect being 
relatively small21. This difference might be explained by the fact that postoperative 
length of stay is shorter for EC (4-5 days) compared to colorectal cancer patients 
(11-12 days), making it more difficult to establish a difference between different 
groups.
Strengths and limitations
Strengths of this study include the study size, the inclusion of all histological 
subtypes and stages and the subdivision of EC in two different subtypes. Our study 
has limitations due to its retrospective design, including non-randomization and 
completeness of previously recorded data. In addition, this is a single institution 
study, and therefore population level variations in quality of care due to low quality 
providers and institutions in poor neighbourhoods are not accounted for. 
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Furthermore, the Indices of Multiple Deprivation have limitations. They are based 
on geographical areas rather than individual (not all deprived people live in deprived 
areas and vice versa) and they are relative, rather than absolute measures of 
deprivation. However, since they cover a wide range of socioeconomic indicators, 
we believe it to be an accurate measurement for socioeconomic deprivation which 
has been used extensively in previous research22–24.
Conclusion
Socioeconomic deprivation is associated with survival in EC; however, this does 
not remain after correcting for confounders. Only age at diagnosis, stage and BMI 
are independent prognostic factors for survival. Furthermore, recurrence rates 
are higher in more affluent patients. In addition, this study shows no association 
between deprivation and peri-operative morbidity and mortality in EC. 
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Abstract
Background
In endometrial cancer (EC), haematological parameters such as haemoglobin level, 
platelet- and leucocyte counts have shown to be of prognostic relevance. Yet, it 
remains unclear whether these three parameters reflect tumour aggressiveness 
or merely indicate a poorer health status. We hypothesise that anaemia and 
thrombocytosis reflect tumour aggressiveness, whereas leucocytosis may also 
reflects a poorer health status including obesity and comorbidity, with impacting 
survival.
Objectives
To define the relationship of pre-operative anaemia, thrombocytosis and 
leucocytosis with clinicopathological characteristics in EC patients. Furthermore, 
to explore the prognostic relevance in terms of survival of these haematological 
parameters in EC patients, taking into consideration their comorbidities. 
Study design
A retrospective multicentre cohort study of women diagnosed with endometrial 
cancer was performed in 10 hospitals. Pre-operative haematological parameters 
including haemoglobin level, platelet- and leucocyte counts were collected. Defined 
cut-offs were; anaemia: haemoglobin <7.45mmol/L (<12 g/Dl), thrombocytosis: 
platelets >400x109 platelets/L, and leucocytosis: leucocytes >10x109/L. 
Correlations-, Kaplan Meier- and Cox-regression analysis were performed.
Results
A total of 914 women were included. Anaemia was present in 103 (11.3%), 
thrombocytosis in 79 (8.6%) and leucocytosis in 114 (12.7%) women. Anaemia was 
correlated with thrombocytosis, and both were associated with advanced-stage 
disease (Federation International of Gynecology and Obstetrics (FIGO)  III-IV) (P < 
0.001). Leucocytosis was significantly associated with diabetes mellitus (DM), Body 
Mass Index (BMI) >35 kg/m2 and advanced-stage disease (P < 0.001). Patients with 
leucocytosis and DM or high BMI did not show worse outcomes compared to patients 
without DM or high BMI. Anaemia was significantly associated with decreased 
overall- and disease-specific survival, whereas thrombocytosis was associated 
with significant decreased disease-specific survival. Furthermore, age ≥ 65 years, 
anaemia, grade 3 tumour histology and advanced-stage disease (FIGO III-IV) were 
independently associated with reduced overall- and disease-specific survival.
Conclusion
Pre-operative anaemia, thrombocytosis and leucocytosis are related to tumour 
aggressiveness in EC. Anaemia is the most important prognostic factor, whereas 
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leucocytosis is more related to obesity and comorbidity and reflects a poorer 
health status, without impacting survival. Abnormal pre-operative haematological 
parameters can be used to identify patients at risk for advanced-stage disease 
and/or need for additional surgical or adjuvant treatment.
Introduction 
Endometrial cancer (EC) is the most common gynaecologic malignancy in 
industrialized countries with incidence rates rising due to aging population and 
increased rates of obesity1. Most patients are diagnosed at an early-stage and 
therefore have a favourable prognosis, whereas patients with advanced-stage 
disease have a high risk of recurrence and poor outcome1,2. 
Pre-operative risk stratification is important to identify patients with increased 
disease-related risk of mortality. Currently, primary surgical and subsequent 
adjuvant treatment strategies in EC are mostly based on pre-operative tumour type 
and grade of an endometrial biopsy, and final histopathological FIGO (Federation 
International of Gynecology and Obstetrics) stage3. Available clinical biomarkers 
such as haematological parameters might contribute to improved risk stratification 
by identifying patients with advanced-stage disease implicating aggressive tumour 
behaviour4.  
Endometrial carcinogenesis is characterized by chronic inflammation with 
elevated pro-inflammatory cytokines and acute phase proteins5. Overexpression 
of inflammatory cytokines could cause shortened survival of red blood 
cells, suppression of erythroid progenitor cells, impaired iron utilisation, and 
inadequate erythropoietin (EPO) production. Including numerous other factors, 
this inflammatory mechanism contributes to the development of cancer-related 
anaemia6. Furthermore, thrombocytosis and leucocytosis can also be induced by 
tumour derived cytokines or growth factors, which generate a pro-tumorigenic 
environment promoting angiogenesis7-9. Leucocytosis is frequently observed in 
obese patients, in whom adipose tissue in itself establishes a pro-inflammatory 
environment, stimulating carcinogenic cellular proliferation pathways. In this 
way, leucocytosis and obesity may relate to an adverse outcome in EC patients10. 
Furthermore, an association between high leucocyte count and high glucose level 
was found in female cancer patients, related to diabetes11. 
Several studies in EC have studied the relationship of pre-operative haematological 
parameters (anaemia, thrombocytosis and/or leucocytosis) with clinicopathological 
characteristics and the prognostic relevance2,7-9,12-20. However, only the study of 
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Njolstad et al. studied all three pre-operative haematological parameters, without 
specifying the correlation of anaemia, thrombocytosis and/or leucocytosis with 
clinicopathological characteristics13. Therefore, it remains unclear whether these 
parameters reflect tumour aggressiveness or merely indicate a poorer health status.
We hypothesise that anaemia and thrombocytosis reflect tumour aggressiveness, 
whereas leucocytosis may also be related to a poorer health status, including 
obesity and comorbidity, impacting survival in EC. Therefore, the aim of this study 
was to define the relationship of anaemia, thrombocytosis and leucocytosis with 
clinicopathological characteristics in EC patients. Furthermore, we aim to explore 
the prognostic relevance in terms of survival of these haematological parameters 
in EC patients, taking their comorbidities into consideration.
Materials and Methods
Study cohort
An observational multicentre cohort study was performed in women diagnosed 
with EC in 10 hospitals; nine in the Netherlands and one in the United Kingdom 
(UK; Royal Cornwall Hospital Trust). Patients who underwent surgical treatment 
in the nine Dutch participating centres were prospectively included between 
September 2011 until December 2013 in the PIpelle Prospective ENDOmetrial 
carcinoma (PIPENDO) study1. For the participating centre in the UK, data 
were collected retrospectively; the study population consisted of women who 
underwent surgical treatment for EC between January 2006 and January 2015. 
Data collection
For the Dutch participating hospitals, patient characteristics (including age, Body 
Mass Index (BMI), diabetes mellitus (DM) and hypertension), post-operative tumour 
histology, grade and FIGO staging were collected prospectively. Pre-operative 
haemoglobin level, leucocyte- and platelet counts were collected retrospectively 
from hospital records. For the UK centre, all the clinicopathological characteristics 
and pre-operative haematological parameters were collected retrospectively. 
Patients were included if one of the haematological parameters was available 
for analysis. Furthermore, outcomes, including overall survival (OS) and disease-
specific survival (DSS) were collected.
Definition pre-operative haematological parameters 
Anaemia was defined as haemoglobin level <7.45mmol/L= <12g/Dl, thrombocytosis 
as platelet count >400x109 /L and leucocytosis as leucocyte count >10x109/L. 
Outcome measurements
Defining the relationship of anaemia, thrombocytosis and leucocytosis with 
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clinicopathological characteristics in EC patients. Furthermore, to define the 
prognostic relevance in terms of survival of these haematological parameters 
in EC patients, taking into consideration their comorbidities (age, DM, BMI and 
hypertension).
Statistical analysis 
For statistical analyses, Statistical Package for the Social Sciences (SPSS), version 
25.0 (IBM, New York, NY, USA) was applied. The results were considered significant 
with p-value less than 0.05 (p < 0.05). A non-parametric Mann-Whitney U-test was 
used to compare continuous data of haematological values between categories. 
Differences between categories in haematological values and categories were 
compared with χ2 or Fisher’s exact test. 
BMI was subdivided into five categories: BMI < 25, BMI 25 - 30, BMI 30 - 35, BMI 
35 - 40, BMI > 40 kg/m2. FIGO stage was divided binary; stage I-II (early-stage) 
and stage III-IV (advanced-stage). 
Survival analyses were performed using Kaplan-Meier curves (first 10 year after 
diagnosis) and univariate and multivariate Cox-regression. Associations are shown 
as hazard ratio (HR), 95% Confidence Interval (CI) and p-value. OS was defined as 
time from date of diagnosis to date of death from any cause and DSS was defined 
as time from date of diagnosis to date of death by EC, all censored by date of 
last contact. OS and DSS were chosen as survival outcomes to compare overall 
mortality (i.e. while considering factors influencing survival such as comorbidity 
and BMI) with EC-related mortality.
Institutional Review Board approval
For the participating Dutch centres, this study was revised and approved by the 
local medical ethical committee Brabant on November 2018 (Protocol 1129, 
METC, Brabant). 
For the participating UK centre, ethical approval was obtained through the London–
Fulham Ethical committee on January 2015 (reference number 15/LO/0149) and 
the study had full hospital approval. 
Results
Patients
A total of 920 patients with EC were included with a median follow-up of 4.5 years 
(range 0-10 years). Six patients were excluded; two patients based on abnormal 
leucocytosis (>50x109/L) caused by either chronic lymphatic leukaemia or by 
unknown cause, and four patients following final tumour pathology (no malignancy 
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of the uterus). Therefore, the final study population consisted of 914 patients. 
Clinicopathological characteristics of the study cohort are shown in Table 1. The 
mean age of the study population was 66 years with median BMI 29.6 kg/m2. 
Nearly half of all patients were diagnosed with hypertension (n = 433, 47.4%), and 
152 patients (16.6%) with DM. Haemoglobin level was measured in 894 (97.8%) 
patients, platelet count in 721 (78.9%) and leucocyte count in 667 (72.9%) patients. 
Median haemoglobin level was 8.4 mmol/L, median platelet counts 298.3x109 
platelets/L and median leucocyte level 8.1x109/L. Anaemia was present in 103 
(11.3%) patients, thrombocytosis in 79 (8.6%) and leucocytosis in 114 (12.5%). 
Most patients were diagnosed with low-grade (grade 1-2) EC and endometrioid 
histology (71.6% and 83.5%, respectively). Lymphadenectomy was performed in 
209 (22.9%) patients of whom 35 (16.7%) patients had lymph node metastasis. A 
total of 130 (14.2%) patients developed recurrent EC, and 163 (17.8%) patients 
were deceased of whom 101 (62.0%) directly related to EC.
Table 1. Clinicopathological characteristics
Patient characteristics Value (n = 914)
Age (years) 66.2 (27.2-93.8) 
BMI (kg/m2) 29.6 (16.4-60.9)
Diabetes mellitus 152 (16.6)
Hypertension 433 (47.4)
Serum values
Haemoglobin mmol/L 8.4 (3.9-10.6)
<7.45mmol/L 103 (11.3)
Platelets x109 /L 298.3 (13.9-781.0)
>400x109 79 (8.6)












Clear cell 15 (9.9)
Mixed 74 (49.0)
Others 7 (4.6)













Patient characteristics Value (n = 914)
Lymph node status
Positive (N1) 35 (3.8)
Negative (N0) 174 (19.0)
















Data is presented in numbers (%), mean or median (range)
Abbreviations: BMI = Body Mass Index (in kg/m2), CA-125 = cancer antigen 125, FIGO = International 
Federation of Gynecology and Obstetrics, n = number 
1no lymphadenectomy performed
Association of haematological parameters with clinicopathological 
characteristics  
The correlations between anaemia, thrombocytosis and leucocytosis as well as 
their association with clinicopathological characteristics are shown in Table 2. 
There was a significant correlation between anaemia and thrombocytosis (p < 
0.001) and thrombocytosis and leucocytosis (p < 0.001) (shown in detail in Figure 
1). No association between anaemia and leucocytosis was found. Furthermore, 
anaemia, thrombocytosis and leucocytosis were significantly more prevalent in 
patients with advanced-stage disease (FIGO III-IV) (p < 0.001, p < 0.001 and p = 
0.030, respectively) compared to patients presenting with early-stage (FIGO I-II) 
(Figure 2). In addition, anaemia was significantly more often observed in patients 
with grade 3 tumours (p = 0.006). Anaemia and thrombocytosis were significantly 
related to patient outcomes. Anaemia was related to distant recurrence, EC-
related- and overall mortality (p<0.001 for all), and thrombocytosis associated 
with EC-related mortality (p = 0.015) (Table 2). 
Association of haematological parameters with patient comorbidities
Pre-operative haemoglobin, leucocyte- and platelet count in relation to patients’ 
characteristics are shown in Table 3. Leucocytosis was significantly associated 
with increased BMI (p = 0.015) and DM (24.3% vs 14.8%, p = 0.031, odds ratio 
(OR) 1.72 [CI 1.04-2.83]). In Figure 3, the percentage of patients with leucocytosis 
is shown for the overall patient population and the BMI subcategories. Only BMI 
35-40 and >40 kg/m2 were significantly associated with leucocytosis (OR 1.98 [CI 
1.15-3.42] p = 0.014, OR 2.29 [CI 1.31-3.97] p = 0.003, respectively).
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Figure 1. Percentage of patients with anaemia or leukocytosis distributed by platelet count
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≥7.45mmol/L  66.3 ± 
9.7
0.481 30.9 ± 
6.9
0.701 127 (85.2) 0.174 372 (87.9) 0.635




22 (14.8) 51 (49.5)
Platelets 
≤400x109/L 66.7 ± 
10.0
0.008* 31.2 ± 
7.1
0.256 108 (90.0) 0.713 319 (49.5) 0.276




12 (10.0) 34 (43.0)
Leucocytes
≤10x109/L  66.6 ± 
10.2
0.229 30.7 ± 
6.8
0.015* 81 (75.7) 0.031* 266 (81.1) 0.222




26 (24.3) 62 (18.9)
Data is presented in numbers (%), mean ± SD and median ± IQR
Abbreviations:  BMI = Body Mass Index
* p < 0.05
Figure 3. Overall patient population and Body Mass Index subgroups in relation to 
leucocytosis
Pre-operative haematological parameters and their association with survival outcomes
Explorative survival outcomes with all haematological parameters, individual 
and combined, are shown in Supplementary Figure 1A-B. Patients with anaemia, 
thrombocytosis and leucocytosis (n = 10) combined showed significantly poorer 
10-year OS and DSS (60% and 70% respectively) compared to patients with 
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normal levels of haemoglobin, thrombocytes and leucocytes (n = 456) (86.2% and 
92.8% respectively). Anaemia showed to be the most important prognosticator. 
Detailed 10-year survival of anaemia and thrombocytosis is demonstrated 
in survival curves Figure 4A-B. Patients with anaemia or both anaemia and 
thrombocytosis showed comparable poor 10-year OS and DSS (67.2% vs. 66.7% 
and 77.6% vs 75.0% respectively). The detailed 10-year survival of leucocytosis 
and anaemia is shown in Figure 4C-D. Patients with anaemia and leucocytosis had 










Figure 4. Kaplan-Meier survival curves of anaemia and thrombocytosis and anemia and 
leukocytosis 
A. Overall survival for anaemia with and without thrombocytosis. 
B. Disease-specific survival for anaemia with and without thrombocytosis. 
C. Overall survival for anaemia with and without leucocytosis. 
D. Disease-specific survival for anaemia with and without leucocytosis.
Women with leucocytosis and comorbidities (DM / hypertension / age ≥ 65 years 
/ age ≥ 70 years / BMI ≥ 30 kg/m2 / BMI ≥ 35 kg/m2 / BMI ≥ 40 kg/m2) did not 
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have a significantly worse survival compared to women with leucocytosis without 
comorbidities (data not shown). Only patients with leucocytosis and normal BMI 
(BMI < 25 kg/m2) showed significantly lower 10-year DSS of 85% (p = 0.041) 
compared to all patients with leucocytosis (data not shown). 
Prognostic relevance of pre-operative haematological parameters
Univariate analysis showed significantly decreased OS and DSS for patients with 
anaemia, and significantly decreased DSS for patients with thrombocytosis (Table 4-5). 
Table 4. Cox regression analysis univariate and multivariate of overall survival
Variable Univariate OS Multivariate OS
HR 95% CI of 
HR




BMI ≥ 30 0.89 0.65-1.22 0.495
Age ≥ 65 2.89 2.03-4.13 <0.001* 2.94 2.01-4.29 <0.001*
Diabetes Mellitus 1.63 1.13-2.35 0.008* 1.39 0.95 -2.04 0.090
Hypertension 1.56 1.14-2.14 0.005* 1.18 0.84-1.66 0.321
Haematological parameters
Anaemia 2.73 1.89-3.96 <0.001* 2.29 1.55-3.37 <0.001*
Leucocytosis 1.49 0.96-2.31 0.085
Thrombocytosis 1.27 0.77-2.10 0.336
Post-operative histology
Histology - grade 3 tumour 4.30 3.09-5.97 <0.001* 2.69 1.90-3.83 <0.001*
FIGO stage
I-II vs III-IV 9.34 6.75-12.91 <0.001* 5.49 3.79-7.95 <0.001*
Abbreviations: CI = Confidence Interval, HR = Hazard Ratio, OS = Overall Survival 
* p < 0.05
Table 5. Cox regression analysis univariate and multivariate of disease-specific survival
Variable Univariate DSS Multivariate DSS
HR 95% CI of 
HR




BMI ≥ 30 0.74 0.49-1.10 0.138
Age ≥ 65 2.58 1.65-4.00 <0.001* 2.68 1.57-4.58 <0.001*
Diabetes Mellitus 0.98 0.57-1.67 0.945
Hypertension 1.42 0.95-2.09 0.083
Haematological parameters
Anaemia 3.16 2.00-4.99 <0.001* 1.84 1.04-3.26 0.034*
Leucocytosis 1.66 0.95-2.87 0.072
Thrombocytosis 1.91 1.09-3.35 0.024* 1.33 0.72-2.45 0.355
Post-operative histology
Histology - grade 3 tumour 8.54 5.33-13.71 <0.001* 4.65 2.64-8.19 <0.001*
FIGO stage
I-II vs III-IV 17.12 11.52-25.44 <0.001* 7.79 4.73-12.84 <0.001*
Abbreviations: CI = Confidence Interval, HR = Hazard Ratio, DSS = Disease Specific Survival 
* p < 0.05
119
6
In multivariate analysis, age ≥65 years, DM, anaemia, grade 3 tumour and 
advanced-stage disease (FIGO III-IV) were independently associated with reduced 
OS (Table 4). Age ≥65 years, anaemia, grade 3 tumour and advanced-stage disease 
(FIGO III-IV) were independently associated with reduced DSS (Table 5).
Discussion 
Principal findings
To our knowledge, this is the largest study to date investigating the relationship of 
pre-operative haematological parameters with clinicopathological characteristics 
and survival in EC. Preoperative anaemia and thrombocytosis are significantly 
associated with advanced-stage disease. Moreover, anaemia is associated with 
thrombocytosis and grade 3 tumour. EC patients with anaemia or both anaemia 
and thrombocytosis showed comparable poor survival (OS and DSS). Furthermore, 
anaemia was identified as an independent prognostic factor for both OS and DSS, 
in addition to age ≥ 65 years, grade 3 tumour and advanced-stage disease. Pre-
operative leucocytosis was significantly associated with increasing BMI, DM and 
advanced-stage disease, yet did not show a significant poorer survival in EC patients.
Results
A significantly higher rate of anaemia in patients with advanced-stage disease 
was found, in line with earlier published data12,14,15. The relation between anaemia 
and grade 3 tumour supports the overall more aggressive tumour behaviour in 
these grade 3 tumours. Previous studies also support the association between 
anaemia and thrombocytosis as found in our study12,15. This correlation may be 
explained by the involvement of erythropoietin (EPO) in the development of 
thrombocytosis that is associated with cancer-related anaemia. Increased EPO 
levels result in an increase of megakaryocyte maturation which causes increased 
platelet production21. As a consequence, the common aetiology of anaemia and 
thrombocytosis may explain our observed relation between thrombocytosis 
and advanced-stage disease, and is in line with three recent meta-analyses9,16,17. 
The studies by Bai et al. and Nie et al. showed a significant association between 
thrombocytosis and clinicopathological characteristics, in particular for advanced-
stage disease9,16. Although increased EPO levels may partly explain the occurrence 
of anaemia and thrombocytosis, further mechanisms are not fully elucidated. 
Some studies hypothesised that platelets infiltrate tumour tissue and contribute to 
tumour growth by secreting pro-tumorigenic factors and pro-angiogenic factors, 
while others suggested a platelet-cancer interaction is formed to facilitate cancer 
cell migration, which contributes cancer metastasis22-24. 
Furthermore, a correlation between leucocytosis and advanced-stage disease 
was found, similar to previous studies2,8,18,20. This mechanism may be related by 
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upregulation of inflammatory cytokines and hematopoietic growth factor through 
tumour cells and promoting enhanced inflammation, leucocytosis, angiogenesis 
and tumour cell proliferation5,25. Njolstad et al. studied all three pre-operative 
haematological parameters and showed an association between advanced-stage 
EC and lower haemoglobin levels, elevated platelet- and elevated leucocyte 
counts. Yet, in specifically this analysis, they did not further dichotomize into 
anaemia, thrombocytosis and leucocytosis13. Our findings support the theory that 
pre-operative anaemia, thrombocytosis as well as leucocytosis may reflect tumour 
aggressiveness in EC.
Besides the increased leucocyte levels in advanced-stage EC, we hypothesised 
leucocytosis to be a poor prognostic factor especially in patients with inflammatory-
related comorbidities such as DM and obesity. However, while women with DM 
and obesity were more likely to show leucocytosis10,11, leucocytosis was not an 
independent prognostic factor in EC, and even combined with obesity or DM it 
did not impact outcome. 
Pre-operative haematological parameters also appear relevant in survival outcomes 
of EC8,9,14-18,20. In our study, anaemia was an independent prognostic factor in 
multivariate analyses, which has not been reported by previous studies14,15. 
However, our study included the largest number of patients to date (n = 914 vs. n = 
61 and n = 228). Three recently performed meta-analyses, including 2500-3500 EC 
patients, reported conflicting results regarding pre-operative thrombocytosis and 
outcome9,16,17. Our study showed no reduced OS for patients with thrombocytosis, 
which is in line with two meta-analyses16,17. We did, however, show significant 
reduced univariate DSS, in line with two previous studies also included in meta-
analyses13,26. Furthermore, the study of Worley et al. described leucocytosis as an 
independent prognostic factor for EC8, however our study and the recent study of 
Salem et al. did not replicate this finding20. 
Pre-operative haematological parameters may be used separately or combined to 
increase prognostic significance. Njolstad et al. showed significantly worse DSS in 
patients with anaemia, leucocytosis and thrombocytosis combined, which is in line 
with our results13. 
Clinical implications
Patients with abnormal pre-operative haematological parameters should be 
identified as high-risk patients, who may require an extended diagnostic work-up 





Future research in prospective trials should be performed by focusing on novel 
treatment strategies for EC patients with abnormal pre-operative haematological 
parameters. For example, examining the effect of surgical staging and/or adjuvant 
therapy in terms of survival on EC patients with abnormal haematological 
parameters compared to EC patients with normal haematological parameters. 
Furthermore, our study did not investigate the metabolic syndrome, this could 
be a next step, in which identification of patients with metabolic syndrome pre-
operatively warrants further treatment of metabolic syndrome post-operatively. 
Limitations and strength
Our results may be limited by the small number of patients who underwent 
complete surgical staging including lymphadenectomy (22.8%). This could have 
influenced our results of anaemia as good prognosticator, however survival 
analyses in patients with early-stage disease (FIGO I-II) still showed shorter OS and 
DSS for patients with anaemia (data not shown). Therefore, we believe this has only 
minimal impact on our study results. Another limitation is the partly retrospective 
collection of data; inherent to the retrospective design of the study, haemoglobin 
level, platelet- and leucocyte count were not available for each included patient. 
To our knowledge, we are the first to study the relationship of all three pre-
operative haematological parameters with clinicopathological characteristics and 
prognostic outcome in EC. Other strengths of this study include its multicentre 
design, the largest patient cohort to date, and the well-documented and long 
follow-up period.
Conclusion
In conclusion, pre-operative anaemia, thrombocytosis and leucocytosis are related 
to tumour aggressiveness in EC. Anaemia has the most important prognostic 
relevance, and could occur with thrombocytosis. Leucocytosis appears more 
related to obesity and comorbidity and reflects a poorer health status, without 
impacting survival.
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Supplementary Figure 1. Kaplan-Meier survival curves of the haematological parameters
A. Overall survival of anaemia, thrombocytosis and leucocytosis, separately and combined.  
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Abstract
Purpose
We conducted a systematic review to evaluate the overall diagnostic accuracy of 
microRNAs (miRNAs) in detecting endometrial cancer (EC).
Methods
A systematic search of Medline, Embase, Cinahl and the Cochrane Controlled 
Register of Trials was performed to identify studies reporting on the diagnostic 
value of miRNA in EC patients. Included were diagnostic studies looking at miRNA 
expression in women diagnosed with EC. Two reviewers independently selected 
studies and assessed quality of studies using the Quality Assessment of Diagnostic 
Accuracy Studies 2 (QUADAS-2) score system. Data extraction was completed 
and the vote-counting strategy was used to rank miRNAs. 
Results
26 studies were included with a total number of 1,400 EC patients reporting on 106 
differentially expressed miRNAs. The most frequently found up-regulated miRNA 
was miR-205 followed by miR-200c, -223, -182, -183 and -200a. In addition, miR-
135b, miR-429, miR-141 and miR-200b were also frequently up-regulated. There 
was less consensus on down-regulated miRNAs.
Conclusion
MiRNAs yield a promising diagnostic biomarker potential in EC, especially miR-
205, the miR-200 family and miR-135b, -182, -183 and -223. However, no 
sufficient high-quality data are available to draw hard conclusions. More research 
is needed to validate the diagnostic potential of these miRNAs in larger studies. In 
addition, the potential of urine as a non-invasive biofluid should be investigated 




Endometrial cancer (EC) is the most common malignancy of the female genital 
tract and the 8th cause of death in women in the United Kingdom (UK)1. Two 
different subtypes of EC have been described: type I tumours are mostly 
endometrioid adenocarcinomas and are associated with unopposed oestrogen 
stimulation and obesity and are often preceded by endometrial hyperplasia2. Type 
II tumours on the other hand are predominantly serous carcinomas, are commonly 
described as oestrogen independent arising in atrophic endometrium and are less 
well differentiated and therefore haver poorer prognosis2,3. The large majority 
of endometrial cancer are type I endometrioid, which is associated with good 
prognosis4. This is largely because women present early with bleeding problems 
and are therefore diagnosed at an early stage5. However, between 15 to 25% of 
women present with advanced stage disease (stage III or stage IV) with a 5-year 
survival varying from 40% to 79% for FIGO stage III, and from 0% to 24% for FIGO 
stage IV disease6. 
At the moment, diagnosis of EC is made by combination of transvaginal ultrasound 
scan (TVUS) and endometrial biopsy, which is an invasive and uncomfortable 
investigation with Visual Analogue Scale (VAS) pain score of 6.5 in postmenopausal 
women7,8. In addition, high numbers of technical problems (12-23%) and insufficient 
amount of tissue (16-68%) in obtaining endometrial biopsy have been described9. 
Therefore, the identification of validated and non-invasive diagnostic biomarkers 
are needed. These biomarkers need to be accurate in order to improve earlier 
diagnosis and outcomes including survival.
MicroRNAs (miRNAs) are small noncoding RNAs involved in posttranscriptional 
regulations of various cellular processes and over 2,000 human miRNAs are 
identified10,11. MiRNAs have been demonstrated to play a major role in a wide 
range of developmental processes including metabolism, cell proliferation, 
apoptosis and developmental timing12. Overexpressed miRNAs may function 
as both oncogenes (through downregulation of tumour-suppressor genes) and/
or regulator of cellular processes such as cell differentiation or apoptosis. This is 
thought to be how miRNAs are associated with the development of different cancer 
types such as colorectal, breast, ovarian and endometrial cancer13–16, although the 
exact pathways are not entirely understood. Because of their potential role as 
agents controlling cell growth and differentiation, miRNAs have been proposed 
to be good candidates for cancer diagnosis and therapy17. In addition, previous 
systematic reviews show a promising diagnostic potential of miRNA in cancer 
types such as ovarian and pancreatic cancer18,19, however the diagnostic value of 
miRNA for endometrial cancer remains unclear. Results of published studies are 
inconsistent due to differences in study design, specimen types and miRNAs and 
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different groups have obtained conflicting conclusions. 
MiRNAs can be detected in fixed tissue specimens but also in blood, serum, urine 
and other body fluids20. To date it is unclear which specimen type can be used to 
achieve the most reliable and feasible biomarker for the detection of EC. 
Therefore, this systematic review was conducted to summarize the global 
research and to evaluate the potential diagnostic value of miRNAs in detecting 
endometrial cancer. The aim of this systematic review is to provide guidance for 




This review was performed according to Preferred Reporting Items for Systematic 
reviews and Meta-Analyses (PRISMA) guidelines, and in accordance with the 
principles outlined in the Cochrane Handbook21. Systematic searches were 
performed in Medline (1946 until May 2019), Embase (1980 until May 2019) and 
Cinahl (1981 until May 2019) and the Cochrane Controlled Register of Trials with 
the following terms: (‘microRNA’ OR ‘miRNA’ OR ‘miR’) AND (‘endometrial cancer’ 
OR ‘endometrial carcinoma’ OR ‘endometrial neoplasm’ OR ‘uter* carcinoma’ OR 
‘uter* cancer’ OR ‘uter* neoplasm’). Search strategies were adapted accordingly 
to each database. In addition, grey literature was searched including abstracts 
of scientific meetings as well as manually checking the reference lists of eligible 
studies to identify any additional studies to include in this review. 
Study inclusion/exclusion criteria
Studies were considered eligible if publications met all the following criteria: (1) 
the study concerned the diagnostic value of miRNAs; (2) histological subtype was 
specified as primary endometrial cancer; (3) studies used real-time quantitative 
reverse transcription polymerase chain reaction (qRT-PCR) techniques to detect 
miRNA expression, (4) the study was in English; (5) the study was conducted in 
human subjects; (6) the study was not a review, abstract or editorial article. Cell 
line models were excluded due to the limitations cell lines models have in terms of 
the in vitro adaptation of cells to culture conditions, which sometimes leads to the 
discrepancy between the experimental and clinical outcomes22.
Study selection
Two reviewers (HD and KG) independently assessed titles and abstracts of all 
identified studies. Those studies that clearly did not meet the inclusion criteria 
were excluded. Potentially relevant studies were retrieved in full text and were 
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further reviewed for eligibility by both reviewers.
Data extraction
Data extraction was completed by two reviewers (HD and KG) and disagreements 
were resolved by consensus. The necessary information and data were extracted 
from the final eligible articles as follows: first author, year of publication, country 
of origin, number of cases and controls, histology type, miRNA expression test 
methods, type of specimens, cut-off values, expression changes and sensitivity 
and specificity.
Trial quality assessment
The methodological qualities of the selected eligible articles were assessed by the 
Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) score system23. 
The QUADAS-2 tool combines the patient selection index, index test, reference 
standard, flow and timing to evaluate risk of bias and applicability. The seven items 
(four items on risk of bias and three items on applicability) were assessed for all 
included articles. Two authors independently tested the pilot QUADAS-2 items 
(HD and KG) and discrepancies were resolved by consensus.
Ranking of miRNA
In order to collect and sum up the results of the included studies, the vote-
counting strategy was used24. The vote-counting strategy ranks biomarkers on the 
basis of one principal and two secondary criteria and is the most common and 
most frequently cited strategy to rank biomarker candidates systematically24,25. 
The principal criterion is made up of the number of studies in which each study 
showing significant differential expression in the same direction (either up- or 
down-regulated) for a biomarker counts as a vote in favour of that biomarker 
being real. The secondary criteria are (1) total sample size summed across all of 
the supporting studies (the assumption being that larger studies tend to be more 
reliable) and (2) mean fold change (based on the idea that large differences in 
biomarker expression are more likely to be confirmed than small differences). 
Results
Study selection
The flow diagram of the selected studies is depicted in Figure 1. 
The initial literature search identified 3,253 articles, from which 42 duplicates 
were excluded. Of the remaining 3,211 articles, 3,142 were excluded based on 
title and abstract screening. The search identified 69 full texts, of which 43 articles 
were excluded for the following reasons:
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 − In vitro studies (using cell lines)
 − Not diagnostic
 − Only included patients after adjuvant radiotherapy
 − Compared EC with ovarian cancer
 − Did not have a comparison group
 − Abstracts only
 − Only focused on sarcomas 
 − Focused on the prediction of lymph node metastasis and miRNA expression 
In addition, no other potential articles from the references of other reviews in the 








The flow diagram of the selected studies is depicted in Figure 1.  
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Figure 1. PRISMA flow diagram
Study characteristics and quality assessment





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2. Summary of bias risk assessment results for QUADAS-2
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In this review, 26 articles were included with a total of 2,110 women of which 1,400 
had EC, 71 had either simple or complex atypical hyperplasia and 639 women had 
benign endometrium or polyps. The majority of studies were conducted in Asia 
(12 articles), 8 in Europe and 6 articles were conducted in United States/Canada. 
There were 16 studies that detected miRNAs in tissue specimens (Formalin-Fixed, 
Paraffin-Embedded (FFPE) or fresh frozen tissue), 5 studies that used serum15,26–29, 
1 study detected miRNA in plasma30 and 1 study used urine as bio-fluid 31. Two 
studies used both tissue and plasma samples and one study used both liquid 
based cytology (LBC) endometrial samples and tissue samples32. The majority 
of the studies only included EEC (13 articles), 6 did not specify which subtype 
they included and 5 articles included both subtypes of EC (EEC and NEEC)15,33–36. 
Furthermore, 1 article only included serous endometrial carcinomas37 and 1 article 
included both serous endometrial carcinomas and EEC but no other EC subtypes38. 
All studies used real-time quantitative reverse transcription polymerase chain 
reaction (qRT-PCR) methods to detect miRNA expression, either solely or after 
microarray or Northern Blot analysis. The risk of bias and applicability of these 
studies were evaluated based on QUADAS-2 and summarized in Figures 2 and 
3. There was a high risk of bias in all studies on patient selection, index test and 
reference standard but a low risk of bias for flow and timing. Furthermore, there 
were no applicability concerns in any of the studies included in this review.
Figure 3. Quality of included studies according to QUADAS-2 guidelines
Differentially expressed miRNAs from ranking
A total of 106 differentially expressed miRNAs were identified of which 19 were 
reported in at least two studies. Out of these 106 miRNAs, 55 were upregulated 
(Table 2). The most frequently found up-regulated miRNA was miR-205, which 
was reported in 10 articles and showed a mean fold change of 198.08 when tested 
in 134 EC patients and 64 control patients. Furthermore miR-200c was reported 
in 8 articles to be up-regulated in EC (mean fold change 27.99), in addition the 
following miRNAs were reported in 5 articles: miR-223 (mean fold change 40.17), 
miR-182 (mean fold change 11.41), miR-183 (mean fold change 8.75) and miR-
200a (mean fold change 5.20). 
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Table 2. Up-regulated miRNAs reported in all studies in all specimen types with fold changes








Studies with fold 
change reported
miR-205 10 134 64 198.08 4
miR-200c 8 164 83 27.99 4
miR-223 5 144 99 40.17 3
miR-182 5 141 79 11.41 3
miR-183 5 141 79 8.75 2
miR-200a 5 155 89 5.20 4
miR-135b 3 96 35 35.59 2
miR-429 3 117 61 6.83 3
miR-141 3 103 51 4.25 2
miR-200b 3 103 51 3.86 2
miR-200a* 2 73 31 26.96 1
miR-222 2 26 22 19.16 1
miR-141-3p 2 77 68 15.36 2
miR-200c-3p 2 28 62 15.34 1
miR-186 2 26 22 11.39 1
miR-200b* 2 73 31 6.52 1
miR-15b 2 40 49 6.10 1
miR-106a 2 68 48 2.80 2
miR-135a 1 23 4 34.05 1
miR-205-5p 1 28 62 24.19 1
miR-182-5p 1 28 62 22.76 1
miR-200b-3p 1 28 62 16.19 1
miR-92a 1 73 31 15.63 1
miR-9-5p 1 16 34 15.05 1
miR-27a 1 40 49 5.63 1
miR-210 1 38 28 5.23 1
miR-96 1 73 31 4.27 1
miR-194 1 38 28 4.11 1
miR-95 1 38 28 4.09 1
miR-155 1 38 28 3.87 1
miR-18a* 1 30 20 3.65 1
miR-222-3p 1 12 28 3.43 1
miR-96-5p 1 49 6 3.20 1
miR-103 1 38 28 3.00 1
miR-151 1 38 28 2.85 1
miR-34a 1 30 20 2.63 1
miR-92a-1* 1 30 20 2.47 1
miR-887-5p 1 50 50 2.41 1
miR-20a* 1 30 20 2.34 1
miR-106b* 1 30 20 2.34 1
miR-449a 1 73 31 2.26 1
miR-17* 1 30 20 1.99 1
miR-185 1 30 20 1.85 1
miR-1228 1 73 31 1.18 1
miR-146 1 141 20 NR 0
miR-425 1 141 20 NR 0
miR-1290 1 73 31 NR 0
miR-944 1 68 20 NR 0
miR-16 1 67 15 NR 0
miR-128a 1 67 15 NR 0
table continues
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Studies with fold 
change reported
miR-148b 1 67 15 NR 0
miR-196a 1 67 15 NR 0
miR-301 1 67 15 NR 0
miR-582-5p 1 67 15 NR 0
miR-499 1 28 14 NR 0
NR = not reported
** mean fold change as found by qRT-PCR
Other promising up-regulated miRNAs listed in 3 articles were: miR-135b, miR-
429, miR-141 and miR-200b. MiRNAs only listed up-regulated in one or two 
articles can be found in Table 2. 
There was less consensus on miRNAs that are down-regulated in women with EC 
(Table 3), with 44 different miRNAs being down-regulated. However, all miRNAs 
were only reported in 1 article15,26,35,37,39–44. MiR-137 and miR-129-3p showed the 
largest mean fold change (115.15 and 42.30 respectively) but were only found in 
a small cohort (sample size EC 23 and sample size control 4 patients)38. MiR-410 
was found to have a mean fold change of 13.91 and was tested in a slightly larger 
cohort (sample size EC 73 and sample size control 31 patients)40.
Table 3. Down-regulated miRNAs reported in all studies in all specimen types with fold 
changes








Studies with fold 
change reported
miR-137 1 23 4 115.15 1
miR-129-3p 1 23 4 42.30 1
miR-410 1 73 31 13.91 1
miR-503 1 14 10 8.60 1
miR-1247 1 30 20 5.31 1
miR-376c 1 30 20 3.64 1
miR-377 1 30 20 3.34 1
miR-26a-5p 1 49 6 3.10 1
miR-214 1 30 20 2.90 1
miR-150-5p 1 49 6 2.70 1
miR-370 1 30 20 2.68 1
let-7f-5p 1 49 6 2.60 1
miR-26b-5p 1 49 6 2.60 1
let-7c-5p 1 49 6 2.50 1
miR-23b-3p 1 49 6 2.40 1
miR-125b-5p 1 49 6 2.30 1
miR-126-3p 1 49 6 2.30 1
miR-195-5p 1 49 6 2.20 1
miR-424-5p 1 49 6 2.20 1
miR-374a-5p 1 49 6 2.10 1
let-7a-5p 1 49 6 2.00 1












Studies with fold 
change reported
miR-125a-5p 1 49 6 2.00 1
miR-542-5p 1 14 10 2.00 1
miR-337-5p 1 30 20 1.94 1
miR-1305 1 73 31 1.77 1
miR-758 1 30 20 1.61 1
miR-300 1 30 20 1.56 1
miR-93 1 176 100 NR 0
miR-125 1 67 15 NR 0
miR-34 1 67 15 NR 0
miR-30a-3p 1 40 26 NR 0
miR-301b 1 34 14 NR 0
miR-10b 1 28 14 NR 0
miR-195 1 28 14 NR 0
miR-30a-5p 1 28 14 NR 0
miR-101 1 21 7 NR 0
miR-10b* 1 21 7 NR 0
miR-133a 1 21 7 NR 0
miR-133b 1 21 7 NR 0
miR-152 1 21 7 NR 1
miR-29b 1 21 7 NR 0
miR-34b 1 21 7 NR 0
miR-411 1 21 7 NR 0
NR = not reported
** mean fold change as found by qRT-PCR
For 7 miRNAs (miR-203, miR-21, miR-204, miR-9, miR-199b, miR-99a and miR-
100) an inconsistent altered expression was found (Table 4). MiR-203 was found 
up-regulated in 3 studies with mean fold change 4.19, however was also found 
down-regulated in one study28,40,45,46. 
Table 4. MiRNAs with inconsistent direction of change
































































































NR = not reported
** mean fold change as found by qRT-PCR
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Differentially expressed miRNAs per specimen type
The included articles were subdivided according to specimen subtype: tissue 
specimens (19 articles), serum/plasma (8 articles), urine (1 article) and LBC (1 
article) (Supplementary Tables 5-12). For tissue specimens, the results were similar 
to the previously reported results with the only difference being that miR-200c was 
listed in 7 articles (previously 8) and miR-223 in 2 (previously 5). For serum/plasma 
samples miR-223 was most often reported up-regulated in 3 studies, followed by 
miR-222, miR-186 and miR-203 in 2 studies. MiR-205 was not reported in serum/
plasma samples to be deregulated. 
Differentially expressed miRNAs per subtype EC
Furthermore, the articles were subdivided according to EC subtype: looking at 
endometrioid versus serous carcinomas, to distinguish if a miRNA signature can be 
found per subtype. There were 12 studies looking at EEC only29,30,40–43,45,47–50 and one 
study by Devor et al. who reported on both endometrioid and serous carcinomas 
but reported the subtypes separately38. There was only one other study looking at 
serous carcinoma only37. For EEC, data was in line with previously reported data; 
the most often up-regulated miRNA was miR-205 (cited in 7 articles), followed by 
miR-200c (6 articles), miR-182, and -200a (5 articles), miR-183 (4 articles) and miR-
135b, -429, -141 and -223 (3 articles), data not shown. For serous type endometrial 
carcinoma, miR-205 was found up-regulated in both studies, furthermore 
miR-200c, -135a and -135b were up-regulated in one of the two studies.
Discussion
EC is the most common malignancy of the female genital tract in developed 
countries with rising incidence and mortality rates51. Although EC is generally 
associated with good prognosis, patients presenting with advanced or recurrent 
EC have poor survival rates6. MiRNAs have been shown to play a significant role 
in tumour genesis and progression and therefore warrant a clinical potential as 
diagnostic and prognostic marker in EC. In this review a systematic search was 
conducted to identify the feasibility and overall diagnostic value of miRNA 
expression in EC. 
MiR-205 was most consistently found to be up-regulated, with a differential 
expression reported among ten studies and mean fold change of 198.0833,36–
38,40,41,45,47,49,50. MiR-205 is involved in the regulation of PTEN expression in EC and 
leads to reduced cell apoptosis52. Furthermore, miR-205 represses the tumour 
suppressor gene JPH4, promoting tumorigenesis and tumour progression52. 
However, miR-205 is not only up-regulated in EC, but also in other cancer sites 
such as lung and ovarian cancer53,54. Therefore, miR-205 on its own seems not 
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adequate as a diagnostic test for the detection of EC. Lee et al. found a panel of six 
miRNAs (miR-205, miR-200a, miR-200c, miR-182, miR-183 and miR-21) to have 
an area under the curve (AUC) of 0.961, sensitivity and specificity of 91% and 94% 
respectively in discriminating EC from hyperplasia or normal tissue47. The results 
of this systematic review confirm the importance of these miRNAs in endometrial 
carcinogenesis. 
MiR-200c and miR-200a were reported consistently up-regulated in 8 and 5 studies 
respectively, in addition miR-200b, miR-429 and miR-141 were reported up-
regulated in 3 studies. These miRNAs are part of the miR-200 family, the expression 
and function of which has been well documented in various tissues and has been 
suggested to play an important role in inhibiting cell malignant transformation 
and preventing tumour initiation55. The miR-200 family targets the expression 
of many genes, including ZEBs (Zinc finger E-box-binding homeobox), which are 
the transcription factors that regulate cellular transformation, more specifically 
epithelial-to-mesenchymal transition (EMT), during cancer development and 
progression through repression of adhesion molecules such as E-cadherin56. 
Members of the miR-200 family also host diagnostic and prognostic potential in 
other cancer sites such as gastric, ovarian, lung and colorectal cancer57–60. 
Furthermore, miR-182, miR-183 and miR-223 were found up-regulated in 5 
articles and miR-135b was found to be up-regulated in 3 articles. MiR-182 
promotes cell proliferation by targeting the tumour suppressor gene TCEAL7, miR-
183 targets CPEB1 while miR-223 targets IGF-1R61–63. MiR-135b targets FOXO1 
to promote cell proliferation in EC cells64. These miRNAs are also up-regulated 
in patients with non-small cell lung cancer, colorectal-, prostate- and pancreatic 
cancer65–67. In addition, a recent systematic review by Delangle et al. found miR-
182 and miR-183 to be associated with poorer prognosis in terms of overall 
survival and recurrence-free survival in EC68. They therefore conclude that miRNA 
analysis merits a role as a prognostic factor in the management of patients with 
EC. For other gynaecological cancer sites such as ovarian and cervical cancer, the 
diagnostic and prognostic significance of different panels of miRNAs have been 
investigated and also show promising results19,69. 
The distinct panel identified in this systematic review (miR-205, the miR-200 
family, miR-135b, -182, -183, and -223) is promising in the detection of EC. 
However, some of the same miRNAs are also upregulated in colorectal cancer, 
therefore, we suggest that these miRNAs may be used in the diagnosis of women 
presenting with specific symptoms such as abnormal or postmenopausal bleeding. 
Since miRNAs can be detected in a huge variety of bodily fluids including urine and 
since miRNAs are stable in urine, urine seems like a promising non-invasive test 
for the detection of EC70. Urinary miRNAs have shown potential in the detection 
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of bladder- and prostate cancer71,72, however in EC only one study has used urine 
for the detection of miRNA31. In addition, Zavesky et al. compared urinary miRNA 
expression levels of pre- and post-surgery ovarian cancer samples and between 
patients with ovarian and endometrial cancer (n = 10) and healthy controls and 
proposed urinary miRNA should be further investigated to test the diagnostic 
potential of urine miRNAs in gynaecological cancers73. A urinary diagnostic test will 
potentially allow for easier access to care, help reduce anxiety among women and 
could prevent the need for painful biopsies. Another potential is possibly reducing 
the burden of travelling long distances to the hospital and costs for patients. In 
addition, if fewer patients need to be referred to the hospitals this will have a 
potential cost reduction implication. Further studies should therefore determine if 
urinary miRNA detection is a valid non-invasive way of reliably detecting EC. 
In addition to the need for new biomarkers to detect EC, there is also the need 
for these biomarkers to accurately distinguish between low (grade 1 and grade 2) 
or high-grade (grade 3) EEC74. Ratner et al. reported unique miRNA signatures for 
EEC, serous carcinomas and uterine carcinosarcomas, but no difference between 
grade 1 and grade 3 EEC75. Further research may help determine if miRNA can 
accurately distinguish low-grade EEC from high-grade EEC. 
Furthermore, there is an increasing interest in improving the preoperative 
classification of EC, in order to allow for non-invasive and more precise diagnostic 
options for patients. In 2013, the Cancer Genome Atlas proposed an additional 
division of EC into four molecular subtypes: Polymerase-ε (POLE) ultramutated, 
microsatellite instability (MSI) hypermutated, copy-number (CN) low and CN 
high76. CN low include most endometrioid tumours and are frequently associated 
with mutations in PTEN, CTNNB1, PIK3CA, ARID1A and KRAS, whereas CN 
high include serous tumours and 25% of high-grade endometroid tumours77. 
POLE and MSI mutated EC tumours show better survival outcomes76. Since miR-
205 is involved in the regulation of PTEN expression in EC, miRNA detection 
could potentially be of use in a molecular based classification system for correct 
preoperative diagnosis and classification of EC.  
Although these findings are encouraging, the main limitations to the usage of 
miRNAs include different platforms of miRNA profiling, including microarray, next 
generation sequencing and RT-qPCR, which leads to inconsistency and difficulties 
in comparing results78. It is difficult to compare data gained with different miRNA 
profiling platforms, as they are only somewhat reproducible and even intraplatform 
variation is common79. Due to differences in the accuracy, reproducibility, 
sensitivity and specificity of PCR kits, the reproducibility of miRNA detection and 
quantification is relatively low80. Furthermore, most miRNAs are not cancer type 
specific, therefore an EC specific miRNA signature needs further testing to determine 
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if these miRNAs can accurately distinguish EC from benign tissue. This systematic 
review has shown the most promising miRNAs to be miR-205, -200a, -200b, 
-200c, -141, -429, -135b, -182, -183 and -223 and therefore need further testing. 
The strengths of this study include a comprehensive systematic search performed 
by two reviewers independently. In addition, to improve comparability, we have 
only included studies in this review that used RT-qPCR for miRNA detection. 
Furthermore, all included studies varied in the subtype EC which they assessed; 
some studies included only EEC, others only NEEC and some studies combined the 
two subtypes in their analyses, even though EEC and NEEC vary in pathophysiology 
and prognosis. However, when subdividing the articles into endometrioid versus 
serous endometrial carcinoma, the data found seems in line with data found when 
combining subtypes.
The limitations to this systematic review are the following; there is a high 
heterogeneity in methodologies used (different platforms, analysis software and 
normalisation strategies) and specimen samples (FFPE, fresh frozen tissue, serum, 
plasma, urine, LBC) among the different studies included. When subdividing the 
articles per specimen type, we found a different expression for tissue specimens 
compared to serum/plasma samples. In addition, the majority of studies only 
included small sample sizes. Finally, the majority of studies were conducted in Asia 
and no studies were conducted in Africa, South-America or Oceania. 
Conclusion
This systematic review shows that miRNAs are potential promising biomarkers 
for the diagnosis of EC, however no sufficient high-quality evidence is available 
to draw hard conclusions. The combination of miR-205, the miR-200 family, miR-
135b, -182, -183 and -223 needs further testing in larger studies with standardised 
protocols to improve the accuracy of using these miRNAs in diagnosing EC in the 
future. In addition, the potential of urine as a non-invasive biofluid should be 
investigated.  
Clinical significance
MiRNA can potentially be used in low resource settings where there is lack of trained 
histopathologists. In addition, a urinary miRNA test can potentially be used as a 
non-invasive test for the detection of EC. This will allow for easier access to care and 
reduction of travelling long distances to the hospital for patients. It could mean a cost 
reduction for the hospital, if patients can be seen in the community instead of hospitals. 
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Supplementary Table 5. Up-regulated miRNAs in tissue samples 








Studies with fold 
change reported
miR-205 10 134 63 198.08 4
miR-200c 7 126 55 27.99 4
miR-182 5 141 79 11.41 3
miR-183 5 141 79 8.75 2
miR-200a 5 121 75 5.20 4
miR-135b 3 96 35 35.59 2
miR-429 3 117 61 6.83 3
miR-200b 3 103 51 3.86 2
miR-200a* 2 73 31 26.96 1
miR-141-3p 2 65 30 22.95 2
miR-200b* 2 73 31 6.52 1
miR-223 2 38 28 4.9 1
miR-141 2 30 20 4.70 1
miR-106a 2 68 48 2.80 2
miR-135a 1 23 4 34.05 1
miR-205-5p 1 16 24 31.52 1
miR-200b-3p 1 16 24 27.68 1
miR-182-5p 1 16 24 27.30 1
miR-200c-3p 1 16 24 24.40 1
miR-92a 1 39 17 15.63 1
miR-9-5p 1 16 34 15.05 1
miR-9 1 73 31 5.46 1
miR-210 1 38 28 5.23 1
miR-96 1 73 31 4.27 1
miR-194 1 38 28 4.11 1
miR-95 1 38 28 4.09 1
miR-155 1 38 28 3.87 1
miR-18a* 1 30 20 3.65 1
miR-96-5p 1 49 6 3.20 1
miR-103 1 38 28 3.00 1
miR-151 1 38 28 2.85 1
miR-34a 1 30 20 2.63 1
miR-92a-1* 1 30 20 2.47 1
miR-20a* 1 30 20 2.34 1
miR-106b* 1 30 20 2.34 1
miR-17* 1 30 20 1.99 1
miR-185 1 30 20 1.85 1
miR-222-3p 1 16 24 1.80 1
miR-146 1 141 20 NR 0
miR-425 1 141 20 NR 0
miR-944 1 68 20 NR 0
miR-15b 1 67 15 NR 0
miR-16 1 67 15 NR 0
miR-128a 1 67 15 NR 0
miR-148b 1 67 15 NR 0
miR-196a 1 67 15 NR 0
miR-301 1 67 15 NR 0
miR-582-5p 1 67 15 NR 0
miR-499 1 28 14 NR 0
NR = not reported
** mean fold change as found by qRT-PCR
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Studies with fold 
change reported
miR-223 3 66 71 57.81 2
miR-222 2 26 22 19.16 1
miR-186 2 26 22 11.39 1
miR-203 2 79 44 NR 0
miR-15b 1 40 49 6.10 1
miR-204 1 26 22 5.79 1
miR-27a 1 40 49 5.63 1
miR-199b 1 34 14 2.89 1
miR-887-5p 1 50 50 2.41 1
miR-99a 1 34 14 1.96 1
miR-100 1 34 14 1.65 1
miR-200a 1 34 14 NR 0
miR-141 1 34 14 NR 0
miR-92a 1 34 14 NR 0
miR-449a 1 34 14 NR 0
miR-1228 1 34 14 NR 0
miR-1290 1 34 14 NR 0
miR-205 1 12 12 NR 0
miR-135b 1 12 12 NR 0
NR = not reported
** mean fold change as found by qRT-PCR









Studies with fold 
change reported
miR-200c-3p 1 22 5 NR 0
NR = not reported
** mean fold change as found by qRT-PCR









Studies with fold 
change reported
miR-182-5p 1 12 28 18.21 1
miR-205-5p 1 12 28 16.85 1
miR-141-3p 1 12 28 11.45 1
miR-200c-3p 1 12 28 6.27 1
miR-200b-3p 1 12 28 4.69 1
miR-222-3p 1 12 28 3.43 1
NR = not reported
** mean fold change as found by qRT-PCR
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Studies with fold 
change reported
miR-137 1 23 4 115.15 1
miR-129-3p 1 23 4 42.30 1
miR-410 1 73 31 13.91 1
miR-503 1 14 10 8.60 1
miR-1247 1 30 20 5.31 1
miR-376c 1 30 20 3.64 1
miR-199b 1 73 31 3.52 1
miR-377 1 30 20 3.34 1
miR-99a 1 73 31 3.29 1
miR-26a-5p 1 49 6 3.10 1
miR-214 1 30 20 2.90 1
miR-150-5p 1 49 6 2.70 1
miR-370 1 30 20 2.68 1
let-7f-5p 1 49 6 2.60 1
miR-26b-5p 1 49 6 2.60 1
miR-100 1 73 31 2.56 1
let-7c-5p 1 49 6 2.50 1
miR-23b-3p 1 49 6 2.40 1
miR-125b-5p 1 49 6 2.30 1
miR-126-3p 1 49 6 2.30 1
miR-195-5p 1 49 6 2.20 1
miR-424-5p 1 49 6 2.20 1
miR-374a-5p 1 49 6 2.10 1
let-7a-5p 1 49 6 2.00 1
let-7e-5p 1 49 6 2.00 1
miR-125a-5p 1 49 6 2.00 1
miR-542-5p 1 14 10 2.00 1
miR-337-5p 1 30 20 1.94 1
miR-1305 1 73 31 1.77 1
miR-758 1 30 20 1.61 1
miR-300 1 30 20 1.56 1
miR-125 1 67 15 NR 0
miR-34 1 67 15 NR 0
miR-30a-3p 1 28 14 NR 0
miR-10b 1 28 14 NR 0
miR-195 1 28 14 NR 0
miR-30a-5p 1 28 14 NR 0
miR-101 1 21 7 NR 0
miR-10b* 1 21 7 NR 0
miR-133a 1 21 7 NR 0
miR-133b 1 21 7 NR 0
miR-152 1 21 7 NR 1
miR-29b 1 21 7 NR 0
miR-34b 1 21 7 NR 0
miR-411 1 21 7 NR 0
NR = not reported
** mean fold change as found by qRT-PCR
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Studies with fold 
change reported
miR-93 1 176 100 NR 0
miR-204 1 46 28 NR 0
miR-30a-3p 1 40 26 NR 0
miR-9 1 34 14 NR 0
miR-301b 1 34 14 NR 0
miR-21 1 12 12 NR 0
NR = not reported
** mean fold change as found by qRT-PCR






































NR = not reported
** mean fold change as found by qRT-PCR
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Abstract
Introduction
MicroRNAs (miRNAs) are noncoding RNAs that regulate gene expression and 
contribute to the development of cancer. MiRNAs have been shown to be stable 
in urine, serum and tissue samples. They may be promising biomarkers for non-
invasive detection of endometrial cancer (EC). 
Methods
A retrospective cohort study of women diagnosed with EC between January 2017 
and December 2017 was performed at the Royal Cornwall Hospital. Archived 
formalin-fixed paraffin-embedded samples were obtained from patients with EC 
and healthy female subjects. MiRNA was isolated and qPCR was used to detect 
expression levels of miRNAs.
Results
A total of 76 women were included; 36 EC patients, 40 healthy controls. A distinct 
panel of miR-200a, miR-200b, miR-200c, miR-205 and miR-182 showed AUC 
of 0.958, sensitivity 92%, specificity 89%, positive predictive value of 89% (95% 
confidence interval (CI) 82 – 94%) and negative predictive value of 91% (95% CI 
85 – 96%) in diagnosing EC. High miR-182 expression levels were significantly 
related to high-grade endometrioid tumours compared to low-grade.
Conclusion
We demonstrated high diagnostic accuracy of miRNA for detecting EC. In addition, 
miRNA contributed to improved distinguishing between high-grade and low-
grade endometrioid tumours. Validation of miRNA expression levels in urine will 




Endometrial cancer (EC) is the 6th most commonly occurring cancer in women 
and the 15th most commonly occurring cancer overall1. Since 1990, the incidence 
of EC has increased by 57% in the United Kingdom (UK), which is attributed to 
the rise in obesity2. EC is generally diagnosed early since patients present early 
with bleeding abnormalities and consequently overall good prognosis is seen3. 
Diagnosis is achieved by combination of transvaginal ultrasound scan  and 
histological confirmation on endometrial biopsy. Outpatient endometrial sampling 
with pipelle is more cost-effective than immediate hysteroscopy, however high 
numbers of technical problems (12-23%) and insufficient amount of tissue (16-
68%) have been described4. Furthermore, endometrial sampling is invasive and can 
be uncomfortable, with Visual Analogue Scale pain score of 6.5 in postmenopausal 
women5. Even with sufficient amount of tissue, there can be large discordancy 
between pre- and postoperative tumour classification6. Discordances in grading 
and histologic subtype in preoperative and final diagnosis can lead to either 
undertreatment or overtreatment with unnecessary surgical procedures and 
associated complications. Therefore, the identification of validated and non-
invasive diagnostic biomarkers are needed to accurately diagnose EC and aid 
correct preoperative classification. 
MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression 
which play crucial roles in biological processes including cellular differentiation, 
proliferation and apoptosis7. Abnormal expression of miRNAs can contribute to 
the development of cancer and can therefore be a candidate in either detection 
or monitoring cancer treatment8. A recent systematic review showed a promising 
diagnostic potential of miRNA panel for EC9. MiR-205, the miR-200 family 
(consisting of miR-200a, -200b, -200c, -141 and -429) and miR-135b, -182, -183 
and -223 were found up-regulated most consistently9. 
MiRNA has been shown to be stable in serum and urine samples as well as formalin-
fixed paraffin-embedded (FFPE) tissue samples, which are routinely archived in 
most hospitals and are therefore widely used for the discovery of clinically useful 
biomarkers10. Therefore, in this study we aim to test and validate the potential of 
a distinct miRNA panel in FFPE tissue as a first step in optimising it as diagnostic 
tool for the detection of EC. 
Materials and methods
Study design and participants
This is a retrospective cohort study in the Royal Cornwall Hospital, Truro, UK, 
in collaboration with Department of Obstetrics and Gynecology, University 
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Medical Centre Freiburg, Germany, on women diagnosed with primary EC. 
Samples were obtained from archived uterine FFPE samples from consecutive 
women who underwent surgical treatment (hysterectomy with bilateral salpingo-
oophorectomy) between January 2017 and December 2017 in the Royal Cornwall 
Hospital. In total, 10 women were excluded for following reasons: histological 
diagnosis of complex atypical hyperplasia (n = 5), carcinoma in situ (n = 1), micro-
invasive cervical squamous carcinoma (n = 1), mucinous borderline ovarian tumour 
(n = 1),  round cell sarcoma (n = 1) or poorly preserved endometrium (n = 1). The 
total study population consisted of 80 women; 40 consecutive FFPE samples from 
women who underwent hysterectomy for EC and 40 who had hysterectomy for 
benign conditions that served as control group.
MiRNA expression profiles
A total of 43 miRNAs have previously been reported deregulated in EC, therefore 
those miRNAs were investigated in this study9. Using findings from a recent 
systematic review, we  furthermore mainly focused on miR-205, -200a, -200b, 
-200c, -223, -182, -183, -135b, -429, and miR-141 as they were previously shown 
to be most consistently up-regulated9. 
MiRNA isolation and quantitative real-time PCR (qPCR) were performed in the 
Department of Obstetrics and Gynecology in Freiburg.
Sample processing and miRNA isolation
Deparaffinisation of the FFPE tissue was achieved by soaking the samples twice 
in 1 ml xylene at 60°C in a thermomixer (Eppendorf, Hamburg, Germany) at 
1,000 revolutions per minute (rpm), then spin at 13,000 rpm. Removal of xylene 
was achieved by washing the samples three times with 1 ml 100% ethanol, then 
spinned at 13,000 rpm. The sections were dried at 60°C for 10 minutes. Tissue 
homogenisation was attained by precellys bead mill at 6,100 rpm for 20 seconds 
(Bertin technologies; Peqlab Erlangen, Germany). Isolation and purification of 
the miRNA was utilized by EURx® FFPE RNA purification kit according to the 
manufacturer’s protocol. The RNA concentration was determined using IMPLEN 
N60 Nanophotometer (München, Germany). RNA was stored at -20˚C until 
further processing. 
Reverse transcription (RT)
For cDNA generation poly(A) tailing-based RT was performed, using a total 
reaction volume of 20 µl. The RT reaction mix included: 4 µl RT-buffer (5X), 1 µl 5 
µM poly A adapter/primer (Integrated DNA Technologies, Inc.), 1 µl 5 mM dNTPs 
(Jena Bioscience), 0.25 µl Maxima™ H Minus reverse transcriptase (Thermo Fisher 
Scientific, Inc.), 0.25 µl SUPERase In™ RNase inhibitor (Thermo Fisher Scientific, 
Inc.), 0.5 µl 10 mM ATP (New England BioLabs, Inc.), 0.25 µl poly A polymerase 
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(New England BioLabs, Inc.) and 100 ng total RNA. cDNA samples were diluted in 
H2O to a final volume of 200 µl and stored at -20°C until further processing.
Quantitative real-time PCR (qPCR) of miRNAs
Quantitative determination of miRNA expression levels was implemented by real-
time qPCR on LightCycler® 480 (Roche, Mannheim, Germany). The PCR reaction 
set up contained: 1 µl cDNA, in-house qPCR buffer (containing TRIS pH8.1, 
dATP, dCTP, dGTP, dTTP, magnesium, potassium ammonium, SYBRGreen (Jena 
Bioscience, Jena, Germany), enhancers) 0.25 units HotStart Taq Polymerase (Jena 
Bioscience) in a total volume of 10 µl. QPCR primers were designed by means 
of ‘miRprimer’ software. The used qPCR program contained the following steps: 
initial denaturation (95°C; 2 minutes); 40 cycles of denaturation (95°C; 5 seconds) 
/ annealing/extension (60°C; 30 seconds) and a final melting curve analysis 
step. Based on DCt method relative quantification of miRNA expression levels 
was conducted in a duplicate analysis normalized on the geometric mean of the 
endogenous controls RNU-44 RNU-48 which were identified as stably expressed 
between malignant and normal tissues11.
Statistical analysis
For normal distributed data continuous outcomes were presented as medians and 
interquartile range, categorical data were presented as frequencies and proportions. 
The non-parametric Mann-Whitney U Test was used for the comparison between 
EC and benign controls and the Fisher Exact Test for the comparison between 
high-grade and low-grade endometrioid EC. The Benjamini-Hochberg correction 
was applied to adjust for multiple comparisons with critical value for false discovery 
rate of 0.2512. The receiver-operator characteristics (ROC) curve was constructed, 
and the cut-off values of each miRNA were selected. The sensitivity and specificity 
in differentiating EC from benign endometrium were calculated for each cut-off 
and the area under the curve (AUC) was estimated. A stepwise logistic regression 
was used to establish a model as a surrogate marker to diagnose EC. P-values less 
than 0.05 were considered significant for all tests. Data were analysed with IBM 
SPSS statistics version 25.0. 
Ethical approval 
This study was approved by the Health Research Authority (HRA) and Health and 
Care Research Wales (HCRW) with REC reference number 19/ES/0007. 
Results
Demographics
Of the 80 women included in this study, FFPE samples of 4 women showed 
insufficient miRNA extraction and were therefore excluded for analysis. The 
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demographics of the total study population of 76 women are presented in Table 1. 
The majority of EC patients had endometrioid histology (78%), followed by serous 
(11%). Most patients were diagnosed with FIGO stage 1 (58%) and grade 1 (36%).
Table 1. Patient characteristics
Variable Value
Number of women 76
Histology (%)
   Benign
   Endometrioid 
   Serous 
   Carcinosarcoma 
   Clear cell 








   Caucasian
   Any other ethnic group






   0
   ≥1





   1
   2
   3
   4







   1
   2
   3





Abbreviations: FIGO = International Federation of Gynecology and Obstetrics
For the control group, patients underwent hysterectomy due to menorrhagia (n 
= 32), ovarian cysts (n = 3), endometriosis (n = 2), pelvic pain (n = 2) or recurrent 
abnormal Pap smears (n = 1). Histology showed proliferative endometrium (n = 
21), secretory phase endometrium (n = 15) or atrophic endometrium (n = 4) and 
adenomyosis in 12 patients.
EC patients were significantly older with median age of 68 years compared to 45 
years for the control group (p < 0.001, Table 2), and had higher Body Mass Index 
(BMI), median of 33 m/kg2 compared to 29 m/kg2 in the control group (p = 0.009). 
There was no difference in total amount of comorbidities; however, diabetes 




Table 2. Differences in baseline characteristics 
Characteristics Benign (N = 40) Endometrial cancer (N = 36) p-value
Age, median (years) (IQR) 45 (7) 68 (17) <0.001*
BMI, median (m/kg2) (IQR) 29 (8) 33 (6) 0.009*
Comorbidities (%)
   None
   One
   Two or more











   Yes







   0 
   1
   2
   3













   Non-smoker
   Smoker
   Ex-smoker










Abbreviations: BMI = Body Mass Index, IQR = Interquartile Range, ECOG = Eastern Cooperative Oncology 
Group
MiRNA expression profiles
Of the 43 miRNAs investigated, 27 miRNAs demonstrated significantly different 
altered expression patterns (Table 3), which remained significant after correction 
for multiple testing. See Supplementary Table 1 for the median expression levels 
of miR-205, -200a, -200b, -200c, -223, -182, -183, -135b, -429, and miR-141.
MiRNA panel
The 10 most promising miRNAs in diagnosing EC in previous literature were 
analysed for their diagnostic value by construction of ROC curves to estimate the 
sensitivity and specificity of these miRNAs. The individual miRNAs exhibited AUC 
values of 0.603 – 0.868 (Supplementary Figure 1 and Table 4) in distinguishing EC 
from benign endometrium, revealing 62-100% sensitivity and 21-88% specificity. 
To further determine the diagnostic value of a panel of miRNAs, a stepwise logistic 
regression analysis was applied to the 10 miRNAs. The best fitting model was 
a panel of miR-200a, miR-200b, miR-200c, miR-205 and miR-182 with AUC of 
0.958 (Standard Error 0.021, Figure 1). Given a specificity of 89%, the composite 
panel revealed a sensitivity of 92% in differentiating EC from normal endometrium 
and a positive predictive value of 89% (95% Confidence Interval (CI) 82% - 94%) 
and negative predictive value of 91% (95% CI 85% – 96%). Supplementary Figure 
2 shows the boxplots of expression levels of these five miRNAs.
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Table 3. Up/downregulation pattern and expression values for all tested miRNAs
MiRNA Benign, median (range) Cancer, median (range) p-value
Down-regulated
let-7a 2.18 (7.17) 0.99 (4.87) 0.021*
miR-10b 0.40 (1.35) 0.30 (1.56) 0.06
miR-15a 0.04 (0.91) 0.03 (0.16) 0.99
miR-16 0.06 (13.87) 0.06 (2.14) 0.69
miR-20b 0.01 (0.10) 0.01 (0.03) 0.90
miR-100 0.73 (3.79) 0.54 (4.55) 0.11
miR-125b 2.84 (14.37) 1.92 (12.84) 0.039*
miR-134 0.00 (0.12) 0.00 (0.07) 0.028*
miR-195 0.34 (6.83) 0.13 (6.23) <0.001*
miR-222 0.10 (1.53) 0.06 (3.35) 0.010*
miR-574-3p 0.07 (0.19) 0.03 (0.09) <0.001*
let-7i 0.29 (0.95) 0.22 (0.79) 0.16
miR-26b 0.65 (3.05) 0.44 (1.35) 0.11
miR-107 0.14 (0.95) 0.11 (0.31) 0.006*
miR-423 0.10 (0.95) 0.07 (0.26) 0.08
miR-424 0.23 (2.07) 0.06 (0.98) <0.001*
let-7b 3.22 (19.14) 1.98 (4.98) 0.012*
let-7c 3.47 (18.08) 2.12 (6.07) 0.003*
let-7d 0.41 (1.13) 0.25 (0.70) 0.06
let-7e 0.83 (3.77) 0.47 (1.87) <0.001*
miR-135a 0.00 (1.41) 0.00 (0.15) 0.001*
miR-132-3p 0.04 (0.12) 0.02 (0.06) 0.001*
miR-139 0.02 (0.08) 0.01 (0.02) <0.001*
Up-regulated
miR-17 0.03 (0.03) 0.03 (0.15) 0.53
miR-21 1.76 (9.82) 2.88 (10.46) 0.11
miR-34a 0.05 (0.17) 0.06 (0.21) 0.17
miR-141-3p 0.00 (0.12) 0.02 (0.34) 0.001*
miR-155 0.01 (0.24) 0.03 (1.39) 0.013*
miR-181b 0.02 (0.25) 0.02 (0.50) 0.85
miR-200a 0.00 (0.11) 0.03 (0.29) <0.001*
miR-200b 0.00 (0.02) 0.02 (0.06) <0.001*
miR-200c 0.09 (1.21) 0.52 (4.15) <0.001*
miR-205 0.00 (8.13) 0.03 (4.56) <0.001*
miR-223 0.00 (0.07) 0.01 (0.13) 0.001*
miR-375 0.01 (1.00) 0.03 (1.08) 0.041*
miR-660 0.01 (0.04) 0.01 (0.09) 0.58
miR-135b 0.00 (0.01) 0.01 (0.08) <0.001*
miR-148b-3p 0.01 (0.33) 0.01 (0.38) 0.95
miR-148a-3p 0.05 (0.09) 0.06 (0.38) 0.11
miR-182 0.00 (0.00) 0.01 (0.17) <0.001*
miR-183 0.00 (0.00) 0.01 (0.08) <0.001*
miR-203-1-3 0.00 (0.00) 0.02 (0.21) <0.001*
miR-429 0.00 (0.00) 0.00 (0.02) 0.029*
Differences in miRNA expression levels between endometrioid versus 
non-endometrioid tumours
We evaluated the difference in miRNA expression level between endometrioid 
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(EEC) and non-endometrioid (NEEC) tumours. In total, 28 women had endometrioid 
tumours, 4 serous subtype EC, 2 carcinosarcoma, 1 clear cell and 1 mucinous 
tumour. There was no difference in expression level of any of the tested miRNAs 
between EEC and NEEC tumours (Supplementary Table 2).
MiRNA to distinguish between low and high-grade endometrioid tumours
To determine if miRNA can accurately distinguish between high-grade (grade 3) 
and low-grade (grade 1 or 2) EEC, we further analysed women with endometrioid 
carcinoma histology. In total, 23 women had low-grade EEC and 4 women had 
high-grade EEC. Only miR-182 had a significant different altered expression 
pattern (P = 0.041), with median expression level of 0.02 (range 0.15) in high-
grade and 0.01 (range 0.03) in low-grade EEC (Supplementary Table 3). 
Figure 1. ROC curve for panel of 5 miRNAs (miR-200a, -200b, -200c-, 205 and -182)
Discussion
In this study, we aimed to test and validate the potential of a distinct miRNA panel 
in FFPE tissue as a first step in optimising it as diagnostic tool for the detection 
of EC. We demonstrated the highest positive and negative predictive value in 
diagnosing EC with the distinct panel of miR-200a, miR-200b, miR-200c, miR-
205 and miR-182. These results are in line with a study done by Lee et al.13, which 
reported a panel of six miRNAs (miR-200a, miR-200c, miR-205, miR-182, miR-
183 and miR-21) with an AUC of 0.961, sensitivity and specificity of 91% and 94% 
respectively in discriminating EC from hyperplasia or benign endometrium. 
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Different miRNAs have their own distinct mechanism of action with miR-205 
being involved in the regulation of PTEN expression, which is the most commonly 
modified gene in EC14. Mutations of PTEN have been described to occur in 25-
83% of cases in EC and are frequently present in endometrial hyperplasia15. PTEN 
has an important inhibitory function, promoting apoptosis and proliferation, and 
its deletion or mutation leads to carcinogenesis16. Inactivation of p53 may result in 
a cellular environment that is contributing to or permissive of oncogenesis17. PTEN 
mutations are more frequently seen in endometrioid type tumours and associated 
with microsatellite instability, while p53 mutations are more frequently seen in 
serous or high-grade endometrioid tumours18,19.
The miR-200 family (which consists of miR-200a, miR-200b, miR-200c, miR-429 
and miR-141) has been shown to negatively regulate two transcription factors, 
ZEB1 (Zinc finger E-box-binding homeobox) and ZEB2, which are well-known 
transcriptional suppressors of E-cadherin20. E-cadherin is a calcium-dependent 
transmembranous epithelial adhesion molecule involved in the cell cohesiveness. 
Decreased E-cadherin expression has been linked to decreased cell-cell adhesion, 
metastatic potential, tumour dedifferentiation and deep myometrial invasion 
in endometrial and other carcinomas21. In EC, loss of E-cadherin is strongly 
associated with histological subtypes, in which loss is more prevalent in grade 3 
EEC compared to serous carcinoma22. Furthermore, ZEB1 expression is elevated 
in NEEC and grade 3 EEC tumours23. 
Finally, miR-182 promotes cell proliferation by targeting the tumour suppressor 
gene TCEAL7, which interacts with E-box sequences of the Myc target gene cyclin 
D1, regulating Myc activity and cyclin D1 expression and thus cell proliferation 
and malignant transformation24,25. 
Although we showed a high diagnostic accuracy for a miRNA panel for EC, we 
could not discriminate between endometrioid and non-endometrioid tumours. 
This is in line with results from our systematic review, although numbers were 
small9. However, Ratner et al. showed distinct miRNA signatures for endometrioid 
tumours, serous carcinomas and carcinosarcomas26. Based on the different 
aetiology of serous and endometrioid EC and subsequent precursor lesions, it 
is expected that discrimination in the diagnostic approach would be possible. 
Therefore, further research is needed to understand the biological differences 
between these types of endometrial cancers and the ability to distinguish between 
these subtypes of EC. 
At the moment, there is interest in preoperative modelling to more accurately 
detect EC patients with high-grade disease and patients with increased risk of 
extended disease prior to surgery. A systematic review by Visser et al. showed only 
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moderate agreement on tumour grade between preoperative endometrial sampling 
and final diagnosis6. Recently, the reproducibility was evaluated with support of 
The Cancer Genome Atlas (TCGA) classification, yet it was demonstrated that this 
was mainly supportive in the abnormal p53 group, underlining the relevance of 
innovative techniques for further improvement. In this study, we found different 
expression levels of miR-182 for high-grade and low-grade endometrioid tumours, 
with higher expression levels in high-grade tumours, however numbers were small. 
A previous study done by Wilcyznski et al. showed lower miR-205 expression 
rates in grade 3 EEC tumours compared to grade 2 EEC tumours, however 
Tsukamoto et al. found that miR-205 was up-regulated in poorly differentiated 
tumours, although again, numbers were limited27,28. In addition, Snowdon et al. 
showed no significant difference in miR-200 family levels between low-grade and 
high-grade tumours, but also commented their study did not have a significantly 
large sample size to see such a difference29. Further research with larger sample 
size on pre-operative samples may help establish if miRNA expression as well as a 
different miRNA panel can accurately distinguish low-grade from high-grade EEC 
and help improve preoperative diagnosis in order to identify those patients that 
need extended surgery and/or additional treatment.
The majority of previous studies have used tissue samples to detect miRNA 
expression levels. However, miRNAs can also be detected in body fluids such 
as serum and urine30. A study by Srivastava et al. showed that a unique miRNA 
signature can be isolated from the urine of women diagnosed with EC including 
miR-200c31. In addition, Erbes et al. showed the feasibility of urinary miRNA 
detection in breast cancer patients and its potential as an non-invasive biomarker32. 
Furthermore, studies have shown a similar potential in the usage of serum and 
plasma33,34. These body fluids are promising as a less invasive way of detecting 
EC and warrant further investigation. Therefore, the panel of miRNA found in 
this study warrants further evaluation in urine and serum samples to validate its 
significance in detecting EC.
Altered miRNA expression patterns are not only associated with the development 
of cancer, but are also linked to various other diseases including obesity, type 2 
diabetes mellitus and cardiovascular diseases35. This is highly relevant as these 
are frequently present in patients with EC and hence could reflect underlying 
comorbidity rather than EC. Several miRNAs have been found to be deregulated 
in serum of obese women or women with type 2 diabetes, including miR-152, 
-17, -138, -593, -150, 205, -376a, -432-5p, -500a, and miR-15b35. In addition, 
miRNA is also associated with age, in which certain miRNAs such as miR-151a-
3p, miR-181a-5p and miR-1248 were down-regulated in elderly compared to 
young individuals36. MiR-181a expression is found to negatively correlate with 
the pro-inflammatory cytokines IL-6 and TNFα and positively correlate with the 
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anti-inflammatory cytokine TGFß. Therefore, this altered expression might be a 
reflection of the increased inflammation that occurs with advanced age36. These 
miRNAs were not tested in our cohort, therefore further studies are needed to 
investigate miRNAs that are consistently altered in EC, age and obesity.
Strengths of this study include the inclusion of all histological subtypes and FIGO 
stages. Furthermore, we have added to the current literature by mainly focusing on 
miRNAs that have previously been described as promising biomarkers. However, 
there are limitations to our study, including the retrospective design of the study 
and the small sample size of EEC patients. In addition, we included samples 
from hysterectomy specimens and not pipelle samples. Furthermore, there were 
differences in baseline characteristics between the cancer and control group, 
which could potentially introduce bias to our results. 
Clinical implications and future perspectives 
Histopathological examination of endometrial tissue is the gold standard to detect 
EC. However, miRNA expression in tissue samples can potentially compliment 
histological diagnosis, aiding in pre-operatively distinguishing between EEC and 
NEEC and low- and high-grade EEC. In addition, as world population numbers 
are rising and obesity is becoming more prevalent in undeveloped low resource 
countries, new technologies that rely less on fully trained pathologists may be 
of value. Therefore, we believe that investigation and development of alternate 
diagnostic and/or screening tests may be of value.  
Conclusion
Our study showed a high diagnostic accuracy of a distinct miRNA panel of miR-
200a, miR-200b, miR-200c, miR-205 and miR-182 to accurately diagnose EC. 
Furthermore, miR-182 can potentially be used to distinguish high-grade EEC from 
low-grade disease. MiRNA expression levels in other body fluid such as urine or 
serum should be further investigated in patients with EC to find a non-invasive 
screening method for the early detection of EC. Future research is needed to 
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Supplemental material
Supplementary Table 1. Expression values for most promising miRNAs (all up-regulated)
MiRNA Benign, median (range) Cancer, median (range) p-value
miR-141-3p 0.00 (0.12) 0.02 (0.34) 0.001*
miR-200a 0.00 (0.11) 0.03 (0.29) <0.001*
miR-200b 0.00 (0.02) 0.02 (0.06) <0.001*
miR-200c 0.09 (1.21) 0.52 (4.15) <0.001*
miR-205 0.00 (8.13) 0.03 (4.56) <0.001*
miR-223 0.00 (0.07) 0.01 (0.13) 0.001*
miR-135b 0.00 (0.01) 0.01 (0.08) <0.001*
miR-182 0.00 (0.00) 0.01 (0.17) <0.001*
miR-183 0.00 (0.00) 0.01 (0.08) <0.001*
miR-429 0.00 (0.00) 0.00 (0.02) 0.029*
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Supplementary Table 2. Expression values for EEC versus NEEC. 
MiRNA EEC NEEC p-value
Median (range) Median (range)
miR-141-3p 0.03 (0.34) 0.01 (0.07) 0.14
miR-200a 0.04 (0.29) 0.02 (0.07) 0.23
miR-200b 0.02 (0.06) 0.01 (0.03) 0.19
miR-200c 0.54 (4.11) 0.22 (0.71) 0.69
miR-205 0.04 (4.56) 0.02 (0.32) 0.82
miR-223 0.01 (0.04) 0.00 (0.13) 0.79
miR-135b 0.01 (0.08) 0.01 (0.02) 0.64
miR-182 0.02 (0.17) 0.01 (0.05) 0.39
miR-183 0.01 (0.08) 0.01 (0.03) 0.65
miR-429 0.00 (0.02) 0.00 (0.00) 0.32
Supplementary Table 3. Expression values for high-grade versus low-grade EEC
MiRNA High-grade Low-grade p-value
Median (range) Median (range)
miR-141-3p 0.02 (0.03) 0.02 (0.21) 1.00
miR-200a 0.06 (0.09) 0.03 (0.29) 1.00
miR-200b 0.04 (0.05) 0.02 (0.04) 0.29
miR-200c 0.54 (0.85) 0.50 (4.11) 1.00
miR-205 0.11 (0.15) 0.03 (4.56) 0.33
miR-223 0.01 (0.02) 0.01 (0.04) 1.00
miR-135b 0.01 (0.08) 0.01 (0.03) 1.00
miR-182 0.02 (0.15) 0.01 (0.03) 0.041*
miR-183 0.01 (0.07) 0.01 (0.02) 0.50
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Abstract
Introduction
To improve early diagnosis for endometrial cancer (EC), novel non-invasive 
diagnostic biomarkers are needed. MicroRNAs (miRNAs) are noncoding RNAs that 
regulate gene expression and contribute to the development of cancer. Therefore, 
they may be promising novel biomarkers for the detection of EC. Furthermore, 
miRNAs play an important role in obesity and obesity-related diseases, which are 
frequently observed among EC patients.
Methods
A prospective cohort study of women presenting with abnormal bleeding between 
March 2019 and November 2019 was performed at the Royal Cornwall Hospital 
Trust Truro. Urine samples were obtained from women diagnosed with EC and 
benign endometrial sampling. MiRNA was isolated and qPCR was used to detect 
expression levels of miRNAs.
Results
A total of 61 women were included in this study; 24 EC patients and 37 controls. 
Median age was 64 years and median BMI 29 kg/m2. MiR-223 was significantly 
up-regulated in urine of EC patients (p = 0.003). Furthermore, let7-i, miR-34a 
and miR-200c were significantly down-regulated and miR-424 was up-regulated 
in obese women. In addition, miR-148a and miR-222 were significantly down-
regulated in elderly women and miR-16, miR-26b and miR-200c were significantly 
deregulated in women with multiple comorbidities.
Conclusion
MiRNA expression levels in urine can potentially be used as non-invasive diagnostic 
test for EC. Furthermore, aberrant miRNA expression in urine is associated with 
patient characteristics. Further research in larger trials is needed to validate the 




Endometrial cancer (EC) is the sixth most common gynaecologic cancer in developed 
countries, accounting for more than 2% of deaths due to cancer worldwide1. The 
prevalence of EC in developed countries has increased in recent years due to the 
rising prevalence of  obesity1. Obesity is associated with an increased risk of EC 
by a variety of mechanisms including increased levels of oestrogen and chronic 
inflammation leading to hyperinsulinemia and hyperglycaemia, both stimulating 
endometrial proliferation2. 
The primary symptoms of EC are postmenopausal bleeding (PMB) and abnormal 
premenopausal bleeding. However, the risk of EC in premenopausal women 
with abnormal uterine bleeding is low and can be mainly attributed to  hormonal 
imbalances, fibroids, and benign endometrial or cervical polyps3. PMB occurs in 
approximately 90% of women with EC; however, only 9% of women with PMB 
are diagnosed with EC, with the vast majority being diagnosed with benign 
conditions such as atrophy, endometrial polyps or unscheduled bleeding in 
women using hormone replacement therapy (HRT)4. As a patient’s age increases 
after menopause, the probability that PMB is caused by EC progressively rises5–7.
Currently, abnormal uterine bleeding is evaluated with transvaginal ultrasound 
scan (TVUS) and endometrial biopsy mainly performed by pipelle endometrial 
sampling. Pipelle endometrial biopsy is an invasive and uncomfortable procedure, 
with Visual Analogue Scale (VAS) pain score of 6.5 in postmenopausal women8. 
Furthermore, referring all women with abnormal uterine bleeding for TVUS and/
or endometrial biopsy carries a considerable cost for healthcare systems. The low 
positive predictive value of PMB emphasises the need for additional triage tests 
with high specificity to improve management of abnormal uterine bleeding and 
avoid unnecessary biopsies in low-risk women. Therefore, novel non-invasive 
diagnostic biomarkers are needed to improve management, patient care and 
acceptability of women presenting with abnormal uterine bleeding. 
In the past years, microRNAs (miRNAs) have gained enormous interest in cancer 
research. MiRNAs are a class of small noncoding RNA molecules that regulate 
several key cellular processes including developmental timing, stem cell division 
and apoptosis9. They play an important role in regulating gene expression; it has 
been proposed that overexpressed miRNAs may function as oncogenes while 
those that are underexpressed behave as tumour suppressor genes10. Abnormal 
expression of miRNA has been found in various disorders including numerous 
cancer sites11. MiRNA expression profiles are becoming promising and useful tools 
in cancer screening, diagnosis and prognosis and may play a future role in cancer 
therapeutics.
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A distinct miRNA panel has shown to be promising in the detection of EC in tissue, 
plasma or serum samples12. In addition, miRNAs have shown to be stable in other 
body fluids such as pap smear and urine13. These body fluids are promising as a 
non-invasive way of detecting EC. 
MiRNAs have emerged as key regulators of lipid and glucose metabolism and play 
pivotal roles in the onset of obesity and obesity-related diseases14. The role of 
miRNAs as potential link between obesity and EC however, is unknown. 
Therefore, the aim of this study is to analyse urinary miRNA expression profiles 
in EC to find dysregulated miRNAs associated with EC as a first step in finding 
a non-invasive new diagnostic biomarker. In addition, we aim to determine the 
correlation of urinary miRNAs with clinicopathological characteristics.
Materials and methods
Study design and participants
A prospective explorative cohort study was performed including women diagnosed 
with primary EC between March 2019 and November 2019 at the Royal Cornwall 
Hospital Trust, Truro, United Kingdom.
Recruitment
Women attending their General Practitioner (GP) with abnormal uterine bleeding 
were referred to PMB clinics for suspected EC. All consecutive women attending 
PMB clinics were considered eligible and were approached to participate in 
the study. Detailed information was given and written informed consent was 
obtained. Those women attending PMB clinics within the described timeframe 
with histological confirmed benign endometrial tissue served as controls. Urine 
samples were collected from participants after informed consent following 
standard protocols and stored at -80°C within 30 minutes after collection until 
further processing. All included women had the standard investigations of TVUS 
followed by pipelle endometrial sampling. 
Exclusion criteria were: prior or coexisting other malignancies, presence of 
autoimmune disorders other than diabetes mellitus, inability to provide a urine 
sample or no endometrial sampling performed.  
Standard treatment for women diagnosed with EC was surgically; hysterectomy 
with bilateral salpingo-oophorectomy, when indicated followed by adjuvant 
therapy (radiotherapy and/or chemotherapy). The histopathology results were 
confirmed by surgical resection of tumours in those patients treated with surgery 
and cancer stage was defined according to the International Federation of 
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Gynecology and Obstetrics (FIGO) staging criteria15. For the 5 (20%) patients who 
did not undergo surgery, the FIGO stage was purely based on clinical examination 
and imaging results (CT-scan or MRI-scan and/or PET-CT scan).
The clinical and pathologic variables of the women were extracted from patient 
records and included age, parity, Body Mass Index (BMI), comorbidities, FIGO 
stage, histologic subtype and grade.
Sampling and Storage
Urine samples were collected in 100 mL sterile urine sampling cups and frozen in 
10 mL aliquots at -80 °C until further processing. 
Sample preparation, RNA Isolation, Reverse Transcription and 
Quantitative real-time PCR (qPCR) of miRNAs
Urine miRNA preparation, RNA isolation and reverse transcription method was 
described in detail by this group in previous publication16. A total of 41 miRNAs 
were investigated, based on previous literature12. Supplementary Table 1 provides 
detailed information on the miRNA types studied, including their target sequences.
Statistical analysis
For normal distributed data continuous outcomes were presented as medians 
and interquartile range, categorical data were presented as frequencies and 
proportions. For analysis purposes, BMI was categorised into normal (<25 kg/
m2), overweight (25-29.9 kg/m2), obese (≥30 kg/m2) and morbidly obese (≥40 kg/
m2). For the data obtained by qRT-PCR, the non-parametric Mann-Whitney U Test 
was used for the comparison between EC and benign controls and the Benjamini-
Hochberg correction was applied to adjust for multiple comparisons with critical 
value for false discovery rate of 0.2517. P-values less than 0.05 were considered 
significant for all tests. Data were analysed with IBM SPSS statistics version 26.0.
Results
Patient characteristics
All consecutive women that consulted PMB clinics for abnormal bleeding were 
approached of whom 77 women met the inclusion criteria (Figure 1, illustrative 
flowchart). Out of these women, 74 women consented to participate in the 
trial. Only three women declined participation due to the following reasons: not 
interested, no time and fear of identity theft. Subsequently, 13 women were 
excluded due to histological diagnosis of endometrial hyperplasia (N = 6), cervical 
cancer (N = 2) or sarcoma (N = 1), due to insufficient RNA extraction (N = 2) or 
inconclusive histology (N = 2), resulting in a final total of 61 patients suitable for 
analysis (Figure 1). 
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= 1), due to insufficient RNA extraction (N = 2) or inconclusive histology (N = 2), resulting in a final total 
of 61 patients suitable for analysis (Figure 1).  
  
Figure 1. Flowchart of recruitment for study. 
 
 













Excluded (N = 13): 
- Histology hyperplasia (N = 6) 
- Histology cervical cancer (N = 2) 
- No histology (N = 2) 
- Insufficient RNA extraction (N = 2) 
- Histology sarcoma (N = 1) 
   
 
Total study population 
of 61 patients 
 
 
Median age of patients included was 64 years (Interquartile Range (IQR) 19) and median BMI 29 kg/m2 
(IQR 8) (Table 1). There were 24 women diagnosed with EC and 37 women with confirmed benign 
histology. 
The majority of women with EC had endometrioid endometrial carcinoma (EEC; n = 19, 79%), were 
diagnosed with FIGO stage I (n = 16, 67%) and grade 1 (n = 13, 54%). Most women diagnosed with EC 
were treated surgically (n = 20, 83%) and four women with advanced-stage disease received hormonal 
treatment (17%). 
Figure 1. Flowchart of recruitment for study
Median age of pati nts included was 64 years (Interquartil  Range (IQR) 19) and 
median BMI 29 kg/m2 (IQR 8) (Table 1). There were 24 women diagnosed with EC 
and 37 women with confirmed benign histology.
The majority of women with EC had endometrioid endometrial carcinoma (EEC; 
n = 19, 79%), were diag osed with FIGO stage I (n = 16, 67%) and gra e 1 (n = 
13, 54%). Most women diagnosed with EC were treated surgically (n = 20, 83%) 
and four women with advanced-stage disease received hormonal treatment 
(17%). Histology of women in the control group included atrophic- (n = 22), and 
proliferative endometrium (n = 15). 
Women in the control group were younger with median age of 59 versus 70 years 
in the EC group, although this did not reach significance (Table 2). 
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Table 1. Baseline characteristics 
Value
No. of patients 61
Age, median (IQR) 64 (19)
BMI, median (IQR) 29 (8)
Ethnicity (%)
Caucasian

























Endometrioid with small area clear cell




































Abbreviations: BMI = Body Mass Index (in kg/m2), FIGO = International Federation of Gynecology and 
Obstetrics, IQR = Interquartile Range
MiRNA expression profiles in endometrial cancer
To establish if urinary miRNA can distinguish women with EC from benign 
endometrium, the differences in expression profiles were assessed. MiR-10b, miR-
15a, miR-135b and miR-223 showed significantly altered expression profiles in EC 
patients (Table 3); however only miR-223 remained significantly up-regulated after 
correction for multiple testing. 
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Table 2. Differences between cancer and healthy control patients
Cancer Benign p-value
No. of patients 24 37 -
Age, median (IQR) 70 (20) 59 (14) 0.07





































Abbreviations: BMI = Body Mass Index (in kg/m2), FIGO = International Federation of Gynecology and 
Obstetrics, IQR = Interquartile Range
MiRNA and patient characteristics
To explore the relationship between miRNA and patient characteristics, urinary 
miRNA expression levels were analysed in relation to BMI, age and comorbidities 
in the complete study population. All 41 miRNAs were examined out of which 
eight showed significant different expression patterns (Table 4). Let7-i, miR-34a 
and miR-200c were significantly down-regulated in women with obesity (BMI 
≥ 30 kg/m2), whereas miR-424 was up-regulated. In addition, only lower let7-i 
expression was associated with morbid obesity (BMI ≥ 40 kg/m2). 
The impact of age on miRNA expression was analysed; miR-148a and miR-222 were 
significantly down-regulated in elderly women. Moreover, miR-16, miR-26b and 
miR-200c were significantly deregulated in women with multiple comorbidities. 
The difference in miRNA expression levels between women with atrophic and 
proliferative endometrium was assessed, which showed a significant different 
expression level of let-7a (p = 0.011), with a median expression level of 1.04 (range 
1.50) in proliferative endometrium and median of 1.50 (range 3.26) for atrophic 
endometrium (data not shown).
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Table 3. Up-regulated and down-regulated miRNAs 
Cancer, median (range) Benign, range (range) p-value
Down-regulated
let-7a 0.99 (2.34) 1.27 (3.26) 0.19
let-7b 2.74 (6.54) 3.06 (16.20) 0.34
let-7c 1.77 (3.75) 2.17 (7.30) 0.21
let-7d 0.15 (0.33) 0.16 (0.55) 0.69
let-7e 0.36 (0.63) 0.40 (1.45) 0.56
let-7i 0.22 (0.50) 0.23 (1.22) 0.62
miR-10b 0.49 (1.40) 0.82 (4.70) 0.020*
miR-17 0.39 (0.89) 0.48 (1.88) 0.41
miR-20b 0.12 (0.36) 0.19 (1.30) 0.26
miR-26b 1.41 (2.74) 1.83 (3.31) 0.10
miR-100 0.87 (1.87) 1.10 (3.65) 0.10
miR-107 0.38 (0.84) 0.43 (1.07) 0.85
miR-125b 0.31 (1.75) 0.41 (2.81) 0.16
miR-148a 0.41 (1.41) 0.50 (3.00) 0.48
miR-148b 0.07 (0.70) 0.07 (1.00) 0.88
miR-182 0.02 (0.16) 0.03 (2.17) 0.36
miR-183 0.03 (0.13) 0.19 (1.23) 0.78
miR-200a 1.28 (3.11) 1.39 (2.80) 0.73
miR-200b 0.15 (0.46) 0.18 (1.93) 0.59
miR-203-1 1.51 (8.37) 2.06 (16.44) 0.89
miR-222 0.23 (1.75) 0.27 (1.84) 0.41
miR-660 0.18 (0.72) 0.33 (1.15) 0.16
Up-regulated
miR-15a 0.41 (0.93) 0.30 (0.85) 0.041*
miR-15b 0.64 (1.42) 0.60 (2.53) 0.59
miR-16 0.71 (1.22) 0.55 (1.68) 0.10
miR-19b 0.90 (1.62) 0.81 (1.88) 0.15
miR-21 9.16 (36.79) 7.21 (49.92) 0.27
miR-34a 0.20 (0.49) 0.12 (0.95) 0.07
miR-135a 0.18 (0.58) 0.13 (0.70) 0.46
miR-135b 0.11 (0.30) 0.06 (0.30) 0.043*
miR-141-3p 0.48 (1.63) 0.26 (1.31) 0.07
miR-155 0.00 (0.02) 0.00 (0.32) 0.34
miR-181b 0.03 (0.08) 0.02 (0.37) 0.91
miR-195 0.04 (0.10) 0.03 (0.27) 0.50
miR-200c 1.77 (5.55) 1.74 (43.99) 0.77
miR-205 0.99 (6.91) 0.93 (12.61) 0.85
miR-223 0.83 (3.09) 0.20 (3.69) 0.003*
miR-375 0.12 (0.68) 0.11 (4.00) 0.44
miR-424 0.52 (1.20) 0.46 (20.53) 0.89
miR-429 0.09 (0.21) 0.08 (0.28) 0.58
miR-574 0.21 (1.95) 0.19 (4.70) 0.79
P-values are presented as raw p-values before Benjamini-Hochberg correction
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Abbreviations: BMI = Body Mass Index (in kg/m2)
Discussion
In this study, aberrant expression levels of miR-223 were observed in urine of 
women with EC. Furthermore, urinary miRNAs were significantly different in obese 
women (let-7i, miR-34a, miR-200c, miR-424), in elderly (miR-148a, miR-222) and 
women with multiple comorbidities (miR-16, miR-26b, miR-200c). 
MiR-223 has been previously been found deregulated in EC tissue, plasma and 
serum samples20 and has a key role in the development and homeostasis of the 
immune system and its involvement has been demonstrated for many types of 
cancers, inflammatory diseases and autoimmune diseases21. Furthermore, miR-223 
is an inflammatory miRNA and is involved in the adipocyte inflammation associated 
with morbid obesity22. In addition, plasma levels of miR-223 were found to be low 
in patients with type 2 diabetes23. Interestingly, we did not observe an association 
of miR-223 with obesity in our study cohort. This enhances the potential of urinary 
miR-223 as diagnostic biomarker for EC, even in obese women. 
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In this study, an association between let-7i, miR-34a, miR-200c, miR-424 and 
obesity was seen. Previous studies have shown that these miRNAs are associated 
with insulin production and resistance pathways, pancreatic development and 
glucose metabolism24. To our knowledge, the association between urinary miRNAs 
and obesity in EC has not been investigated so far. Therefore, the results of our 
study may help in understanding the role of miRNAs in obesity, metabolism, 
inflammation and insulin resistance pathways. Urinary miRNAs are promising 
biomarkers not only in the early detection and screening of EC, but also potentially 
useful to early identify women at risk of excess body fat accumulation and related 
metabolic abnormalities.
Currently, literature regarding urinary miRNA expression in EC is scarce. A study 
by Ritter et al. showed a tendency of miR-10b-5p upregulation and miR-205-
5p downregulation in urine of a small set of endometrial-, ovarian- and breast 
cancer patients18.  They commented that in these limited number of EC cases, 
miRNAs could not be confirmed as diagnostic marker in urine samples. In addition, 
Záveský et al. found urinary miR-106b to be downregulated in 10 EC patients and 
proposed more research should focus on confirming the diagnostic potential of 
urinary miRNAs19. 
After the menopause, the endometrium becomes atrophic as a result of 
ovarian failure. However, a proportion of postmenopausal endometria retain 
weak proliferative patterns for many years despite being atrophic, mainly as a 
response to continuous low level oestrogenic stimulation, especially in obese or 
elderly women25. Since normal endometrium is dynamic and undergoing cyclic 
phenotypic changes, it can be hypothesised that this influences miRNA expression 
patterns. Based on the miRNAs expression in control women, no differences were 
observed between proliferative and atrophic endometrium in the miRNA panel 
we investigated, supporting the fact that this will not influence the discrimination 
between benign and malignant endometrium. However, age, obesity and 
comorbidities alter miRNA expression levels and should therefore be take into 
account in future studies using miRNA expression for improving EC diagnosis. 
Lee et al. examined tissue specimens of women with normal endometrial 
tissue, simple hyperplasia (SH), complex atypical hyperplasia (CAH) and EC and 
suggested that miR-182, miR-183, miR-200a, miR-200c and miR-205 are involved 
in progression from CAH to EC, whereas PTEN has a role in the progression from 
SH to CAH26. To our knowledge, our study is the first to explore the differences in 
urinary miRNA expression levels between women with atrophic and proliferative 
endometrium. In this study, we found a different expression pattern for let-
7a between women with atrophic and proliferative endometrium. A further 
understanding is needed of the role of miRNAs in the development of endometrial 
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hyperplasia and EC carcinogenesis. 
There is limited knowledge on the exact origin of urinary miRNAs. Due to different 
identification methods and normalisation strategies, the miRNA expression 
patterns found in studies in other specimens are not easily comparable to urine29. 
Furthermore, the presence of miRNAs in urine differ from those in other bodily 
fluids such as blood or serum, with lower numbers of detectable miRNA species 
in the urine29. This suggests that the majority of circulating miRNAs are either 
‘’picked up’’ by kidneys through an unknown mechanism or are destroyed in 
urine30. Transrenal passage of the miRNAs from the blood could be suspected 
along with other sources involved in cell-cell communication or passive leakage 
from the injured or dead cells. Urinary miRNAs might originate from the tumour 
itself, or could derive from the cells of the immune system as a form of response 
to the presence of a malignancy31. Further research is needed to understand this 
complex process and comprehend miRNA expression patterns in urine samples of 
EC patients in more depth.
Strengths and weaknesses
The strengths of this study include the prospective inclusion of PMB patients 
suspect for EC and the standardised validation of the urinary miRNA expression 
patterns. However, the study is limited by the small sample size, the inclusion 
of different subtypes of EC and small groups regarding proliferative or atrophic 
endometrium. Furthermore, there were differences in baseline characteristics 
(age) between the cancer and control group. However, we showed that these 
characteristics were not associated with significant altered expression profiles 
of miR-223, therefore we assume this has not affected our results. In addition, 
miRNA expression patterns can be correlated with stage at diagnosis, however 
due to small numbers we were unable to account for stage.
Implications for practice and future research
This study was performed to establish the feasibility of urinary miRNA testing in 
EC as a first step in finding a non-invasive new diagnostic biomarker to improve 
management of women presenting with abnormal uterine bleeding. Ideally, 
a urinary screening test for those women can easily be done at the General 
Practitioner and only women with abnormal screening test can then be send to 
a hospital for further investigations, thereby improving patient care and early 
diagnosis. Further research in larger prospective trials should focus on validating 




In the current study, we demonstrated the feasibility of using miRNA expression 
levels in urine as possible non-invasive diagnostic test for EC. The miRNA levels 
can contribute to improved understanding of the carcinogenesis and its relation 
to BMI and comorbidity. Further research in larger trials is needed to validate the 
potential of these miRNAs. 
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General discussion and conclusion
In this thesis, different factors influencing endometrial cancer (EC), outcomes and 
its relationship with obesity were described. In addition, the diagnostic value of 
miRNA detection in EC in tissue and urine samples was evaluated. The relevance 
and clinical implications of the thesis will be discussed in this chapter, along with 
recommendation for future research. 
Obesity is a complex and multifactorial problem, mainly in the Western world, 
and a significant risk factor for and contributor to increased morbidity and 
mortality1. It has been well-established that EC risk is strongly related to obesity 
with a clear relationship between obesity and EC incidence and carcinogenesis. 
Although obesity as risk factor has been mainly attributed to endometrioid type 
EC (EEC), recent data illustrate that obesity is also relevant in non-endometrioid 
type EC (NEEC)2. However, questions regarding obesity-related endometrial 
carcinogenesis remain. 
Obesity and body composition 
Body Mass index (BMI) is a convenient and accessible measure of weight in the 
clinical setting. However, it does not differentiate between visceral or subcutaneous 
fat and muscle mass3,4. It is becoming increasingly apparent that the distribution 
of fat tissue is at least as important as the total amount of body fat in predicting 
disease-causing complications that are associated with obesity5. Visceral obesity 
is linked to metabolic alterations such as insulin resistance, type 2 diabetes, 
hypercholesterolaemia, cardiovascular disease and chronic systemic inflammation 
leading to cancer development and progression6. Furthermore, in addition to the 
importance of fat distribution, reduced muscle mass is a known risk factor for poor 
clinical outcomes such as post-operative complications, chemotherapy-related 
toxicity and overall survival (OS) in patients with cancer7. Sarcopenia refers to the 
loss of muscle mass and strength and is associated with older age8. Sarcopenia is 
clinically important as it is a major risk factor for physical frailty, falls, prolonged 
hospitalisation, dependency and premature mortality9. Sarcopenia is often seen in 
obese individuals, a condition called sarcopenia obesity, with a prevalence of up 
to 20% in older populations10.
Body composition in EC
We explored the relationship between body composition including fat and muscle 
distribution and outcomes in high-grade EC. In Chapter 2, we showed that high 
visceral fat percentage (VAV%) is associated with reduced OS and disease-specific 
survival (DSS) in NEEC, but not in EEC. This is an unexpected finding and raises 
questions about the pathophysiology of EC carcinogenesis. Setiawan et al. found 
risk factors for NEEC tumours to be similar to EEC, suggesting NEEC tumours are 
202
Chapter 10. General discussion and future perspectives
not completely oestrogen independent, as previously thought2. Van Weelden et al. 
furthermore showed a stronger correlation of subcutaneous fat volume (SAV) with 
oestradiol when compared to visceral fat volume (VAV), hypothesising both SAV and 
VAV are relevant for EC carcinogenesis11. SAV is primarily responsible for oestradiol 
production and therefore related to endometrial hyperplasia and EEC tumours, 
whereas VAV is involved in alterations leading to hyperinsulinemia and inflammation-
related carcinogenesis11. We therefore expected VAV% to be associated with 
survival in both NEEC and EEC tumours. Mauland et al. add to our findings showing 
high VAV% is associated with worse DSS, however they included mainly patients 
with low-grade EC (152 grade 1-2 EEC)12. It can therefore be hypothesised VAV% 
is only prognostically relevant in low-grade EEC tumours, but not in high-grade 
EEC as shown by our study. Our findings underline that, although it is becoming 
increasingly more apparent NEEC are also related to obesity, there still seems to 
be a difference in pathophysiology between the obesity-related NEEC and EEC. 
Furthermore, we showed the association of VAV% with hypertension and diabetes 
mellitus (DM) in high-grade EC. This association was seen for both NEEC and EEC 
tumours. The mechanism behind an increased risk of hypertension associated 
with obesity lies in an altered angiotensin II and aldosterone secretion system 
associated with excess weight, mainly visceral fat13,14. Furthermore, obesity causes 
structural alterations in the kidneys that eventually cause loss of nephron function 
and a further elevation in blood pressure13. In addition, accumulation of visceral fat 
contributes to adipocyte hypertrophy and increased infiltration with macrophages, 
which both secrete several adipokines, creating a complex network of factors 
promoting, maintaining and exacerbating an insulin resistant state15.  
The importance of body fat distribution maybe evident; however, questions 
remain regarding the exact impact of body composition in EC progress. Therefore, 
examining muscle mass in addition to fat distribution is important. Muscle mass 
has been shown to have a protective effect on cardiometabolic alterations in 
obesity16. On the other hand, obesity leads to muscle atrophy and decreased 
muscle strength, worsening the adverse effects of obesity17,18. We showed that 
sarcopenia is not associated with reduced survival in patients with high-grade EC 
in Chapter 3. This is supported by previous data of Nattenmüller et al. and Kuroki 
et al. showing no impact of sarcopenia on OS19,20. However, Kuroki et al. showed 
a negative impact of sarcopenia on recurrence-free survival20. Furthermore, we 
revealed an association between sarcopenic obesity and poor OS in high-grade 
EEC. This association was not seen for NEEC patients and might be contributed to 
the limited number of cases. 
Risk factors for the pathogenesis of sarcopenia include older age, female sex, low 
levels of physical activity or immobility21. At the cellular level, the age-related loss of 
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muscle mass that occurs in sarcopenia is caused by a decrease in both the number 
and size of muscle fibres9. This is an age-related process due to oxidative damage, 
low-grade chronic inflammation, nutritional factors and changes in hormonal 
system9. Studies on body composition in other tumour types showed an impact 
of sarcopenia on outcomes including survival22. This illustrates that underlying 
pathogenic mechanisms are complex and not fully understood. Prospective 
studies are needed to evaluate the composition of adipose tissue as well as muscle 
mass and its influence on prognosis in EC while addressing changes over time. In 
addition, menopause status should be taken into account, since menopause and 
bilateral oophorectomy are associated with an increase in percentage body fat23.
To improve outcome in women diagnosed with EC, issues of obesity and sarcopenia 
should be addressed. Several treatment regimes have been proposed to improve 
visceral adiposity and increase muscle mass, including exercise, diet and medication. 
Resistance exercise remains the intervention with the most supporting evidence 
for the effectiveness to increase muscle mass and is the treatment of choice24. 
There is currently no recommended pharmacological treatment, however trials 
have examined the usage of inhibitors of the myostatin system, testosterone and 
angiotensin-converting enzyme inhibitors25,26. 
The importance of visceral adiposity as well as muscle loss seems evident and we 
propose including body composition measurements as part of standard work-up 
for patients newly diagnosed with EC. In addition, we suggest EC patients should 
be offered specialised training programs and nutritional therapy to aim to achieve 
weight loss including reducing visceral fat volumes and to increase muscle mass. 
Socioeconomic status, obesity and EC
Obesity is a multifactorial problem in which individual, environmental, 
socioeconomic and genetic factors are all linked to the increase in obesity in 
developed countries27. Obesity is more frequently seen amongst individuals with 
lower socioeconomic status (SES) due to less physical activities, unhealthy working- 
and living environment, unhealthier diet due to costs and lack of knowledge 
regarding healthy food and psychological distress28–30. Socioeconomic deprivation 
is an important predictor of health and survival with major inequalities among 
different levels of deprivation31,32. Extensive literature describes the relationship 
between socioeconomic deprivation and poor cancer survival33. In Chapter 4 
and 5, we have shown that socioeconomic deprivation is associated with worse 
survival in EC patients (as shown by our systematic review of the literature, 
Chapter 4), however this is attributed to other factors such as obesity, higher stage 
at diagnosis and age (as shown by our own retrospective cohort study, Chapter 5). 
However, the independent relationship between obesity and OS was only seen in 
EEC patients, but not in NEEC patients. In NEEC patients, stage at diagnosis was 
the most important prognostic factor. 
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The majority of EC patients present early with an overall good prognosis. However, 
low SES patients generally undergo a longer time interval between first symptom 
recognition and first medical consultation due to low awareness of symptoms 
and less ability to afford medical care34. Furthermore, low educational status is 
associated with referral delay35. This health-care delay is associated with more 
advanced stage disease at presentation34. Furthermore, socioeconomic differences 
in treatment modalities have been reported, with more aggressive therapy in 
patients with high SES34. Reasons for this association include differences in 
attitudes towards invasive procedures, disease severity, access to care, differences 
in undergoing staging procedures and issues related to health insurance34. 
Therefore, early diagnosis is the most important adjustable factor in EC to improve 
outcomes. Increasing public awareness on the association between obesity and 
cancer including breast-, colon- and endometrial cancer and early symptoms 
of disease is important. The economic burden of obesity-related cancers is 
substantial and is expected to grow since the prevalence of obesity increases36. 
For that reason, interventions for implementing obesity prevention or treatment 
programs among the general population and cancer patients could have an 
impact on outcomes as well as overall cancer care expenditures. Public health 
interventions include education and prevention including hormonal protection in 
obese women or bariatric surgery. Among obese women diagnosed with complex 
atypical hyperplasia (CAH) or early-stage EC, referral to a bariatric surgeon tends to 
be well received, with approximately 17% going on to pursue surgical intervention 
and 59% subsequently attempting weight loss37. Furthermore, MacKintosh et al. 
showed that in obese women, bariatric surgery-induced weight loss resulted in 
beneficial changes in circulating biomarkers of insulin resistance, inflammation, and 
reproductive hormones, in endometrial morphology, and in molecular pathways 
that are implicated in endometrial carcinogenesis38. 
Obesity and haematological parameters in EC
Obesity is associated with chronic low-grade inflammation with elevated levels of 
pro-inflammatory cytokines and acute phase proteins39. Excessive pro-inflammatory 
cytokine production stimulates the release of platelets from bone marrow to 
peripheral blood and these cause changes in haematological parameters40. In 
Chapter 6, we showed the prognostic relevance of haematological parameters 
and its relationship with obesity and comorbidities in women diagnosed with EC. 
We showed an independent relationship of anaemia with poor OS. Furthermore, 
we showed that leucocytosis was associated with obesity, DM and advanced 
FIGO stage. These results indicate leucocytosis is related to unhealthy patient 
environment and therefore related to adverse outcome, whereas anaemia reflects 
tumour aggressiveness. These haematological parameters can be useful in further 
prognostication of EC patients. 
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MicroRNA, cancer and obesity
As summarised, alterations in body composition are highly relevant in both the 
incidence and the outcome of EC. Although prevention has high priority, improving 
diagnosis might be as important. Early identification of precancerous and early-
stage disease is therefore important, and less invasive diagnostics could facilitate 
early diagnosis. Therefore, the second part of the thesis focused on identifying a 
novel non-invasive test for the detection of EC.
In the past years, microRNAs (miRNAs) have gained enormous interest in cancer 
research. MiRNAs are a class of small noncoding RNA molecules that regulate gene 
expression which play crucial roles in biological processes41,42. Abnormal expression 
of miRNA has been linked to various disorders including cancer and have therefore 
been proposed to be promising diagnostic and prognostic biomarkers43,44. 
Additionally, miRNAs are associated with lipid and glucose metabolism and play 
an important role in the onset of obesity and obesity-related diseases45. 
MiRNAs have shown to be stable in body fluids such as serum and urine46. 
These body fluids are promising as a non-invasive way of detecting EC. Ideally, 
a screening test for EC could be done at the general practitioner (GP). Only 
women with abnormal screening test can then be send to a hospital for further 
investigations. This would lower thresholds for patients and could therefore 
improve early diagnosis. In addition, access to and use of health care vary by SES. 
Even in countries that provide universal coverage, persons with less income and 
education do not use health services in the same way as wealthier individuals do47. 
People with lower SES use GP services more frequently while individuals with 
higher SES more often use specialist medical services48. A urinary screening test 
for EC could improve early diagnosis in patients with low SES. 
MiRNA as diagnostic biomarker in EC
We showed the potential of miRNA as a diagnostic biomarker in EC in Chapter 
7. We performed a systematic review of the literature and found that miR-200a, 
miR-200b, miR-200c, miR-205, miR-141, miR-429, miR-182, miR-183 and miR-
223 were most consistently upregulated in various specimens (tissue, urine, liquid-
based cytology, serum, plasma) in women diagnosed with EC. 
We therefore further analysed this specific miRNA panel in our own cohort in tissue 
samples of women diagnosed with EC to further validate the potential of miRNA 
as a diagnostic biomarker. We showed a high diagnostic accuracy in detecting EC 
with a distinct panel of miR-200a, miR-200b, miR-200c, miR-205 and miR-182 
with sensitivity of 92% and specificity of 89% in distinguishing benign endometrial 
tissue from EC (Chapter 8). 
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As previously stated, miRNAs are stable in urine, opening a potential way for non-
invasive testing for EC. Due to different identification methods and normalisation 
strategies, miRNA expression patterns found in other specimens are not easily 
comparable to urine49. Furthermore, the presence of miRNAs in urine differ 
from those in other bodily fluids such as blood or serum, with lower numbers of 
detectable miRNA species in the urine49. In Chapter 9, we investigated miRNA 
expression levels in urine samples of EC patients and benign control women 
and showed that miR-223 levels were up-regulated in urine samples of women 
diagnosed with EC. We therefore showed the feasibility of urinary miRNA testing 
as a first step in finding a non-invasive biomarker for the screening and detection 
of EC. Further, larger prospective trials are needed to validate the potential of 
these miRNAs in the accurate diagnosis of EC. Not only urine is a potential non-
invasive way to detect or screen for EC, other samples such as serum or pap smear 
could potentially be used and the presence of miRNAs in these samples warrant 
further investigations. 
We found certain urinary miRNAs to be associated with BMI: let-7i, miR-34a, 
miR-200c and miR-424. Additionally, Munetsuna et al. revealed the association 
between circulating miRNAs and SAT and VAT50. Therefore, miRNAs may be useful 
as biomarker for obesity and offer new information to better understand the 
pathogenesis of obesity. They could further aid in explaining gaps in the existing 
knowledge of the obesity-related endometrial carcinogenesis and differences 
between NEEC and EEC tumours.
Future directions
This thesis described and highlights the importance of understanding obesity-
related endometrial carcinogenesis. Although we have shown that EEC differ 
from NEEC with regards to prognostic factors, both seem to be related to obesity. 
Future research should focus on this incomplete understanding while incorporating 
The Cancer Genome Atlas (TCGA) molecular classification. There appears to be 
an association between obesity and the EC integrated clusters, in which POLE 
mutated tumours have the lowest BMI and women with copy-number low tumours 
have the highest median BMI51. However, the association with body composition 
is unknown. Since it’s becoming more apparent that body composition is equally 
or perhaps even more important than BMI, future studies should focus on, and 
take into account body measurements.
We have shown that visceral fat negatively impacts survival in NEEC, however 
it would be clinically useful to establish a prognostic cut-off value of VAV%. 
Studies have been conducted to suggest thresholds of VAT associated with 
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low cardiometabolic risk, but criteria were highly variable across studies6. To 
propose such cut-off risk values, it will be critical to standardise the location of 
the abdominal CT-scan or to clearly identify the abdominal cross-sectional area 
(e.g. L4-L5 or umbilicus) that was used. A prognostic cut-off value for EC could 
help clinicians assess patients at increased risk for poor outcome and establish 
which patients should be counselled for specialised rehabilitation and training 
programs including nutritional therapy. The effects of such lifestyle interventions 
on reducing visceral fat and gaining muscle mass in women diagnosed with EC 
have not yet been assessed and could aid in the development of a comprehensive 
combined lifestyle intervention program while taking into account the frequent 
comorbidities, disabilities and older age EC patients have. This will also help answer 
one of the top 10 unanswered research questions developed by Wan et al. in 
2016: ‘’Do changes in lifestyle, including weight loss, reduce the risk of recurrence 
and improve survival in women who have been treated for endometrial cancer?’’52.
We furthermore revealed that high-grade EEC patients with sarcopenic obesity have 
poorer survival, further emphasising the need for posttreatment rehabilitation. Lee 
et al. previously showed that loss of muscle during cancer therapy was predictive 
for poor survival in advanced EC, however it would be of interest to investigate 
if similar results can be found in early-stage EC with usually better prognosis53. 
Furthermore, the optimal intervention that best preserves skeletal muscles has 
yet to be determined. A program with combined resistance and aerobic exercises 
significantly attenuated sarcopenic obesity in patients with breast cancer, however 
for women with EC, who are often elderly, this has not been investigated54. 
Not only postsurgical therapy is important, establishing and optimising patients’ 
preoperative health status is important. The MUST (Malnutrition Universal 
Screening Tool) is used in several hospitals in the Netherlands to preoperatively 
determine nutritional risk and to identify adults who are malnourished, at risk of 
malnutrition, or obese55. It also includes management guidelines which can be used 
to develop a care plan. The value of this screening tool, however, has not been 
explored for women diagnosed with EC. Furthermore, the time period between 
diagnosis and surgical intervention can be used to optimise patients’ status in 
a prehabilitation program. Multimodal prehabilitation programs could include 
nutritional counselling, training programs, psychological support and optimisation 
of underlying medical conditions as well as cessation of unfavourable health 
behaviours such as smoking and drinking and could optimise patients overall 
health before EC surgery. 
Body composition including fat distribution and muscle mass are important in 
incidence and outcome of EC. With regards to further improving early diagnosis in 
EC and thereby improving survival rates, this thesis aimed to find and describe a 
new non-invasive biomarker. Although we showed the feasibility of using urinary 
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miRNA expression levels in diagnosing EC, we recognise the limitations of our 
study with respect to the small sample size. Therefore, we aim to validate our 
findings in a larger prospective trial. We furthermore would like to include women 
diagnosed with simple hyperplasia and complex atypical hyperplasia, to verify if 
miRNAs can distinguish benign endometrium from hyperplasia and hyperplasia 
from cancer. This could then potentially be useful in management of mainly obese 
women with findings of hyperplasia with or without atypia.  
Additionally, we showed the association between obesity and biomarkers (urinary 
miRNAs and haematological parameters), however we have not assessed the value 
of miRNA or haematological parameters as marker for body composition. If certain 
markers are associated with the presence of sarcopenia or visceral adiposity, they 
could be used to early identify women at risk of body fat accumulation or loss of 
muscle mass and related metabolic abnormalities. Compared to CT-scan, the gold 
standard for assessing body composition, urinary miRNAs and haematological 
parameters are non-invasive and less expensive. These biomarkers could easily be 
used to assess the influence of lifestyle including rehabilitation therapy.
Conclusion
Obesity influences survival and outcomes in EC in different ways. Not only BMI 
is important in EC prognosis, but body fat composition including visceral fat and 
muscle mass are vital. High visceral fat is an independent prognostic factor for 
women with NEEC tumours, whereas sarcopenic obesity is associated with poor 
survival in high-grade EEC patients. In addition, socioeconomic deprivation is 
associated with poor survival, however this is attributed to other factors such as 
obesity. Furthermore, anaemia is an independent prognostic factor in EC, whereas 
leucocytosis is related to obesity and comorbidity. 
MiRNAs are related to obesity and are promising biomarkers in detecting EC. 
Moreover, urinary miRNAs could potentially be useful as a non-invasive diagnostic 
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Endometrial cancer (EC) is the most common gynaecological malignancy in the 
Western world. As described in Chapter 1, these carcinomas are traditionally 
classified as either endometrioid adenocarcinomas (EEC, associated with obesity) 
or non-endometrioid tumours (NEEC, seen in the presence of endometrial atrophy 
and presumed non-related to obesity). However, recent data illustrate that risk 
factors associated with obesity are also relevant in NEEC tumours. Nevertheless, 
questions remain regarding the obesity-related endometrial carcinogenesis.  
To further explore the influence of obesity on EC and outcomes, Chapter 2 and 3 
of this thesis focussed on the relationship between body fat measurements and 
outcomes in EC. In Chapter 2, body fat distribution was measured with CT-scan 
and analysed in relationship to mortality in high-grade EC patients. We showed 
that high visceral fat percentage (VAV%) was associated with reduced overall- 
(OS) and disease-specific survival (DSS) in NEEC, but not in high-grade EEC. 
Furthermore, we showed the association of VAV% with hypertension and diabetes 
mellitus (DM) in high-grade EC. 
In addition to body fat distribution, examining muscle mass is important. In Chapter 
3, we analysed sarcopenia, defined as loss of skeletal muscle, and found sarcopenia 
to be unrelated to survival in patients with high-grade EC. However, we did show 
an association between sarcopenic obesity and poor OS in high-grade EEC, 
although this association was not seen for NEEC patients. We therefore propose 
to incorporate body composition measurements, in addition to Body Mass Index 
(BMI), as part of standard work-up to be able to offer patients specialised training 
programs and nutritional therapy aiming at reducing visceral fat volumes and 
increasing muscle mass, thereby improving outcomes in EC. 
Obesity is a multifactorial problem and is more frequently seen amongst individuals 
with lower socioeconomic status (SES). Hence, we focused on the relationship 
between socioeconomic deprivation, BMI and survival in EC. Socioeconomic 
deprivation was associated with worse survival in EC, as shown by our systematic 
review of the literature (Chapter 4). However, we conducted a retrospective 
cohort study in our own institution and showed that these survival differences 
were attributed to other factors such as obesity, higher stage at diagnosis and 
age (Chapter 5). The independent relationship between obesity and OS was only 
seen in EEC patients. In NEEC patients, stage at diagnosis was the most important 
prognostic factor. 
Since obesity is associated with chronic low-grade inflammation with elevated 
levels of pro-inflammatory cytokines and acute phase proteins, we analysed 
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haematological parameters in relationship to survival in EC38. In Chapter 6, we 
showed the importance of haematological parameters and its relationship with 
obesity and comorbidities. Anaemia is an independent prognostic factor whereas 
leucocytosis is related to obesity and comorbidity; reflecting an unhealthy 
patient environment. We concluded that these markers can be useful in further 
prognostication of EC patients. 
Although obesity and alterations in body composition are highly relevant in both 
the incidence and the outcome of EC, improving diagnosis might be as important 
to increase survival rates. Therefore, in part II of this thesis, we focussed on 
finding a novel diagnostic biomarker for early and accurate detection of EC. We 
focused on microRNA (miRNA) detection, since aberrant miRNA expression has 
been linked to various diseases including cancer and play an important role in the 
onset of obesity and obesity-related diseases. We performed a systematic review 
of the literature and showed a panel of miR-205, miR-200 family, miR-135b, miR-
182, miR-183 and miR-223 to be promising in diagnosing EC (Chapter 7). This 
panel was further tested and validated in our own cohort in Chapter 8, in which 
we examined miRNA expression levels in Formalin-Fixed, Paraffin-Embedded 
(FFPE) samples of patients diagnosed with EC in our institution. We showed that 
the panel of miR-200a, miR-200b, miR-200c, miR-205 and miR-182 was highly 
accurate in distinguishing benign endometrial tissue from EC with sensitivity of 
92% and specificity of 89%. 
We further aimed to find a novel non-invasive diagnostic test for earlier and easier 
diagnosis of EC. In Chapter 9, we therefore focused on miRNA expression in urine. 
We showed miR-223 to be deregulated in urine samples of EC patients. Thus, we 
showed the feasibility of urinary miRNA testing as a first step in finding a non-
invasive biomarker for the screening and detection of EC. In addition, we showed 
that several urinary miRNAs are associated with obesity. Therefore, miRNAs may 
be useful as biomarker for obesity and offer new information to better understand 
the obesity-related endometrial carcinogenesis.
Lastly, in Chapter 10 we discuss these findings in relation to current literature and we 
suggest future directions for EC research. In addition, we make recommendations 




Endometriumcarcinoom (EC) is de meest voorkomende gynaecologische kanker in 
de Westerse wereld. Zoals beschreven in Hoofdstuk 1, wordt EC onderverdeeld 
in endometrioïde endometriumcarcinomen (EEC), vaak geassocieerd met obesitas, 
en non-endometrioïde endometriumcarcinomen (NEEC), die ontstaan vanuit 
atrofisch endometrium en minder gerelateerd zijn aan obesitas. Echter, recente 
data laten zien dat de risicofactoren die gerelateerd zijn aan obesitas ook een 
rol spelen in NEEC. Desondanks zijn er nog veel onduidelijkheden wat betreft de 
obesitas-gerelateerde endometrium carcinogenese.  
Om de invloed van obesitas op EC en uitkomstmaten verder te bestuderen, 
worden in Hoofdstuk 2 en 3 van dit proefschrift de invloed van vetverdeling en 
spiermassa in EC beschreven. In Hoofdstuk 2 bekijken we de vetverdeling op 
basis van CT-scan-metingen in relatie tot mortaliteit in hooggradige EC-patiënten. 
We hebben aangetoond dat een hoog visceraal vetpercentage samenhangt met 
een verminderde totale en ziekte-specifieke overleving in NEEC, maar niet in 
hooggradige EEC-tumoren. Daarnaast hebben we het verband laten zien tussen 
een hoog visceraal vetpercentage en comorbiditeit zoals hypertensie en diabetes 
mellitus (DM) bij patiënten met hooggradige EC. 
Naast overgewicht hebben een toenemend aantal studies laten zien dat ook 
spiermassa een belangrijke rol speelt bij de gezondheidsstatus van patiënten. In 
Hoofdstuk 3 hebben we gekeken naar sarcopenie, wat gedefinieerd wordt als het 
verlies van spiermassa, en hebben we aangetoond dat sarcopenie niet gerelateerd 
is aan overleving bij patiënten met hooggradige EC. Er bleek echter wel een 
relatie te bestaan tussen sarcopene obesitas en slechtere OS in hooggradig EEC, 
hoewel bij patiënten met NEEC-tumoren dit verband niet werd gevonden. Om de 
overlevingscijfers van patiënten met EC te verbeteren, zouden we ons niet alleen 
op Body Mass Index (BMI) moeten richten, maar ook aandacht moeten besteden 
aan spiermassa en type vetverdeling. Daarmee zouden we de counseling van deze 
patiënten kunnen verbeteren, door met hen de mogelijkheden van gespecialiseerde 
trainingsprogramma’s en voedingsadviezen te bespreken.
Obesitas is een multifactorieel probleem en wordt vaker gezien bij mensen met 
een lagere sociaal-economische status (SES). In dit proefschrift hebben we de 
correlatie onderzocht tussen sociaal-economische deprivatie, BMI en overleving 
in EC. In Hoofdstuk 4 worden de resultaten van een systematic review van de 
literatuur gepresenteerd, waaruit blijkt dat patiënten met EC een slechtere 
overleving hebben wanneer zij uit een laag sociaal-economisch milieu komen. 
Ter aanvulling hebben we een retrospectieve cohort-studie verricht in het Royal 
Cornwall Hospital, waarin we demonstreren dat de verschillen in overleving bij EC 
220
Chapter 11. Samenvatting
met name te maken hebben met factoren zoals obesitas, gevorderd stadium bij 
diagnose en leeftijd (Hoofdstuk 5). De onafhankelijke relatie tussen obesitas en 
overleving was alleen significant bij patiënten met EEC. Bij patiënten met NEEC 
was het stadium ten tijde van de diagnose de belangrijkste prognostische factor. 
Obesitas veroorzaakt een chronische inflammatie waarbij een stijging van pro-
inflammatoire cytokinen en acute fase-eiwitten wordt gezien. In Hoofdstuk 6 
hebben we de invloed van hematologische parameters op overlevingscijfers in EC 
onderzocht, alsmede de relatie van deze parameters met obesitas en comorbiditeit 
(hypertensie, DM). We hebben laten zien dat anemie een onafhankelijke 
prognostische factor is, terwijl leukocytose met name gerelateerd is aan obesitas 
en de aanwezigheid van comorbiditeit. Deze parameters kunnen in patiënten met 
EC een belangrijke rol spelen in het voorspellen van de uitgebreidheid van de 
ziekte, prognose en de gezondheidsstatus. 
Naast het feit dat obesitas en veranderingen in lichaamssamenstelling belangrijk 
zijn in de incidentie en de overleving bij EC, is het vroeg ontdekken van EC 
misschien wel even belangrijk om de overlevingscijfers te vergroten. 
In deel II van dit proefschrift focussen we daarom op het vinden van een nieuwe 
diagnostische biomarker voor vroege en accurate diagnose van EC. We hebben 
hierbij gekeken naar microRNA (miRNA) expressie, aangezien afwijkende miRNA 
expressie gezien wordt in een breed scala aan ziekten, waaronder kanker. 
Daarnaast speelt miRNA een belangrijke rol in het ontstaan van obesitas en 
obesitas-gerelateerde ziekten. In Hoofdstuk 7 laten we middels de resultaten 
van een systematic review van de literatuur zien dat een panel met: miR-205, de 
miR-200 familie, miR-135b, miR-182, miR-183 en miR-223, veelbelovend is om 
de diagnose van EC te stellen. We hebben dit panel van miRNAs verder getest 
en gevalideerd in ons eigen cohort in Hoofdstuk 8. Hierin hebben we gekeken 
naar miRNA expressie levels in formaline-gefixeerd paraffine-ingebed weefsel 
van patiënten gediagnosticeerd met EC in het Royal Cornwall Hospital. Een panel 
van miR-200a, miR-200b, miR-200c, miR-205 en miR-182 kon accuraat benigne 
endometriumweefsel onderscheiden van kankerweefsel met een sensitiviteit van 
92% en specificiteit van 89%. 
Daarnaast hebben we een nieuwe niet-invasieve methode geëxploreerd om de 
diagnose van EC te bespoedigen en vereenvoudigen. In Hoofdstuk 9 hebben we 
laten zien dat miR-223 gedereguleerd is in urine van patiënten met EC. Daarmee 
hebben we gedemonstreerd dat het mogelijk is om miRNA uit urine te isoleren, 
als eerste stap voor het vinden van een nieuwe niet-invasieve diagnostische 
test om te screenen op EC. We hebben tevens aangetoond dat de expressie van 
meerdere miRNAs in urine afwijkend is bij vrouwen met obesitas ten opzichte van 
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vrouwen met een normaal BMI. MiRNAs kunnen dus niet alleen belangrijk zijn bij 
het diagnosticeren van EC, maar ook een biomarker zijn voor obesitas en daarmee 
nieuwe informatie verschaffen voor een beter begrip van de obesitas-gerelateerde 
endometrium carcinogenese.
In Hoofdstuk 10 worden tenslotte de resultaten van de verschillende studies in 
dit proefschrift bediscussieerd en worden onze bevindingen vergeleken met de 
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